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Abstract 
Aminopeptidase N/CD13 is a metallopeptidase that is highly expressed by fibroblast-like 
synoviocytes (FLS) and may play a role in rheumatoid arthritis (RA).  The goal of this study was 
to define CD13 function in the RA joint by monitoring CD13 expression in vivo and in vitro, 
analyzing regulation by pro-inflammatory cytokines of CD13 expression on FLS, describing the 
mechanisms by which CD13 is released from FLS, and defining potential roles for CD13 in 
homing of T cells to the RA joint and in regulating the growth and migration of RA FLS.  In 
overview, we find that CD13 is expressed in synovial fluids, sera, FLS lysates, and culture 
supernatants as measured by ELISA, with a significant increase of CD13 in RA synovial fluids 
when compared to osteoarthritis.  In FLS, pro-inflammatory cytokines (TNFα, IFNγ, IL-17) are 
able to upregulate CD13 mRNA.   However, as surface expression of CD13 did not correlate 
with CD13 mRNA, and soluble CD13 is present in RA synovial fluid, potential mechanisms for 
CD13 release from FLS were examined.  CD13 was detected in sera, synovial fluids, and FLS 
culture supernatants, on extracellular vesicles and in soluble form.  The release of soluble CD13 
from FLS could be blocked by metalloproteinase inhibitors and siRNA directed against MT1-
MMP/MMP14.  With regard to biological functions, recombinant human CD13 was chemotactic 
for cytokine activated T-cells (Tck) through a G-protein-coupled receptor and contributed to the 
chemotactic properties of synovial fluid independently of enzymatic activity.    Furthermore, 
inhibition of CD13 function in FLS, using enzymatic activity inhibitors or anti-CD13 antibodies, 
resulted in decreased growth and diminished migration of RAFLS.  We conclude that CD13 is 
x 
 
upregulated in the RA joint by pro-inflammatory cytokines where it is released on extracellular 
vesicles and shed as a soluble molecule from the FLS surface by metalloproteinases, including 
MMP14.  Following its release from the FLS surface, CD13 induces chemotaxis of Tck, a T cell 
population similar to that found in RA synovium.  Moreover, CD13 increases FLS growth and 
migration, thereby contributing to synovial hyperplasia in RA.  Our data implicates CD13 in the 
pathogenesis of RA through enhancement of both T cell infiltration and aggressive FLS 
outgrowth. 
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                                                                                                        Chapter 1
Introduction 
 
Rheumatoid Arthritis 
Rheumatoid Arthritis (RA) is an inflammatory autoimmune disease that primarily targets the 
synovial tissue (the soft tissue lining of the joint), leading to destruction of the bone and cartilage 
of multiple affected joints 
1
.  RA can cause inflammation in other tissues as well, including the 
lungs and heart 
2,3
.  RA affects approximately 0.6% of the world’s adult population and can lead 
to significant disability for those affected 
1
.  Important progress has been made in understanding 
and treating RA; however, the etiology of RA remains unknown.  Theories about the causes of 
RA involve genetic loci that affect susceptibility to RA (notably MHC and PTPN22), 
environmental factors (such as cigarette smoke), triggering infections (periodontal disease), 
autoantibodies (rheumatoid factor and anti-citrullinated peptides), and T cell autoreactivity
4–6
.  
The pathogenesis of RA is a complex process involving many cell types, including cells of the 
joint (synoviocytes and osteoclasts) and immune cells (T cells, B cells, dendritic cells, and 
monocytes).  This study will focus primarily on interactions between T cells and fibroblast-like 
synoviocytes (FLS). 
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T cells 
T lymphocytes are key mediators of adaptive immunity, and it is well established that T cells 
play an important role in RA
7
.  They have been identified as crucial in many mechanisms of RA 
pathology including inflammatory cytokine production, osteoclast differentiation (formation of 
bone resorbing cells), and stimulation of synovial cells and antigen-presenting cells (APCs) to 
proliferate and express increased levels of cytokines and chemokines 
8–11
.   A major question that 
remains unanswered is how autoreactive T cells in RA become activated.  One proposed 
mechanism involves human leukocyte antigen-DR (HLA-DR), specifically HLA-DR alleles that 
contain an amino acid sequence that has been termed the shared epitope
12,13
.  HLA-DR is the 
most significant genetic locus that affects susceptibility to RA, with different alleles acting to 
either confer RA susceptibility or protection.   Human leukocyte antigen (HLA) is the genetic 
locus that encodes the major histocompatibility complex proteins (MHC).  MHC proteins present 
peptides to T cells.  The T cells express a T cell receptor protein dimer (TCR) that recognizes 
MHC and discriminates as to whether the peptide being presented is self or foreign.  This 
TCR/MHC recognition event and subsequent downstream signaling is the primary mechanism 
by which pathogens are recognized by T cells leading to T cell activation.  HLA-DR is an MHC 
class II molecule.  MHC class II molecules are typically found on antigen presenting cells and 
present peptides from extracellular proteins.  The other class of MHC is MHC class I molecules 
which are present on most cells in the body and express peptides from cytosolic proteins.  The 
shared epitope is a concept that proposes a common amino acid sequence in the peptide-binding 
cleft of the HLA-DR RA susceptibility alleles.  It is unknown how the  HLA-DR alleles that 
contain the shared epitope predispose individuals to RA, but one possibility is that arthritogenic 
autoantigens, especially modified proteins (such as citrulinated peptides), are presented and 
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recognized as foreign
8,14,15
.   Other lines of evidence support novel mechanisms by which MHC 
alleles influence autoimmunity in ways unrelated to antigen recognition
8,16,17
.   
 
There is also data to suggest that T cells of the joint may become activated in ways other than 
through the canonical TCR/MHC pathway.  Fractalkine, a cytokine strongly expressed in the RA 
synovium, directly induces activation of senescent RA CD4+ T cells 
8,18
.  Cytokine activated T 
cells (Tck) have been shown to closely resemble the T cells found in the RA joint and can 
potentiate a proinflammatory environment 
19
.  Tck are an in vitro cell population created by 
treatment of peripheral blood T cells with IL-2, TNFα, and IL-6.  Tck are activated without any 
classical stimulation through the TCR.  While this is an in vitro cell type, their phenotypic 
similarity to RA synovial T cells indicates a high probability that a similar pathway may exist in 
vivo 
19
.   Tck are useful for experiments to mimic RA synovial T cells.  It is not possible to 
isolate the numbers of synovial T cells necessary for many experiments.  However, Tck make it 
possible to estimate functions of RA synovial T cells.  It is likely that the extent to which RA T 
cell activation occurs through classical or nonclassical pathways is influenced by the surrounding 
inflammatory environment and joint-specific cells.   
 
T cells can be divided into two main subsets: cytotoxic T cells and helper T cells.  Cytotoxic T 
cells (CD8+) recognize and destroy virally infected or tumor cells
20
.  Helper T cells (CD4+) 
assist and regulate other immune cells (cytotoxic T cells, B cells, macrophages) in immunologic 
processes both through direct cell-cell contact and by secretion of cytokines that govern the 
immune response
20
.  At one time, helper T cells were considered to be comprised of two subsets, 
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Th1 or Th2, each with distinct patterns of cytokine secretion
21
.  The Th1 subset is marked by 
production of interferon-γ (IFNγ) and aids in defense against intracellular bacteria while, Th2 
cells produce predominately interleukin-4 (IL-4) and aid in defense against parasites
20
.  RA and 
other forms of autoimmunity were thought to be mediated primarily by Th1 cells and IFNγ22.  
However, the concept that Th1 cells were key to autoimmunity was later shown to be flawed as 
anti-IFNγ antibodies exacerbated mouse models of autoimmunity, including collagen-induced 
arthritis (CIA) a model of RA 
23,24
.   
 
A primary reason that RA was thought to be a Th1-mediated disease was that Th2 cytokines, 
such as IL-4, suppress animal models of arthritis 
25
.  This suppression was thought to act through 
IL-4 down regulation of IFNγ.  However, more recent evidence indicates that IL-4 instead acts 
by suppressing production of IL-17, a cytokine produced primarily by a third subset of helper T 
cells known as Th17 cells that were discovered in 2005 
26,27
.  Murine dendritic cells (DCs) 
modified to express IL-4 were shown to suppress CIA in mice, not through an effect on IFNγ, 
but rather by suppressing production of IL-17
28
.  Another cytokine that is part of the Th1/IFNγ 
pathway is IL-12.  IL-12 is a crucial facilitator of Th1 differentiation and is composed of the two 
subunits IL-12p35 and p40.  Anti-IL-12 antibodies suppressed mouse models of arthritis; 
however, later studies showed that the observed improvement occurred as a consequence of the 
fact that the treatments targeted the IL-12p40 subunit that is shared with IL-23 (a cytokine 
known to support Th17 expansion)
23
.  Hence, the anti-inflammatory effects attributed to and 
effect of IL-12 on Th1 differentiation was actually mediated through a suppression of the IL-23-
driven up-regulation of Th17 cells.  Moreover, IL-17 is essential for multiple mouse models of 
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RA
8,23,29,30
.  For example, CIA was significantly suppressed in IL-17 knockout mice
30
.  These 
data suggests that Th17 cells and IL-17, rather than Th1 cells and IFNγ, play a key role in CIA. 
 
Refinement of our understanding of the roles of T cell subsets in RA animal models has 
redirected the focus of inquiry toward the Th17/IL-17 pathway in human RA.  IL-17 is up-
regulated in human RA serum and synovial fluid samples
31–33
.   Th17 cells are more numerous in 
the peripheral blood of early RA patients versus osteoarthritis (OA) or healthy controls and the 
numbers were even higher in the synovium of RA patients than in the blood.  In addition, 
decreased numbers of Th17 cells were found in patients who respond to treatment versus 
nonresponders
34
.  
 
The mechanism of action for Th17/IL-17 in RA is complex, and multiple relevant functions have 
been identified that may potentiate RA.  IL-17 can stimulate production of other cytokines that 
are pathogenic in RA, such as tumor necrosis factor α (TNFα) by APCs and IL-6 by FLS23,35.  
TNFα is a cytokine that has been strongly implicated in the pathogenesis of RA, and is 
significantly elevated in RA synovial fluids
36
.  Indeed, the positive response observed in RA 
patients treated with anti-TNFα therapeutics convincingly supports a role for TNFα in the 
disease process
37,38
.  IL-6, along with transforming growth factor-β (TGFβ), is critical for Th17 
differentiation and other pro-inflammatory processes, such as B cell proliferation and antibody 
production
39
.   
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IL-17 itself can increase joint destruction
32
.  It acts directly on chondrocytes (cartilage cells) and  
osteoblasts (bone producers) to up-regulate RANK ligand which promotes osteoclastogenesis 
(formation of bone destroying cells) leading to joint destruction 
32
.  In RA synovial explants the 
most effective strategy to inhibit inflammation and the capacity for tissue destruction was 
combination blockade of TNFα, IL-1, and IL-17 40.  However, even when TNFα or IL-1 are 
inhibited, IL-17 can act independently in mechanisms relevant to RA pathology 
8,41
.  This makes 
IL-17 an attractive therapeutic target in RA, especially for patients in whom the TNFα blockers 
are ineffective.  The newer discoveries concerning Th17 cells also underline the need for a better 
understanding of the mechanisms underlying joint inflammation, including interactions of T cells 
with synovial cells such as FLS. 
 
Fibroblast-Like Synoviocytes 
RA synovium is primarily comprised of monocyte/macrophage-like synoviocytes (type A) and 
fibroblast-like synoviocytes (type B)
42
.  Fibroblast-like synoviocytes (FLS) are a structural 
component of the synovium and play several key pathogenic roles in RA
43
.  In RA FLS undergo 
extensive hyperplasia, thereby expanding the synovial tissue.  This proliferation of FLS, 
combined with increased monocyte/macrophage and lymphocyte ingress and angiogenesis, leads 
to the formation of pannus tissue
44
.  This pannus migrates within the joint over cartilage and 
bone where it actively participates in tissue destruction 
44
.  An essential part of pannus 
development is the formation of three-dimensional sheet-like aggregates of FLS.  These FLS 
sheet-like formations are also important to normal joint architecture 
44
.  Cadherin-11 is one 
molecule that is crucial to the formation of these sheet-like structures 
44,45
.  Cadherin-11 plays an 
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important role in FLS adhesion in both normal synovial lining and RA synovium 
44,46,47
.  
However, Cadherin-11 has also been shown to mediate inflammatory and pathogenic properties 
of FLS in RA.  Cadherin-11 null mice developed a disorganized synovium, and  are resistant to 
development of inflammatory arthritis with decreases in FLS migration, FLS invasion, and 
destruction of cartilage
47
.  Anti-Cadherin-11 also showed therapeutic benefit in a serum-induced 
inflammatory arthritis mouse model (K/BxN model) 
47
.  These data support an important role for 
cadherin-11 in joint destruction in RA.  Basic fibroblast growth factor (bFGF) is another 
molecule linked to FLS proliferation and RA pathogenesis.  bFGF increases telomerase activity 
and decreases Fas-mediated apoptosis in RA FLS leading to aberrant persistence and overgrowth 
of FLS
48
.  A variety of molecules, such as cadherin-11 and bFGF, along with metalloproteinases, 
adhesion molecules, and growth factors have been linked to FLS growth and migration
49–51
.  
While our knowledge of FLS is expanding, the understanding of how FLS interact with each 
other, proliferate to form the pannus, and migrate through the joint, instigating cartilage and bone 
destruction, is still incomplete.  Another question to be asked is: what other molecules can affect 
FLS growth and migration through either paracrine or autocrine mechanisms? 
 
Initial theories of FLS involvement in RA purported that FLS pannus formation and FLS 
pathogenic activity were primarily initiated by the surrounding inflammatory milieu from 
immune cells; however, it has become apparent that FLS play a more active role in 
inflammation.  RA FLS maintain a pro-inflammatory, invasive, and aggressive growth 
phenotype in vitro indicating a more permanent pathogenic program of gene expression in the 
RA FLS
39,43,52–54
.  FLS are even capable of spreading arthritis.  In an immunodeficient (SCID) 
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mouse model, implanted RA FLS migrated from one piece of implanted cartilage to a distant 
cartilage implant and initiated destruction 
55
.   
 
A major question that remains is how do the FLS become activated and develop this pathogenic 
phenotype?  One potential mechanism for FLS activation is through pattern recognition receptors 
(PRRs), such as Toll like receptors (TLRs).  FLS express TLRs which can respond to pathogen 
associated molecular patterns (PAMPs) or damage associated molecular patterns (DAMPs) 
resulting in initiation of an inflammatory process.  TLRs are proteins that function as part of the 
innate immune system, and signaling through TLRs results in activation of cells and production 
of proinflammatory mediators.  Rather than recognizing specific peptide sequences presented by 
MHC, as the TCR does, TLRs recognize molecular patterns such as double-stranded RNA 
(viruses) or bacterial components such as lipopolysaccharide (LPS).  PAMPs are molecular 
patterns that are found on pathogens, such as viruses, fungi, or bacteria, while DAMPs are host-
derived molecular patterns that occur with cell damage or death.  DAMPs often involve the 
presence of self-molecules where they are not normally located, such as nuclear proteins or DNA 
outside the nucleus.  FLS express the TLRs 2, 3, 4, 5, and 9 
56–58
.  Activation of TLRs on the 
FLS can result in production of proinflammatory cytokines, chemokines, and angiogenic factors.  
For example, one study showed activation of FLS leading to production of IL-6, IL-8, matrix 
metalloproteinase-1 (MMP1), and MMP3 in the presence of TLR2,3,4, and 5 ligands 
57
.  Another 
study showed that stimulation of FLS with TLR2 or TLR4 ligands followed by co-culture with 
monocytes induced high levels of receptor activator of nuclear factor κ B (RANK), MMP9, and 
other factors that lead to osteoclast differentiation
59
.  It is uncertain however whether similar 
activation occurs naturally in RA.   While bacteria have been found in some arthritic joints, 
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DAMPs are a more likely source of TLR activation in the synovium as cellular damage would be 
found much more frequently.  One study proposed necrotic cells in the joint as a possible source 
of TLR ligands.  This study showed that stimulation of TLR3 on FLS by RNA from necrotic 
cells induced FLS to produce IFNβ, CXCL10, CCL5, and IL-6 56.  In addition to independent 
functions for FLS in RA, FLS also interact with other cells in the synovium, both through 
secreted factors and direct cell-to-cell contact.  Co-culture of monocytes with RA synoviocytes 
resulted in a synergistic increase of IL-6, IL-8, granulocyte-macrophage colony-stimulating 
factor (GM-CSF), and leukemia inhibitory factor (LIF).   IL-6 production in the co-cultures was 
further enhanced by stimulation with IL-1β, GM-CSF, IFNγ, or TNFα60.  The enhancement with 
T cell-derived cytokines indicates that T cells also likely impact monocyte-synoviocyte 
interactions in the RA joint.  Overall, FLS are central to multiple mechanisms in RA pathology 
acting both as a distinct pathogenic cell type and in co-operation with other inflammatory cell 
populations. 
 
FLS/T cell interactions 
A central paradigm of immunology involves the interaction between T cells and antigen 
presenting cells (APCs) resulting in T cell activation and an immune response.  While 
professional APCs (such as monocytes and dendritic cells) are present in the RA joint and 
undoubtedly play a role in pathogenesis, there is also increasing interest focused on interactions 
between T cells and cells that are not considered classic immune APCs.  FLS are a tissue-
specific cell type that can interact with T cells in multiple ways.  FLS can act as APCs, 
expressing MHC and presenting epitopes to the T cell receptor 
8,45
.  While FLS do not express 
10 
 
the canonical CD80/CD86 (B7-1/B7-2) co-stimulation molecules, they do express many surface 
structures that can engage corresponding T cell receptors/ligands and induce T cell activation in 
vitro
8,10
.  B7-H3, a molecule similar to CD80 and CD86, has been found to be highly expressed 
on FLS and to localize to the point of T cell-FLS interaction
10
.  However, the T cell ligand for 
B7-H3 remains undefined.  CD6 expressed on T cells is another potential co-stimulatory 
molecule and can bind to CD166/ALCAM and at least one other ligand on FLS
61,62
.  Cytokines 
also play a key role in FLS/T cell interactions.  RA FLS also produce IL-15 which up-regulates 
IL-17 and TNFα production by T cells 63.   
 
T cells can also activate FLS leading to FLS proliferation 
45
.  Even resting T cells have been 
shown capable of activating FLS, leading to secretion of IL-6, IL-8, and PGE2 with further 
increases in activation seen with addition of IL-17 
64
.   FLS activation can often function in a 
pro-inflammatory cycle through up-regulation of chemokines from the FLS.  For example, co-
culture of RA FLS and CD4+ T cells resulted in an increase in SDF-1/CXCL12 (a T cell 
chemokine) production by the FLS.  This effect was inhibited by either anti-IL-17 or anti-CD40L 
with an additive effect when both were used, indicating both a cell contact and cytokine 
dependent activation 
65
.  This production of a T cell chemokine results in more T cells being 
brought to the joint.  This leads to further increases in inflammation, stimulation of the FLS by T 
cells, and increased production of chemokines, reinforcing the cycle.  While the initiating step in 
RA synovial inflammation is unknown, it is clear that FLS and T cell interactions in the joint 
support a pro-inflammatory cycle leading to RA pathology. 
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Aminopeptidase N/CD13 
 CD13 was first defined in 1984 as a marker for myeloid cells and leukemia cell lines in the 
report on the First International Workshop on Human Leucocyte Differentiation Antigens
66
.  
Human Aminopeptidase N was first cloned and sequenced in 1988 from intestinal microvilli
67
.  
In 1989, CD13 was identified as being identical to Aminopeptiase N by Look et al
68
.  
Aminopeptidase N/CD13 (EC 3.4.11.2) is a metallopeptidase of the M1 family and its enzymatic 
activity is dependent on zinc binding through a HELAH motif.  CD13 is a 130-150 kDa 
glycoprotein with multiple N and O glycosylation sites.  The 130kDa form is believed to be an 
intracellular precursor that is further modified to its final 150kDa state on the cell surface 
68
.  
Sequential immunodepletion suggests that within a population of CD13 molecules there is 
variability in the glycosylation states.  Different CD13 antibodies were able to recognize distinct 
isoforms of the metalloenzyme, but following deglycosylation multiple antibodies recognized all 
of the detectable CD13 
69
.  Since CD13 contains multiple glycosylation sites, with 25-30% of the 
molecular weight contributed by sugar molecules, this variability likely explains the different 
isoforms of CD13; however, there is no known difference in function for the different 
glycosylation states.  Structurally, CD13 is a type II transmembrane protein that exists primarily 
as a homodimer.  It has a short cytoplasmic tail (9 amino acids) and a helical membrane spanning 
region
68,70,71
.  CD13 is ubiquitously expressed and can be found on the cell membranes of many 
tissues and cell types, including cells relevant to RA, such as monocytes, fibroblasts, and 
endothelial cells. 
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CD13 is an exopeptidase that hydrolyzes the N-terminal amino acid of a substrate preferentially 
after a neutral amino acid (excluding bonds preceding proline).   The mechanism of cleavage 
suggested for CD13 is similar to that of thermolysin and other metallopeptidases
72
.  The two 
regions most crucial to enzymatic activity are the highly conserved HELAH and GAMEN 
domains; these two motifs are also commonly found in other metalloproteinases/peptidases.  The 
glutamic acid (E, Glu) in the GAMEN domain is critical for enzymatic activity, and along with 
the Glu in the HELAH domain and Zn+2 are believed to form a binding cleft for the substrate 
72
.  
The X-ray crystal structure of CD13 bound to one of its substrates, Angiotensin IV, confirmed 
that the Glu from the GAMEN domain along with a Glu just upstream of the HELAH domain 
participates in substrate binding, while the histidines (H, His) of the HELAH domain are 
involved in the binding of Zn+2  to the native conformation of CD13 
73
.  Antibodies that inhibit 
enzymatic activity bind to this area of Zn+2 binding, that is vital to enzymatic activity of 
CD13
74
.  CD13 contains six extracellular cysteines which are also important for CD13 function.  
Mutation of any of the six cysteines resulted in very low enzymatic activity and retention of the 
protein in the endoplasmic reticulum, and alteration of the thiol status by protein disulfide 
isomerase resulted in decreased aminopeptidase activity and altered antibody binding
75
.  This 
suggests that disulfide bonds are critical for the correct folding of CD13.  X-ray crystallography 
has also confirmed that CD13 exists primarily as a homodimer, with the two CD13 molecules 
surrounding an internal cavity forming the catalytic site 
73
.  This catalytic cleft, with its key 
regions HELAH and GAMEN, is a possible target for inhibition of CD13 enzymatic activity.   
 
CD13 expression is known to be regulated through multiple pathways.  First, CD13 has two 
promoter regions.  One promoter region controls transcription in epithelial/endothelial cells and a 
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second promoter controls transcription in myeloid and fibroblast cells 
76,77
.  While the two 
promoters result in different length RNA sequences, the resulting protein is the same.  Second, 
CD13 is regulated by a variety of cytokines and other factors in various cell types.  One of the 
first identified roles for CD13 was as a myeloid maker.  CD13 was later shown to be upregulated 
with myeloid activation and differentiation; although, it is also present on resting myeloid cells
78
.  
It is upregulated on monocytes in response to IFNγ or LPS, in parallel to MHC class II 
upregulation and increases as monocytes transition to macrophages 
78
.  TGF-β also increased 
CD13 on monocytes and monocytic cell lines 
79
.  Other studies showed that fetal bovine serum 
(FBS), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF) 
could induce augmented CD13 expression by an endothelial cell line, while dermal fibroblasts 
increased CD13 expression in response to IL-4 and IFNγ 80,81.   Gingival fibroblasts upregulated 
CD13 in response to IL-4 as well as IL-13, but CD13 expression was unaffected by IL-2 and IL-
15 
82
.  In thyroid carcinoma cells CD13 was up-regulated by epidermal growth factor (EGF), IL-
6, TNFα, and bFGF 83.  However, differences in regulation between different cell types have 
been observed.  Dermal fibroblasts did not increase surface expression of CD13 with either 
TNFα or TGFβ 84.  This is in contrast to myeloid cells in which TGFβ up-regulated CD13 and 
thyroid carcinoma cells in which TNFα up-regulated CD13.  This may indicate a difference in 
regulation on different cell types, a concept which is supported by the presence of two different 
promoters.   
 
A third possible source of regulation involves cellular localization of CD13.  CD13 trafficking to 
the cell surface and its cellular recycling back into the cell has been proposed as another 
mechanism of regulation 
85
.  On FLS and monocytes, CD13 is found on the surface in caveolae 
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lipid rafts 
86,87
.  Caveolae lipid rafts are cholesterol rich domains that contain caveolins.  The 
rafts can aid in keeping proteins proximate to each other, and the inclusion of caveolins can lead 
to cellular internalization of the rafts and associated proteins.  However, CD13 localization is not 
limited to the cell surface.  CD13 is also known to exist as in a soluble form (sCD13).  sCD13 
has been identified by Western blot and by assay of its enzymatic activity in human serum and 
tumor effusions
88,89
.  CD13 identified in human serum is shorter than surface CD13.  Two 
isoforms have been identified in normal serum.  The major isoform lacks the amino acids 1-58, 
and the minor isoform lacks amino acids 1-43 
90,91
.  Both isoforms notably lack the intracellular 
region, amino acids 1-9, and the transmembrane domain, amino acids 9-32
90
.  The release of 
CD13 by cells presents another possible site of CD13 regulation.  A study examining the role of 
IFNγ regulation of CD13 on the monocytic cell line HL-60 suggests that cytokines may have a 
more complex role in CD13 regulation than initially thought.  Surface expression was initially 
down regulated at 24 and 48 hours and later up-regulated at 72 and 96 hours.  A peak mRNA 
expression was observed at 72hours, and the up-regulation could be blocked by the inhibition of 
de novo protein synthesis 
92
.  However, as this study only examined surface CD13 and mRNA 
for CD13 it doesn’t fully explain this observation.  One possible explanation is that IFNγ is 
initially promoting release of CD13 from the cell surface with later replenishment and 
upregulation of CD13 on the surface by protein synthesis.  Multiple questions remain about 
soluble CD13, including how sCD13 is released from cells and how this process is regulated. 
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CD13 Functions  
CD13 is known to have a wide range of functions.  CD13 has many known biological substrates 
including enkephalins (opioid receptor ligands), angiotensins (hormones that cause 
vasoconstriction), neurokinins (neurotransmitters), chemokines, and cytokines
70,93–96
.  CD13 is 
ubiquitously expressed in the body on immune cells, skin, intestinal epithelium, brain, joints, and 
many other tissue and cell types.  CD13’s biological functions vary depending on where it is 
expressed.  For example, CD13 is involved in antigen processing by trimming peptides for 
presentation on MHC class I and II 
70,76
.  In the central and peripheral nervous system, CD13, 
along with neutral endopeptidase/CD10, can degrade enkephalins, thereby lowering the analgesic 
effects of these molecules.  Therefore, inhibition of CD13 has been targeted in controlling pain
97
.  
It has been suggested that CD13 can play a role in both cholesterol crystallization and cholesterol 
uptake 
98,99
.  CD13 is also a known receptor for NGR peptides (Asparagine-Glycine-Arginine) 
and for viruses, including coronaviruses and cytomegaloviruses
100–102
.  CD13 is expressed in 
higher amounts on highly phagocytic cells, and it has been demonstrated that CD13 aids in 
phagocytosis on these cells
103
.  One  possible mechanism for this observed function is its 
association with Fcγ receptors, which aid in phagocytosis of particles104.   
 
Several putative functions for CD13 involve its association with other molecules.  CD13 
frequently works together with other peptidases, especially CD10 and CD26/dipeptidyl peptidase 
IV.  Cooperation of CD13 with CD10 and/or CD26 aids in the degradation of proteins/peptides, 
and all three molecules are present in lipid rafts
86
.   CD26 is also expressed on FLS and has been 
linked to RA (and murine RA models) through putative effects on FLS invasion and T cell 
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proliferation.   However, this work has mostly been done with enzymatic inhibitors
105–107
.  CD26 
removes dipeptides preferentially with proline (and less efficiently alanine) in the penultimate 
position.  When combined with CD13, which cannot degrade proteins with proline in the 
penultimate position, this allows for degradation of a large number of peptides/proteins
108
.  The 
presence of other peptidases may also be a point of regulation for CD13.  While a combination of 
CD13 and CD26 was shown to cleave substance P (a neurokinin) in mice, substance P was 
shown to inhibit either purified porcine CD13 or CD13 on a leukemic cell line
109,110
.  While this 
may be due to differences between species, the more likely explanation is the presence of a 
proline in the penultimate position at the amino end of substance P.  When only CD13 is present, 
the enzymatic activity is inhibited because CD13 cannot degrade past the proline; however, with 
both CD13 and CD26 substance P is efficiently degraded.  Dual inhibition of CD13 and CD26 
delays disease onset and decreases severity of experimental autoimmune encephalomyelitis 
(EAE) and ameliorates disease activity in the sodium dextran sulphate mouse colitis model
111,112
.  
This dual inhibition likely alters the profile of cleavage targets and the end products.  For 
example, substance P, while primarily a neurotransmitter, can activate immune cells and 
putatively mediate inflammation
113
.  However, while this treatment is useful in mouse models it 
doesn’t address CD13 functions, and possibly CD26 functions, independent of the enzymatic 
activity. 
 
While CD13 function has been linked primarily to its enzymatic activity, the protease can exert 
biological effects independently of its enzymatic activity.  While CD13 has a very short 
cytoplasmic tail (9aa), it does have the ability to trigger intracellular signaling
114
.  Antibody 
crosslinking of CD13 on the surface of monocytes leads to the phosphorylation of the 
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intracellular signaling molecules MPK, extracellular-signal-regulated kinases-1 and 2 (ERK1/2), 
c-JUN N-terminal kinase (JNK), and p38.  Crosslinking can also induce a Ca
2+
 flux and 
homotypic monocyte aggregation 
85,114
.  Signal transduction is also important in CD13-mediated 
monocyte-endothelial cell adhesion which is crucial to monocyte invasion during 
peritonitis
115,116
.  Adhesion and migration of the monocytes is dependent on CD13 expression by 
both the monocytes and the endothelial cells
116
.  This indicates that CD13 may be involved in 
cellular interactions through self-adhesion/association.  These data demonstrate a mechanism of 
CD13 mediated intracellular signaling where association of multiple CD13 molecules (through 
cell/cell adhesion or crosslinking) induces signal transduction cascades critical to effective cell 
function.   
 
Dermal fibroblasts demonstrate another mechanism of CD13 mediated cellular signaling.  
Knockdown of CD13 on skin fibroblasts blocked p38-dependent induction of expression of 
MMP1 by stratifin (14-3-3-sigma, a protein released by keratinocytes (cells of the epidermis) 
which strongly promotes MMP1 on fibroblasts) 
117
.  Furthermore, dermal fibroblasts treated with 
keratinocyte conditioned medium showed differences in extra cellular matrix (ECM)-related 
protein mRNA when CD13 was knocked down.  Decreases were seen in MMP1, MMP3, 
MMP12, tenascin-C, integrin alpha 1,  and catenin alpha 1, and increases were seen in 
fibronectin, SPOCK, and integrin alpha 3 
118
.  While knock down of the CD13 protein elicited 
these effects, treatment of the cells with the enzymatic inhibitor, bestatin, had no effect 
118
.  
These studies suggest another signaling role for CD13 independent of its enzymatic activity.  
The short cytoplasmic tail does not have any signaling motifs; therefore, it can be hypothesized 
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that these signaling events occur through CD13 interaction with a secondary protein.  The 
identity of this associated protein remains unknown.   
 
Many suggested functions of CD13 are disease associated, especially in cancer.  CD13 is over 
expressed on tumor cells, where it is known to be involved in angiogenesis and metastasis.  
Angiogenesis is the formation of new blood vessels from existing blood vessels and can be seen 
in most types of tissue outgrowth (such as wound healing, tumor growth, or RA hyperplasia) to 
feed the newly forming tissues.  In solid tumors, endothelial cell-associated CD13 was identified 
on newly forming capillaries.  CD13 expression was specific to endothelial cells undergoing 
angiogenesis (although not just tumor angiogenesis) and was not found on established capillaries 
and only faintly in arteries 
102
.  One suggested mechanism for CD13 mediated angiogenesis 
involves binding of galectin-3 (a pro-angiogenic molecule) to CD13 carbohydrate motifs on 
endothelial cells
119
.  While Petrovic et al implicated enzymatically active CD13 in membrane 
organization and filopodia formation in bradykinin-mediated angiogenesis
120
.  These two studies 
present different mechanisms by which CD13 may mediate angiogenesis; however, the exact 
process remains unknown.  The first proposed mechanism is independent of enzymatic activity 
while the second mechanism is dependent on enzymatic activity.  It is possible that CD13 is 
playing multiple roles in angiogenesis which may be dependent on other angiogenic molecules.   
 
CD13 has also been implicated in tumor migration and adhesion.   In melanoma cell colonies 
CD13 relocates to sites of cell-cell contact and associates with ECM components
76
.  CD13 has 
also been shown to aid in the migration of tumors through ECM (using various metastatic tumor 
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lines)
76
.  A third potential role for CD13 in tumors relates to cell proliferation and resistance to 
apoptosis
121
.  Inhibition of CD13 as a strategy to treat cancer has encompassed study of a wide 
variety of both natural and synthetic enzymatic inhibitors
122
.  To summarize, CD13 has been 
commonly found in tumors and is believed to have a role in cancer pathogenesis with putative 
functions in angiogenesis, tumor cell migration, invasion into host tissues, aberrant outgrowth of 
tumor cells, and tumor cell resistance to apopotosis.  Some of these processes parallel important 
components of the behavior of synovial cells in RA. 
 
There are problems however with many CD13 studies involving angiogenesis, proliferation, and 
migration.  One major problem with most of these studies is that they have been done with the 
chemical inhibitor, bestatin (or occasionally other chemical inhibitors).  There is evidence, 
however, that bestatin is not specific for CD13 and may also inhibit cell proliferation 
independently of CD13 
123
.  It is also possible that the chemical inhibitors may lead to apoptosis, 
although not necessarily through CD13 targeting.  Bestatin and actinonin (a second CD13 
inhibitor) prompted an increase in leukemic cell line apoptosis, but the apoptosis was not directly 
related to CD13 as an anti-CD13 antibody with enzyme inhibitory activity did not exert similar 
results 
124,125
.  Studies with anti-CD13 antibodies do support a role for CD13 in cell proliferation 
and survival, but the mechanisms surrounding the effects of CD13 inhibition (chemical or 
antibody mediated) on proliferation and resistance to apoptosis remain poorly understood 
85
.  
Another issue is that this work has been done primarily in tumor cell lines, and as such, the 
biologic significance under in vivo conditions is uncertain.  However, the data from cancer 
studies may be suggestive of similar roles in cell types and biologic functions outside of tumors.  
For example, the RA disease process is also associated with angiogenesis, aberrant cell 
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migration/invasion, and excessive cell proliferation.  As CD13 can be found on both cancer cells 
and FLS another question is: can CD13 play similar roles in FLS migration and growth as it does 
in cancer?   
 
While cancer is the most studied disease in connection to CD13, CD13 has reputed roles in 
several other human diseases, including inflammatory and/or autoimmune processes (e.g. 
multiple sclerosis, inflammatory bowel disease, psoriasis, and chronic graft-versus-host 
disease)
126–129
.  One study showed increased expression of CD13 on the surface of peripheral 
blood monocytes from patients with active multiple sclerosis (MS) compared to either MS in 
remission or non-inflammatory neurological diseases 
126
.  CD13 has also been linked to 
inflammatory bowel disease (IBD).  CD13 has been suggested as the link between human 
cytomegalovirus (HCMV) infections and IBD
127
.  Many IBD patients have active HCMV 
infections, and CD13 is a known receptor for cytomegaloviruses 
100,130
.  Rahbar et al showed the 
presence of cytotoxic anti-CD13 autoantibodies in the serum of a majority of IBD patients 
127
.  
However, it has not been shown that these antibodies contribute to pathogenicity.  Also, the 
concept that IBD is related to IBD is still controversial
131
.     
 
CD13 has also been found in skin cells, especially on dermal fibroblasts and keratinocytes, and it 
has been implicated in a variety of skin conditions including psoriasis, acne, and wound 
healing
132
.  CD13 inhibitors help slow proliferation and promote accurate differentiation of 
fibroblasts and keratinocytes in a mouse tail model of psoriasis
128,132
.  Another study found that 
anti-CD13 antibodies inhibited migration of dermal fibroblasts in wound healing
133
.  Since 
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effective wound healing requires keratinocyte migration, while excessive fibroblast migration 
can lead to ineffectual wound healing and scar formation, this indicates CD13 expression may be 
important in regulating wound healing.  The same group went on to show that topical anti-CD13 
antibodies accelerated wound closure
134
.  Though not examined, topical CD13 inhibition may 
also be a potential strategy in psoriasis treatment.   
 
Chronic graft-versus-host disease (cGVHD) is another immune-mediated condition with which 
CD13 is associated.  Soluble CD13 and anti-CD13 antibodies have been found in plasma from 
patients with cGVHD
129,135–137
.  Similar to the IBD studies, a link between HCMV infection and 
GVHD has been hypothesized.  Transplant patients were tested for anti-CD13 antibodies and 
HCMV.  All patients with anti-CD13 antibodies were shown to have cytomegalovirus (CMV) 
viremia or CMV disease (although not all CMV infected patients had anti-CD13 antibodies), and 
all of the patients with anti-CD13 antibodies later developed cGVHD 
136
.  A study by another 
group showed that sCD13 enzymatic activity was significantly increased in early cGVHD; 
however, there was no apparent connection between the sCD13 and the anti-CD13 antibody in 
cGVHD
135,137
.  Protein levels of sCD13 were also shown to be significantly elevated in sera of 
cGVHD patients.  It was also noted in this study that higher CD13 levels were found in patients 
in whom the cGVHD involved the liver
129
.  While these data show a strong relationship between 
CD13 and cGVHD, the function for CD13 in cGVHD remains undetermined.  Overall, these 
data implicate CD13 in autoimmune diseases and inflammatory functions. 
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It is interesting, though, to note that not all studies involving CD13 point to a pro-inflammatory 
role.  The preponderance of evidence in either mouse models or in vitro cell studies indicates a 
role for CD13 in inflammation, in experiments that employ  either anti-CD13 antibodies or 
CD13 enzymatic inhibitors, as discussed above.  However, a study using CD13 knockout (KO) 
mice showed no difference in four models of inflammation (dextran sodium sulfate colitis, 
collagen antibody-induced arthritis, thioglycollate-induced peritonitis, and croton oil-induced 
contact hypersensitivity) with a lack of CD13 
138
.  However, these systems tend to focus on the 
involvement of neutrophils, mast cells, or monocytes and are not necessarily appropriate models 
for lymphocyte driven diseases, like RA.  Despite this caveat, other studies have demonstrated 
that CD13 may not be entirely pro-inflammatory.  The steroid dexamethasone increases surface 
CD13 enzymatic activity on dermal fibroblasts in a protein synthesis dependent manner 
81,139
.  
As steroids are anti-inflammatory this indicates CD13 may in some way be involved in an anti-
inflammatory pathway.  Furthermore, the production of pro-inflammatory cytokines (IL-1 and 
IL-2) were increased in splenocytes when mice were treated with the CD13 inhibitor bestatin, 
suggesting a potential suppressive role for CD13 in regulating inflammatory responses 
140
.  
These three studies are suggestive of anti-inflammatory CD13 properties.  While several 
processes that involve CD13, such as angiogenesis and monocyte migration, are inflammatory 
(as previously discussed), the cytokine regulation pattern related to CD13 is mixed.  Both pro-
inflammatory cytokines, such as TNFα and IFNγ, and anti-inflammatory cytokines, such as IL-4 
and TGFβ, can up-regulate CD13.  Altogether these data are interesting as they suggest a 
complicated role for CD13 in inflammatory conditions.    
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CD13 on T cells 
CD13 has been linked to various autoimmune diseases, but the mechanisms by which CD13 may 
mediate inflammation/pathogenesis are poorly understood.  Some proposed mechanisms involve 
CD13 functions on T cells, but there is debate regarding the presence of CD13 on T cells.  
Generally, it is accepted that mature lymphocytes (peripheral blood, splenic, tonsillar) are CD13 
negative, although there are also reports of aminopeptidase activity on T cells
76,141
.  T cells at the 
early stages of development, such as thymic stem cells and multipotent thymic progenitors, are 
CD13 positive but T cells lose CD13 expression as they mature
142
.  However, CD13 expression 
has been reported on T cells from disease fluids
143,144
.  For example, T cells from the synovial 
fluid of RA or juvenile chronic arthritis as well as pericardial fluid from cardiac disease patients 
were positive for CD13 by flow cytometry, thereby supporting the hypothesis that CD13 can be 
induced on activated T cells
143,144
.  The best evidence so far indicates cell-cell contact between T 
cells and CD13 expressing cells (such as fibroblasts, synoviocytes, monocytes/macrophages) is 
necessary for this induction of CD13.   
 
One study found CD13 mRNA to be upregulated in tonsillar T cells when incubated with 
mitogens, but did not see a corresponding increase in cell surface CD13
145
.  Only when the cells 
were incubated with CD13
+
 cells (including FLS, macrophages, human vascular endothelial cells 
[HUVECs], or cancer cell lines) was CD13 expression seen; furthermore, addition of mitogens 
could further increase this expression.  This study suggests that CD13 itself may be involved in 
the induction.  Further studies narrowed the mechanism of expression by showing that membrane 
fractions from FLS could induce CD13 mRNA in T cell cultures, while an aminopeptidase 
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activity inhibitor, actinonin, inhibited this mRNA induction 
145
.  Moreover, both membrane 
fractions and fixed FLS induced CD13 mRNA and protein on T cells, but soluble CD13 or 
separation of T cells and FLS by a membrane did not induce T cell CD13 
146
.  This indicates that 
cell-cell adhesion signals are necessary for induction of CD13 by T cells, and it is likely that both 
CD13 and a secondary cell surface molecule are needed.  And while the T cells take an active 
role in this process, the CD13-presenting cells do not.  In contrast, another study claims to have 
found CD13 on resting lymphocytes which was upreglated by concanavalin A, while another 
paper showed CD13 on T cells after mitogen activation
147,148
.  The first paper found CD13 
positive T cells by double staining and flow cytometry as well as the use of the CD13 enzymatic 
inhibitor probestin
147
.  However, the antibodies employed in this study are not commonly used 
and are perhaps inadequately tested.  Furthermore, this data was not confirmed by other groups 
using different antibodies
146
.  The antibodies that were used showed only about 60% of 
monocytes as CD13 positive, while other antibodies typically show all monocytes as CD13 
positive
147
.  The study also showed that probestin only partially inhibited CD13-like activity in 
their samples, indicating that either the enzymatic activity assay or the inhibitor or both are not 
CD13 specific.  A second paper, by the same group, showed CD13 on the surface of mitogen, 
phytohemagglutinin-L (PHA-L)/phorbol myristate acetate (PMA), stimulated T cells using the 
more commonly used WM15 antibody.  In this study they found that the surface expression was 
inhibited by protein synthesis inhibitors
148
.  Another study indicated that the T cell lines HuT78 
and H9 have CD13 mRNA and enzymatic activity, but did not show the presence of CD13 
protein
149
.   
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Some of the differences between studies could be explained by the use of different antibodies, 
differences in sensitivity of assays, or differences in how CD13 was measured (protein blots 
versus mRNA).  It is possible that molecules similar to CD13 are present on activated T cells and 
are detected in the various assays, especially the aminopeptidase activity assays.  One possibility 
is that since CD13 mRNA has been found by some groups in mature lymphocytes, either the 
protein is not efficiently made in T cells or  a form of CD13 not recognized by all antibodies is 
on T cells (for example a differently glycosylated form).  Another possibility could be in the 
differences in T cell isolation and purity.  It is possible that if a higher number of CD13 
expressing monocytes remain in the T cell experimental population (in the mitogen only studies) 
the CD13 seen on the T cells is actually being induced through the combination of stimulus with 
cell-cell contact with the monocytes.  Overall the best evidence seems more in support of T cells 
only expressing CD13 after cell-to-cell contact with CD13 positive cells.   
 
Chemotaxis 
Chemotaxis is the directed movement of cells toward a chemical signal.  It is a crucial part of 
immune function that directs movement of cells into immune tissues, such as lymph nodes, and 
to sites of infection or damage
20
.  Chemotaxis is a key component of inflammatory disease 
pathology, including RA.  It is central in bringing immune cells (monocytes, T cells, B cells, 
neutrophils) into the joint to mediate disease development
150
.  Chemotaxis includes 4 main steps: 
rolling/tethering, activation, firm adhesion, and transmigration
20
.  This migration typically 
involves a combination of adhesion molecules and chemokines.  Chemokines are a group of 
cytokines that induce directed chemotaxis 
20
.  In response to a chemokine gradient, responding 
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leukocytes establish transient interactions with the blood vessel wall and display a rolling 
behavior mediated by loose coupling between adhesion molecules on leukocytes and endothelial 
cells.  Then, cell interactions with a chemokine activate the cell in a manner that leads to firm 
adhesion between adhesion molecules.  Once cell movement along the vessels is arrested, the 
responding cell migrates between endothelial cell junctions and moves into the tissue.  
Chemokines and other chemotactic molecules help direct the cells during rolling and allow them 
to arrest movement at the site of infections/inflammation; as well as, aiding in migration into and 
through the tissue
151–153
.  Chemokines are a set of small proteins divided into CXC, CC, C, and 
CX3C families.  They function primarily by binding to members of the chemokine receptor 
family (CXCR, CCR, CR, and CX3CR).  Several chemokines have been identified in the RA 
joint including IL-8/CXCL8, ENA-78 (epithelial-derived neutrophil-activating peptide-
78)/CXCL5, RANTES (regulated on activation, normal T cell expressed and secreted)/CCL5, 
MIP-1α (macrophage inflammatory protein-1α)/CCL3, SDF-1 (stromal cell-derived factor-
1)/CXCL12, and fractalkine/CX3CL1
152
.  Chemokines in the joint are produced primarily by 
FLS and monocytes, and production is often up-regulated by pro-inflammatory molecules such 
as TNFα, IL-1, or IFNγ.   
 
The second component of chemokine function is the chemokine receptor, a superfamily of G-
protein-coupled receptors.  There are 19 known major chemokine receptors, each with a common 
seven-transmembrane motif coupled to an internal G-protein and a flexible N-terminal region
154
.  
The identity of the cell types responding to a given chemokine gradient is dictated by the pattern 
of chemokine receptor expression.  While neutrophils, monocytes, and lymphocytes each express 
distinct patterns of chemokine receptors, chemokine receptor expression can be further fine-
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tuned even within subclasses of immune cell populations.  For example, Th1 cells express 
CCR5, CXCR3, and CXCR6; Th2 express CCR3, CCR4, and CCR8; and Th17 express CCR4 
and CCR6 
151
.  While some receptor-ligand interactions are discrete, most receptors recognize 
multiple chemokines and many chemokines can bind to multiple receptors
154
.  This means that 
there may not be a direct correlation between specific chemokines and chemokine receptors.  
Nevertheless, many of the chemokine receptors found in the RA joint match to chemokines 
linked to RA.  Chemokine receptors that have been found on RA T cells include CCR4, CCR5, 
CXCR3, and CX3CR1
155
.  To complicate matters chemokine receptors can be either constitutive 
or induced
154
.  This may help explain a degree of variability seen in chemokine and receptor 
studies in RA, with differently activated cell states expressing different sets of receptors.  For 
example, CD4+ cytokine-activated T cells (Tck, produced by culture of resting T cells with a 
combination of TNFα+IL-2+IL-6) have increased expression of the chemokine receptors 
CXCR4, CXCR7, CXCR2, CXCR3, CCR5, CCR6, and CCR8 when compared to resting CD4+ 
T cells
156
.  This is one example which suggests that the complex milieu in the RA joint likely 
modulates the chemokine receptor profile of T cells. 
 
There is debate as to the identity of receptors that are critical to directing T cells into the RA 
joint.  Effector memory T cell clones (CD4+CD28-), generated from RA peripheral blood 
express CCR7, CCR5, and CXCR4, but while a subset migrated to RA synovium in an RA 
tissue- SCID mouse chimera the T cells preferentially migrated to the lymph nodes.  However, 
IL-12 treatment of the cells upregulated CCR5 and skewed the migration toward the implanted 
human synovium 
157
.  While these findings suggest that CCR5 is central to T cell migration in 
RA, these results stand in contrast to a study that  identified CXCR4 as the most common 
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chemokine receptor found on memory T cells isolated from RA synovial tissue 
158
.  The major 
chemokines for CCR5 and CXCR4, SDF-1 and RANTES respectively, have been detected in the 
RA joint, supporting a potential role for both receptors in RA
65,159
.  Though characterizing 
chemokine receptor expression in T cell populations harvested from RA synovial tissue or fluids 
can be informative, it is worth noting that chemokine receptor expression on circulating T cell 
populations may be different.  RA peripheral blood contains significantly higher numbers of T 
cells expressing CCR2, CCR4, CCR5, and CX3CR1 than does normal peripheral blood.  
However, T cells in synovial fluid expressed higher levels of CCR5 alone, while synovial tissue 
T cells were enriched for CCR4 and CXCR3 
155
.  These data may indicate different roles for 
chemokines in attracting cells to the synovium versus retaining the cells in the synovium.  While 
there are a variety of explanations for the differing results of these studies it is clear that 
chemotaxis in RA is a complex mechanism involving multiple chemotactic factors.   
 
While chemotaxis is the primary function of chemokines, these molecules can display multiple 
other functions in RA.  For example, IL-8 can induce synovial inflammation, and Groα/CXCL1 
can stimulate FLS proliferative responses
152,160
.  Multiple chemokines are also able to promote 
angiogenesis (IL-8, ENA-78, Groα, SDF-1, MCP-1)152,161.  Interestingly, RA FLS themselves 
can express chemokine receptors, e.g. CCR2, CCR5, CXCR3, and CXCR4.  Depending on the 
chemokines that bind to these receptors, both general and more specific cell responses can be 
elicited.  For example, MCP-1/CCR2, IP-10/CXCR3, SDF-1/CXCR4 induced FLS migration, 
proliferation, and collagenase activity, while RANTES/CCR5 only increased the collagenase 
activity 
162
.  Chemokines have also been linked to structural joint changes.  The chemokine, 
BCA-1/CXCL13, and its receptor, CXCR5, have been identified as a likely initiator of lymphoid 
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like germinal center formation in affected joints 
163
.  Given the range of chemokine-associated 
effects in RA, from classical functions in cell migration/infiltration to roles in stimulating and 
organizing cells within the diseased joint, these molecules have considerable potential as 
therapeutic targets. 
 
Overall current data shows that chemotactic molecules play important roles in perpetuating a 
pro-inflammatory loop in RA.  In this regard, cell-cell interactions between FLS and activated T 
cells increase chemokine production (IL-8, MCP-1, MIP-1α) by the FLS164.  Hence, chemokines 
produced by FLS trigger T cell infiltration into the joint, and T cells in turn stimulate the FLS to 
produce more chemokines.  Ultimately, this can result in a positive feedback loop reinforcing 
inflammation and RA progression.  An additional consideration is that while chemokines are the 
primary effectors of chemotaxis, other molecules can also display chemotactic properties.  For 
example, the activated complement factor, C5a, as well as lipids and carbohydrates can also 
direct immune cell chemotaxis
165
.  While a variety of chemokines and other molecules have been 
identified in RA, the key factors responsible for controlling T cell ingress and retention in the 
RA joint remain subject to conjecture and the possibility that other chemotactic molecules are 
involved in immune cell trafficking to the joint deserves additional consideration.  Could other 
molecules expressed in the RA synovium be contributing to T cell trafficking to the joint? 
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CD13 and chemotaxis 
In considering the potential identity of other chemotaxins operative in RA, it is interesting to 
note that CD13 has been implicated in chemotaxis in a variety of ways.  First, the chemokines, 
CXCL8/IL-8 and CXCL11/I-TAC, are known substrates of CD13.  In both cases, CD13 is 
known to degrade the respective chemokine, resulting in loss of chemotactic activity 
95,166
.  A 
second mechanism supports a role for CD13 in regulation of chemokine receptors, by down-
regulating CXCR4, thereby decreasing responses to CXCL12/SDF-1
167
.  While these data 
demonstrate negative effects of CD13 on chemotactic activity, CD13 may also promote 
chemotaxis.  Crosslinking CD13 on the surface of monocytes induces IL-8 mRNA expression 
while inhibiting CD13 enzymatic activity represses IL-8 production, although it is uncertain how 
this affects overall chemotaxis as CD13 can also cleave IL-8 to a less active form
114,168
.  In sum, 
these data point to a variety of indirect roles for CD13 in chemotaxis, but a more direct role for 
CD13 in chemotaxis has also been suggested.  Interestingly, purified human CD13 was shown to 
be chemotactic for T cells with a preference for CD4+ over CD8+ T cells
169
.  CD13 has been 
proposed as either a chemotatic molecule in-itself or as a regulator of other chemotactic 
molecules, but there are still many questions about the relevance of these roles in vivo.  Could 
CD13 be involved in the chemotaxis of T cells to the RA synovium? 
 
Metalloproteinases: MMPs and ADAMs 
Matrix metalloproteinases (MMPs), a family of zinc-dependent metalloenzymes implicated in 
matrix-remodeling events, were first discovered in 1962 with the characterization of the first 
mammalian collagenase
170
.   With the discovery of twenty or more structurally-related MMPs,  it 
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is recognized that these proteinases can be involved in a wide variety of functions, including 
cleavage of extracellular matrix (ECM) proteins, the processing of cytokines/chemokines, the 
activation of downstream targets (including other metalloproteinases), and participating in 
intracellular signaling 
171–175
.  It is commonly believed that MMPs play an important role in the 
joint destruction that characterizes RA.  FLS typically express several MMPs 
176,177
.  
MMP14/MT1-MMP is expressed in both the lining and sublining of RA joint synovium and is 
strongly expressed on RA FLS 
178
.  MMP16/MT3-MMP has also been identified in RA synovial 
tissue while MMP15/MT2-MMP and MMP17/MT4-MMP appear to be only marginally 
expressed in RA tissue 
178
.  The soluble MMPs MMP1, 2, 3, 8 and 9 were found in higher levels 
in synovial fluid from RA patients than OA patients, and mRNA of MMP1, 2, 13, 14, and 15 are 
expressed by stimulated RA synoviocytes 
49,179,180
.  However, another study did not find MMP15 
mRNA in RA, OA, or normal synovial tissue samples 
181
.  MMPs only represent a small 
subcategory of metalloproteinases, however, and other metalloproteinases are also found in the 
joint. 
 
Specifically, a disintegrin and metalloproteinases (ADAMs), another subfamily of 
metalloproteinases, have also been identified in synovial tissue 
182
.  ADAMs are a class of 
predominantly membrane bound metalloproteinases, many of which are known sheddases
183
.  
Some ADAMs are tissue specific (testis or brain) and/or do not have an active metalloproteinase 
site but several may be important in the joint including: ADAMs 8,9,10,12,15,17,19, and 33
183
.  
The mRNA of ADAMs 9, 10, 15, and 17 was found in most RA and OA synovial tissues while 
other ADAMs were expressed in lower numbers of samples.  Only ADAM15 was found to be 
expressed at significantly higher levels in RA over OA
182
.  In another study ADAM8 was found 
32 
 
in the RA pannus specifically next to erosions, and it was linked to osteoclastogenesis
184
.  
ADAM10 has also been found to be elevated in RA synovial tissue (versus OA or normal) both 
in the lining and on endothelial cells and has been linked to RA angiogenesis
185
.  These studies 
implicate ADAMs 8, 10, and 15 in RA disease pathology; however, other ADAMs may also be 
involved. 
 
Of the metalloproteinases, MMPs and ADAMs are the most commonly linked to RA.  The main 
role suggested for MMPs involves the degradation of ECM and the invasion of FLS.  Natural 
inhibitors of MMPs can inhibit FLS proliferation and invasion through either collagen or 
Matrigel (a mixed ECM substance), while ADAM15 has been directly linked to FLS apoptosis 
resistance 
186,187
.  ADAM17 and MMP8 shed lymphotoxin α1β2 (a pro-inflammatory mediator) 
which in turn binds to receptors on FLS and results in inflammation 
188
.  When MMPs and 
ADAMs become upregulated in the RA synovium these various functions may contribute to 
disease pathology. 
 
MMP14/MT1-MMP 
MMP14/MT1-MMP is expressed on a variety of cells including fibroblasts, 
monocytes/macrophages, dendritic cells, natural killer cells, and mast cells
189
.  One of the most 
studied targets of MMP14 is MMP2/gelatinase A (a soluble, type IV collagenase).  However, 
MMP14 can cleave many substrates, including ECM components (such as collagen, gelatin, and 
fibrin) as well as a variety of non-ECM targets associated with inflammatory events including, 
pro-TNFα, CD44, ICAM-1, and IL-8 189,190.  While MMP14 is best known for cleaving 
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molecules proximal to the cell membrane, it has also been linked to the shedding of cell surface 
proteins including MUC1 (a mucin) from epithelial cells and endoglin (TGFβ co-receptor) from 
HUVEC
191,192
.  Interestingly, MMP14 can also display functions independent of its enzymatic 
activity, by triggering the activation of phosphinositide 3-kinase delta (PI3Kδ) during its 
trafficking to the nuclear compartment leading to a more inflammatory profile of cytokines
175
.   
 
In addition to its ability to hydrolyze a variety of target substrates, MMP14 has also been linked 
to cell invasion.  MMP14 expression is often localized to the invading front and podosomes of 
migrating cells such as FLS and macrophages 
193,194
.  While all MMPs, possess collagenolytic 
activity, membrane bound expression seems essential for degradation leading to tissue-
invasion
193
.  Transfection and expression of MMP14 or MMP15 was able to confer invasive and 
angiogenic capabilities on cells while the secreted MMPs 1,2,3,7, or 9 could not 
193
.  In addition, 
in MMP14 deficient fibroblasts transfection of a mutant membrane-bound form of MMP1 could 
confer a collagen-invasive phenotype
177
.  Of the membrane bound MMPs MMP14 has been 
found to be crucial for cell invasion.  In fibroblasts MMP14 alone was shown to be essential to 
type I collagen degradation and the collagen invasive phenotype 
177
.  These findings are not 
confined to fibroblasts as mesenchymal stem cells likewise express multiple MMPs (MMPs 
1,2,13,14, and 16) and degrade collagen, but only MMP14 was required for their invasion and 
differentiation 
195
.  Interestingly, MMP14 has also been linked to CD8+ T cell invasion into 
pancreatic tissue in type I diabetes 
196
.  Because of its critical nature in a variety of functions, 
regulating MMP14 is vital to maintaining homeostasis in the synovium and other tissues.   In 
addition to natural inhibitors (tissue inhibitor of metalloproteinases [TIMPs]) MMP14 can also 
be regulated by endocytosis and its intracellular trafficking to either the cell surface or lysosomal 
34 
 
network
197
.  Similar to CD13, MMP14 can be found on lipid rafts and may be internalized into 
the cell through caveolae-dependent pathways, although another study indicated that MMP14 
inclusion in caveolae within lipid rafts enhanced membrane persistence at the cell surface rather 
than internalization 
190,197
.  Regardless, caveolae and lipid rafts may be a point of regulation for 
both MMP14 and CD13. 
 
MMP14 is of particular interest to this study because it has been strongly linked to RA in 
multiple aspects of the disease process.  MMP14 is highly expressed in the RA pannus especially 
at the invasion front where the pannus and cartilage meet 
198
.  Furthermore, RA FLS invasion 
into a collagen matrix or cartilage was correlated with MMP14 expression
198
.  More specifically, 
Sabeh et al demonstrated that while RA synoviocytes express multiple MMPs (e.g. 
MMPs1,2,13,14,16), only MMP14 conferred FLS with collagen degradation and invasion 
activity 
49
.  These studies suggest a specific role for MMP14 in invasion of RA FLS.   
 
Other specific functions for MMP14 in arthritis include leukocyte migration, bone 
formation/destruction, and angiogenesis
189,199,200
.  One key component of RA is the increased 
influx of leukocytes into the joint.  MMP14 has been linked to leukocyte mobility through 
cleavage of cell adhesion molecules and ECM components
189
.  MMP14 can also activate TGF-β 
produced by osteoblasts resulting in decreased osteoblast apoptosis and increase in conversion to 
osteocytes 
199
.  While it is uncertain whether the conversion of osteoblasts to osteocytes could 
contribute to RA bone destruction, there exists a delicate balance of osteocytes (bone 
homeostasis), osteoblasts (bone formation), and osteoclasts (bone absorption) and disruption of 
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the balance can accelerate bone loss as well as destructive bone remodeling.  Functionally, 
MMP14 may also impact RA bone destruction by regulating monocyte fusion, a process critical 
to osteoclast formation
200
.   
 
In RA, the increased mass of synovial tissue in the RA joint is supported by an increased blood 
flow through angiogenesis and additional process that can be linked to MMP14 activity.  RA 
synovial tissue can induce a strong angiogenic response in model systems (i.e. the developing 
chick embryo) and silencing MMP14 not only blocks invasive activity, but angiogenesis as 
well
49
.  While endothelial cell derived MMP14 had been linked directly  to angiogenesis (i.e. by 
controlling the tissue-invasive activity of sprouting endothelial cells), synoviocyte-induced 
angiogenesis demonstrates that MMP14 can also generate a pro-angiogenic factors that stimulate 
neovascularization
201
.  However, the synoviocyte induced angiogenesis data indicates that 
MMP14 can cleave a pro-angiogenic factor that may mediate angiogenesis in RA.  Currently the 
effectors responsible for MMP14-induced angiogenic responses remain unknown.  
 
Extracellular vesicles and exosomes 
Extracellular vesicles (EVs) of various origins are of increasing interest in immunology and 
immunologic diseases, including RA
202
.  EVs have interesting potential in immunology as they 
could allow for the interactions of surface proteins apart from direct cell-cell contact, even 
transporting surface proteins to act in autocrine, paracrine, or endocrine fashions.  Classifications 
of EVs include exosomes, microparticles, microvesicles, and apoptotic bodies.  While there is a 
good deal of debate over categorizing of EVs, the individual groups of EVs are primarily defined 
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by size, method of generation, and/or cellular orgigin
203,204
.  Here extracellular vesicles will refer 
to the overall group, microvesicles will refer to EVs 50-1,000 nm in size shed by budding from 
the cell surface, microparticles will refer to microvesicles from platelets or erythrocytes, and 
exosomes will refer to small EVs that originate intracellularly.   
 
Exosomes are secreted by most cell types and the proteins expressed reflect the cell surface of 
the cells from which they are released.  Exosomes are bi-layer lipid membrane vesicles, 40-
100nm in size.  In addition to being representative of the secreting cell, exosomes also typically 
contain some conserved proteins including intracellular proteins (like actin, tubulin, and Rab 
proteins) and signaling proteins (kinases and heterotrimeric G-proteins)
203
.  These proteins likely 
contribute to basic exosome structure and function.  Exosomes are found in culture supernatants 
of most cells as well as in many bodily fluids including: blood, urine, tumor ascites, and synovial 
fluid
203,205
.  Exosomes are formed intracellularly in multivesicular bodies (MVBs).  MVBs then 
fuse with the plasma membrane, releasing the exosomes; a process dependent on small GTPases 
in most cells
202
.  While the exact mechanism of release is undefined, metalloproteinases appear 
to be involved.   Treatment of human vascular endothelial cells (HUVECs) with a broad 
spectrum zinc-metalloproteinase inhibitor significantly decreased their release of exosomes
206
.  
In addition to exosomes having surface proteins, they also contain cytoplasmic proteins and can 
carry mRNA and microRNA (miRNA)
207
.   
 
One main suggested function for exosomes is cell-cell communication.  This can occur by 
interaction of surface proteins, for example, DCs can secrete exosomes with surface MHC 
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capable of activating T cells through interaction of the exosomal-MHC with the cell surface TCR 
208
.  Alternatively, exosomes can aid in cellular communication following internalization by 
target cells and release of their contents inside the cell, such as micro RNA generated in one cell 
can be transported inside an exosome to a target cell population where it suppresses or activates 
responses 
203
.  Exosomes may also function by allowing exchange of proteins or lipids from one 
cell to another, such as exchange of MHC or cholesterol, or they can simply serve as a means of 
elimination of cellular proteins
205,207
.  Another suggested function of exosomes in the body is in 
persistence of signaling molecules.  Exosomes not only have a lipid bilayer, but have a high 
concentration of sphingomyelin, cholesterol, GM3 (a glycolipid), and proteins like CD55 that 
protect against complement
203
.  The presence of this lipid and protein profile suggests that 
exosomes may be a way of increasing stability of proteins outside the cell, compared to soluble 
proteins.  In addition to the biological functions of exosomes, they are of interest in diagnosis as 
biomarkers for various diseases (such as renal disease or malignancies)
203
.   
 
Extracellular vesicles have been found in RA and other forms of arthritis.  Microparticles have 
been identified in RA synovial fluid and other inflammatory arthritides, but not in OA synovial 
fluid, and were determined to originate primarily from platelets
209,210
.  When RA synovial fluid 
microparticles were isolated and added to FLS cultures, they induced production of monocyte 
chemotattractant protein 1 (MCP-1), IL-8, IL-6, ICAM-1, VEGF, and RANTES
211
.  By contrast, 
others have reported that microvesicles in the RA joint arise primarily from monocytes or 
granulocytes but not platelets 
212
.  Interestingly, microvesicles isolated from either monocyte or 
T cell line cultures can induce the production of pro-angiogenic chemokines (CXCL-1,2,3,5,6) 
and matrix metalloproteinases (MMP1,3,9,13) by RA FLS in vitro
213,214
.   
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Exosomes have also been found in OA, RA, and reactive arthritis synovial fluids.  Of particular 
interest, it was noted that the synovial fluid exosomes expressed citrullinated proteins
215
.  
Citrullination is a posttranslational modification, and anti-citrullinated protein antibodies 
(ACPAs) have been linked to RA
216
.  Exosomal citrullinated proteins included: SPα (CD5 
antigen-like protein), fibrinogen fragment D, fibrinogen β-chain (and precursor), fibrin 
fragments, and other unidentified proteins.  Non-citrullinated proteins were also identified 
including fibronectin, IgG1 γ-chain, and α2-macroglobulin
215
.  While ACPAs are specific for 
RA, exosomal citrullinated proteins were found in the synovial fluids of OA and reactive arthritis 
patients as well as those of RA patients.  This may indicate that exosome-associated citrullinated 
proteins function in disease-independent mechanisms, or that it is only when ACPAs are 
produced to the proteins that citrullination is pathogenic.  
 
FLS also produce exosomes in vitro.  RA FLS-derived exosomes express membrane-bound 
TNFα while OA FLS derived exosomes are TNFα-negative217.  The RA FLS exosomes also  
induced apoptosis resistance in CD3+ T cells
217
.  While it was suggested that this apoptosis 
resistance was related to the TNFα presentation, the mechanism of resistance is uncertain. 
Overall, the profile of exosomal proteins/molecules in RA and from FLS is not complete.  Many 
proteins associated with RA, and known to be expressed on synovial cells, have not been 
examined on exosomes in synovial fluid.  However, some RA associated proteins have been 
found on exosomes derived from other cell types.  Exosomes can express multiple 
metalloproteinases, and CD13 has been found on exosomes derived from microglia cells or mast 
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cells
203,207
.  MMP14 has been found on fibrosarcoma- and melanoma-derived exosomes, and 
ovarian carcinoma-derived exosomes contained ADAM17 and ADAM10
218,219
.  Not only do we 
not know all the possible relevant proteins on exosomes in RA, but the potential functions of 
these proteins in the context of exosomal presentation are unknown.  Is CD13 on exosomes 
produced by RA FLS, and are CD13 positive exosomes present in RA synovial fluid? 
 
Potential roles of CD13 in rheumatoid arthritis 
As discussed previously, CD13 has been linked to a variety of inflammatory mechanisms.  CD13 
is known to be expressed on multiple cell types involved in the pathogenesis of RA, including 
macrophages/monocytes, epithelial cells, and fibroblasts.  Studies of dermal fibroblasts have 
shown CD13 can affect fibroblast migration and expression of MMPs
117,118,133,134
.  It is possible 
that these effects could extend to synovial fibroblasts as well.  Tumor cells are another cell type 
where CD13 expression has been linked to cellular migration
220
.  CD13 has been identified in 
synovial tissue via immunostaining, and surface CD13 has been identified on OA and RA FLS 
169
.  In addition, aminopeptidase activity (attributed to CD13) is reportedly increased in RA 
synovial fluid as well as FLS (with accompanying increases in CD13 mRNA and protein levels) 
when compared to OA 
169
.  Nevertheless, these findings remain controversial as other studies 
failed to detect differences in CD13 levels in RA versus OA FLS  as assessed by flow cytometry 
221
.   
 
Previously, CD13 protein levels have not been definitively measured on FLS.  Typically, CD13 
protein amount is inferred based on its enzymatic activity.  The conflicting data using Western 
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blot analysis versus surface staining may reflect differences in cellular localization of CD13 
(intracellular versus cell surface).  In addition to cellular CD13 on FLS, CD13 aminopeptidase 
activity is found in the synovial fluid.  However, the distribution of this activity between 
extracellular vesicles and soluble CD13 remains to be determined.  It is also unknown whether 
soluble/EV-associated CD13 is present or potentially pathogenic in RA.   
 
A putative role for sCD13 in T cell chemotaxis has been specifically suggested to play a role in 
RA by Shimizu et al 
169
.  This group showed a correlation of N-aminopeptidase activity and 
lymphocyte counts in RA synovial fluid samples.  They also showed inhibition of peripheral 
blood T cell chemotaxis toward RA synovial fluid by bestatin.  While this evidence is suggestive 
of a role for CD13 in RA, it is inconclusive.  CD13 has yet to be measured in RA samples, and 
the enzymatic activity assays are not specific to CD13.  Without a true measure of CD13 it is 
difficult to determine whether the amounts of purified human CD13 shown to be chemotactic for 
T cells are biologically relevant 
222
.  Bestatin is also not specific to CD13 and could potentially 
be affecting other aminopeptidases in synovial fluid 
123
.  This study will therefore examine the 
expression, regulation, and localization of CD13 produced by FLS and asses potential roles for 
CD13 first as a chemotactic molecule for T cells in RA and as a mediator of RA FLS growth and 
migration. 
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                                                                                                               Chapter 2
CD13 in Rheumatoid Arthritis 
 
T cells and FLS have been shown to interact in RA in a variety of ways.  One prime mechanism 
is through T cell secreted factors, such as cytokines, activating FLS resulting in regulation of 
pathogenic proteins.  Two main cytokines involved in RA disease pathogenesis are TNFα and 
IL-17.  Both molecules bind to receptors on FLS and induce subsequent effects.  IL-17 can 
upregulate IL-6, various chemokines, MMPs, and growth factors 
35
.  TNFα can induce FLS 
proliferation, production of collagenase, and GM-CSF 
223
.  Because of these and other 
mechanisms, IL-17 and TNFα are both of interest as therapeutic targets in RA.  However, there 
is still much we don’t understand about the pathogenesis of RA and novel pathways on FLS may 
lead to new therapeutics. 
 
CD13 involvement has been previously suggested in RA, and phenomena that can be 
functionally linked to CD13 are seen in RA (angiogenesis, cellular migration, monocyte 
activation)
70,76,85,169
.  However, a definitive role for CD13 in RA has not been shown, and the 
protein has not been directly measured.  Enzymatic assays of CD13 activity and chemical 
inhibition of its enzymatic activity have been employed, but neither the assays nor the inhibitors 
of CD13 are specific for CD13 versus other aminopeptidases
123
.  Our goal in this chapter was to 
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measure CD13 protein in RA in vivo and in vitro.  This will provide better evidence for CD13 
involvement in RA. 
 
Identification of CD13 as an IL-17-induced protein on FLS  
TNFα and IL-17 are two cytokines strongly linked to RA.  Currently TNFα inhibition is a target 
for several therapeutic agents used to treat RA.  However, many patients either do not respond or 
have inadequate responses to TNFα therapeutics.  Therefore, TNFα independent pathways are of 
increasing interest in identifying new RA therapeutic targets.  This study commenced as a 
screening experiment to identify a pathway dependent on IL-17, but independent of TNFα.  To 
identify a surface structure on FLS that was regulated by IL-17 independently of TNFα, IL-17 
treated FLS were used to immunize BALB/c mice and hybridoma clones were created.  The 
clones were screened on resting FLS, IL-17 treated FLS, and TNFα treated FLS.  A hybridoma 
was selected that produced an antibody (591.1D7.34) that recognized an FLS surface protein 
upregulated by IL-17 but not TNFα at 48 hours (Figure 2.1A).  The antibody 1D7 was screened 
on a variety of cell types to determine which cells are positive for the protein recognized by 1D7 
(Figure 2.2).  Of the cell types tested, the monocytic cell line, U937, showed the strongest 
expression of the molecule identified by 1D7.  We therefore used 1D7 to immunoprecipitate a 
protein from U937 that migrated on SDS-PAGE as a single band of 150kDA, and that was 
identified as CD13/Aminopeptidase N by sequencing of multiple peptide fragments (Figure 2.1B 
and C). 
 
Since there is debate over whether CD13 is expressed on activated T cells we did a more 
extensive screening looking for any CD13 present on various T cell types.  We tested: resting 
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peripheral blood T cells, phytohaemagglutinin (PHA) activated, concanavalin-A (conA) 
activated, phorbol 12-myristate 13-acetate/ionomycin (PMA/Iono) activated, cytokine activated 
(Tck), JURKAT, and HUT78.  We looked for CD13 by mRNA with quantitative real time PCR 
and protein using a novel CD13 ELISA, aminopeptidase activity, and flow cytometry.  We did 
not find CD13 by any of our methods on any of the T cell types tested (data not shown). 
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Figure 2.1 Identification of the protein recognized by mAb 591.1D7.34 and upregulated by 
IL-17 as CD13.   
A, FLS were treated for 48 hours with medium alone, TNF-α (10ng/ml), or IL-17 (10ng/ml) 
before staining with 1D7 and Alexa Fluor 488-conjugated goat anti-mouse IgG .  Cell surface 
CD13 was measured by flow cytometry. (method p138) B, An OA FLS cell line was biotinylated 
and lysed.  Immunopreciptiation was used to isolate protein recognized by 1D7, MsIg (isotype 
control), or anti-CD98.  The proteins from the 1D7, MsIg, and anti-CD98 beads were resolved 
by SDS-PAGE under reducing or non-reducing conditions.  Protein from the same number of 
cells was loaded in each lane.  C, Myeloid line U937 was lysed and 1D7 was used to 
immunoprecipitate the recognized protein, which was run on two gels.  One was stained with 
Coomassie blue.  The second gel was excised at a spot corresponding to the primary band in the 
stained gel.  The protein was extracted and multiple peptide fragments sequenced, each of which 
matched portions of Aminopeptidase N/CD13 (bolded sequences). (method p136) 
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Figure 2.2 Staining of different cell types with 591.1D7.34. 
Various cell types were stained with the antibody produced by the hybridoma 591.1D7.34 and 
secondary Alexa Fluor 488-conjugated goat anti-mouse IgG.  Cells were screened by flow 
cytometry.  Positive and negative staining is as indicated, with degree of positivity indicated by the 
number of Xs.  The highest degree of staining was observed on the myeloid cell line U937. (method 
p138) 
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CD13 in vivo 
Having identified FLS CD13 as a potential part of an IL-17 induced pathway we next sought to 
determine whether the concentration of a putative soluble form of CD13 is elevated in the RA 
joint.  This was previously suggested by determination of levels of aminopeptidase activity in 
synovial fluid (SF) samples, but without direct measurement of CD13 protein 
169,222
.  We 
developed a novel ELISA to measure CD13 in healthy control (HC) serum (n=23), RA serum 
(n=33), and both RA and OA SFs (n=98).  RA SFs (n=39) had an average CD13 concentration of 
1191.09±121.58 ng/ml with an activity of 3402.45±239.58 μM/hr, and OA SFs (n=59) had an 
average CD13 concentration of 646.11±45.64 ng/ml and an activity of 2250.28±93.18 μM/hr 
(Figure 2.3A). The RA SFs were significantly higher in both amount (p<0.00001) and activity 
(p<0.00001).  RA SF CD13 concentration was also significantly higher than in RA sera, 
397.95±72.18 (n=33, p<0.00001), or HC sera, 683.34±203.37 (n=23, p=0.0023) (Figure 2.3B).  
CD13 was significantly higher in HC sera than in RA sera, p=0.0040.  The results are consistent 
with the observation that IL-17 upregulates CD13 expression by FLS and leads to the hypothesis 
that generation of sCD13 in the RA joint may play a role in a pro-inflammatory pathway.   
 
CD13 was also examined on tissue sections from RA, OA, and normal synovium.  CD13 was 
observed on the synovium in all three with higher expression in RA and OA.  CD13 also co-
localized with cadherin-11 (a FLS cell marker) in RA and OA, as shown by yellow (Figure 2.4).  
Both overall CD13 expression and CD13/cadherin-11 co-localization were higher in RA over 
OA.  In RA synovium infiltrating myeloid cells were also observed as indicated by CD11c (a 
myeloid/monocyte marker).  Only low levels of CD11c were seen in OA and normal.  In RA 
there was co-localization between CD11c and CD13 on myeloid cells indicating CD13 is present 
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not only on FLS but myeloid cells as well in the RA joint (Figure 2.4).  CD13 was also expressed 
on vasculature in RA (Figure 2.5).  These data are consistent with previous publications showing 
CD13 on FLS, myeloid lineage cells, and neovasculature 
66,86,224
. 
 
We also examined CD13 concentrations in the serum from inflammatory conditions other than 
RA.  CD13 and CD13 aminopeptidase activity were measured in chronic graft-versus-host 
disease (cGvHD, n=19), myositis (n=4), Sjogrens syndrome (n=6), scleroderma (n=51), and 
systemic lupus erythematosus (n=3), as well as RA and HC serum as discussed above (Figure 
2.6).  CD13 and its enzymatic activity were found to be significantly elevated in cGvHD over 
healthy controls.  Serum from cGvHD patients contained 2431.49±2192.31 ng/ml with an 
activity of 5977.87±1995.00, p=0.0026 and 0.0051 respectively.  Similar to RA, myositis serum 
was significantly lower in both CD13 amount (p=0.00025) and enzymatic activity (p=0.046) 
than HC serum, 236.93±89.00 ng/ml with activity of 3400.30±1053.22 μM/hr.  Lupus, while 
significantly lower in CD13 amount (231.78±5.97 ng/ml, p=0.00092), was not significantly 
different in its aminopeptidase activity (3678.44±1273.99 μM/hr, p=0.26).  Scleroderma samples 
had a significant decrease in serum aminopeptidase activity from normal serum 
(3649.41±1436.14 μM/hr, p=0.00021) but no significant difference in CD13 amount 
(565.65±1120.84 ng/ml, p=0.62).  Scleroderma samples were also analyzed after subdividing the 
samples into limited and diffuse groups.  This did not change the overall results, with both 
groups showing a significant decrease in enzymatic activity and no significant difference in 
CD13 protein concentration; however, there was one new observation.  When separated into 
limited (n=33) and diffuse (n=18) the limited scleroderma samples contained lower levels of 
CD13 (435.27±720.72 ng/ml) than normal samples while the diffuse samples contained higher 
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levels of CD13 (804.68±1619.77 ng/ml) than normal samples.  Sjogren’s syndrome samples 
were not significantly different than HC samples, 505.23±632.62 ng/ml with an activity of 
3626.94±908.73 μM/hr. 
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Figure 2.3 CD13 is found in vivo and is higher in RA than in OA synovial fluid.   
A, CD13 was measured by enzyme-linked immunosorbent assay (ELISA, method p 139) and 
enzymatic activity (method p138) in RA (n=39) and OA (n=59) synovial fluids.  B, CD13 was 
measured by ELISA in serum from healthy controls (n=23), serum from RA patients (n=33) and 
in synovial fluids from RA patients (n=39, not matched to serum). * p<0.05; ****p<0.00001, by 
One-way ANOVA 
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Figure 2.4 CD13 staining is present in synovial tissue from normal, OA, and RA patients.  
CD13 staining more strongly co-localizes with FLS (cadherin-11) and monocytic lineage 
cells (CD11c) in RA tissue.   
Tissues were harvested form normal, OA, and RA patients during surgery.  Tissue sections were 
frozen with liquid nitrogen and 7 µm frozen sections were made using a cryostat.  The slides 
were fixed in Acetone at 4⁰C for 30 minutes, washed, and blocked in 20% Fetal Bovine Serum 
and 5% goat serum in PBS.  Slides were incubated with the primary antibodies anti-human CD13 
(1D7, 10µg/mL) and rabbit anti-human CD11c (Abcam, 1:100 dilution) or rabbit anti-human 
Cadherin 11 (Zymed 10µg/mL).  Controls were rabbit and mouse IgG at equivalent 
concentrations.  Secondary antibodies for both sets of slides were Alexa fluor goat anti-mouse 
488 and goat anti-rabbit 555 (Life Technologies 10µg/mL), and DAPI (Invitrogen, 1:5000 in 
PBS) was used on all slides.  Slides were mounted with Fluoromount-G (Southern Biotech).  
Pictures were taken on an Olympus BX microscope at 40x magnification.  Arrows point to 
examples of co-localization. (method p139) 
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Figure 2.5 CD13 staining is present on neovasculature in RA synovium.   
Tissues were harvested form normal, OA, and RA patients during surgery.  Tissue sections were 
frozen with liquid nitrogen and 7 µm frozen sections were made using a cryostat.  The slides 
were fixed in Acetone at 4⁰C for 30 minutes, washed, and blocked in 20% Fetal Bovine Serum 
and 5% goat serum in PBS.  Slides were incubated with the primary antibodies anti-human CD13 
(1D7, 10µg/mL) and rabbit anti-human CD11c (Abcam, 1:100 dilution).  Controls were rabbit 
and mouse IgG at equivalent concentrations.  Secondary antibodies for both sets of slides were 
Alexa fluor goat anti-mouse 488 and goat anti-rabbit 555 (Life Technologies 10µg/mL), and 
DAPI (Invitrogen, 1:5000 in PBS) was used on all slides.  Slides were mounted with 
Fluoromount-G (Southern Biotech).  Pictures were taken on an Olympus BX microscope at 40x 
magnification.  Arrow points to an example of vasculature. (method p139) 
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Figure 2.6 CD13 is significantly elevated in chronic graft-versus-host disease 
serum over CD13 in healthy control serum, and is significantly decreased in RA, 
myositis and lupus serum compared to healthy control serum.   
Serum was collected from patients with various inflammatory immune mediated 
conditions and CD13 was measured by ELISA and aminopeptidase activity assay. 
*p<0.05; **p<0.001 (methods p138-139) 
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CD13 on FLS from RA and OA 
Having identified CD13 on FLS and sCD13 in synovial fluid, we asked whether the difference 
between RA and OA SFs corresponded to an increase in CD13 expression by RA FLS.  We used 
antibodies WM15 and SJ1D1 in addition to 1D7 to measure CD13 by flow cytometry (Figure 
2.7A).  Each antibody detected CD13 on FLS, but with no significant difference in surface CD13 
between resting RA (n=7) and OA (n=5) FLS.  Moreover, measurement of total cell CD13 in 
lysates of RA and OA FLS by ELISA (p=0.74) and enzymatic activity assay (p=0.15) showed no 
significant differences (Figure 2.7B).  We found 4867.39±1196.81ng/ml of CD13 with an 
activity of 2993.65±743.40 μM/hr in RA FLS and 4256.74±1306.71ng/ml of CD13 with 
2123.05±1203.81 μM/hr of enzymatic activity for OA FLS.  To determine whether FLS could 
release sCD13, we measured CD13 in FLS culture supernatants.  FLS were cultured in serum 
free media to eliminate interference from bovine CD13.   sCD13 was detected by ELISA in the 
supernatants and was enzymatically active, with almost identical results from RA (51.28±5.15 
ng/ml, 957.69±819.02 μM/hr) and OA (50.78±7.16ng/ml, 962.69±552.26 μM/hr) FLS (Figure 
2.7C).   
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Figure 2.7 Equivalent expression of CD13 by RA and OA FLS.   
A, FLS were immunostained for CD13 using three antibodies which recognize different epitopes 1D7, 
WM15, SJ1D1.  All three showed high expression as measured by flow cytometry.  Mean fluorescent 
intensity (MFI) was adjusted for the isotype control as follows MFI CD13 – MFI MsIg = corrected 
MFI.  B, RA (n=7) and OA (n=5) FLS were grown to confluence in 20% CMRL and switched to 
serum free media for 48 hours prior to harvesting.  Cells were lysed and CD13 was measured by 
ELISA and enzymatic activity assay.  C, The 48 hour FLS culture supernatants were concentrated 
from 25mls to 1ml through at 30KDa centrifugal filter and measured by ELISA and enzymatic activity 
assay. (methods p138-139) 
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CD13 and aminopeptidase activity in the joint 
Although we found elevated levels of CD13 protein and enzymatic activity in RA in vivo, we did 
not find any differences in vitro between RA and OA FLS.  We next sought to confirm that the 
N-aminopeptidase activity attributed to CD13 in SF samples was really due to CD13.  The 
correlation between the concentration of CD13 and the aminopeptidase activity was R2=0.1365, 
p=4.24x10-9 by ANOVA in SF samples.  Considering the OA samples separately, this correlation 
remained highly significant, R2=0.418, p=3.17x10-8.  However, in the RA samples the correlation 
was non-significant, R2=0.0947, ANOVA p=0.057 (Figure 2.8A).  Several outliers could indicate 
the variable presence of other proteins with aminopeptidase activity.   
 
To further assess the issue, we decided to perform immunodepletions on SFs.  To determine 
which antibody to use for the immunodepletion we tested three antibodies (1D7, WM15, and 
SJ1D1) for inhibition of CD13 enzymatic activity and degree of CD13 protein depletion.  First, 
we tested for inhibition of enzymatic activity to ensure that the depletion did not also affect the 
aminopeptidase activity.  We found as previously reported that WM15 did inhibit 
aminopeptidase activity and SJ1D1 did not
74
.  We also found that 1D7 is not an inhibitor of 
aminopeptidase activity (Figure 2.9A).  Since immunodepletion did not always result in 
complete removal of CD13 we tested one synovial fluid with either each antibody alone or all 
three combined to determine if there was a difference in degree of depletion.  We found that 
there was no difference with any of the depletions in amount of CD13 remaining (Figure 2.9B).  
Even serial depletion with all three antibodies did not significantly reduce the remaining CD13 
over any antibody alone.  From this data we decided to use 1D7 for the immunodepletion since it 
was the closest to MsIg in effect on enzymatic activity.  We immunodepleted RA (n=6) and OA 
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(n=3) SFs using 1D7 and assayed the depleted fractions for CD13 and aminopeptidase activity.  
Successful immunodepletion of CD13 (partial or complete) was verified by ELISA.  We showed 
significant depletion of both the CD13 protein amount (11.50%±0.26% remaining, p=0.00055) 
and enzymatic activity (55.74%±0.31% remaining, p=0.0027) (Figure 2.8B).  In most SFs the 
remaining percentage of aminopeptidase activity was higher than the remaining percentage of 
CD13 protein.  Moreover, 100% depletion of CD13 protein failed to remove all of the 
aminopeptidase activity.  An example in Figure 2.8C shows one RA SF with complete depletion 
of CD13 as measured by ELISA in which the enzymatic activity in the sample went from 
876.61±36.06 μM/hr in the control depleted down to 356.00±17.47 μM/hr (p=2.3x10-5) in the 
CD13 depleted sample.  Much of the enzymatic activity in this sample appeared in the eluate 
from the 1D7 immunopreciptation (3888.00±39.97 μM/hr).  However, this only accounted for 
approximately 60% of the starting enzymatic activity.   
 
 
57 
 
 
 
 
 
 
 
Figure 2.8 CD13 accounts for most but not all of the aminopeptidase activity in synovial 
fluid.  
A, ELISA and enzymatic activity assay results for RA and OA synovial fluids were correlated 
separately and together.  Correlations were analyzed by ANOVA, all points together R
2
=0.1365, 
p=4.24x10
-9
, OA alone R
2
=0.418, p=3.17x10
-8
, RA alone R
2
=0.0947, p=0.057. (methods p138-
139)  B, Synovial fluids (n=9) were immunodepleted with anti-CD13 (1D7), Ig isotype control 
(MsIgG), or an isotype matched non-relevant antibody (7F8 [CD98]) using an 
immunoprecipitation kit.  The removed protein was eluted off the beads by low pH.  Values are 
the mean±SEM. * p<0.05; ** p<0.001 (method p140) C, Example of complete depletion of an RA 
synovial fluid as measured by enzyme-linked immunosorbent assay (ELISA) and the 
corresponding enzymatic activity (1 synovial fluid 3 replicates).   Left, values are the mean±SEM.  
Right, values are mean±SD  ***p≤0.0001 unpaired two tail t-test (methods p139-140) 
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Figure 2.9 1D7 efficiently depletes CD13 from synovial fluid and does not inhibit 
CD13 enzymatic activity.   
A, Recombinant human CD13 (rhCD13) at various concentrations (25ng/ml-
200ng/ml) was incubated with the anti-CD13 antibodies 1D7, WM15, and SJ1D1 and 
with an isotype control MsIgG for 1hour at 37°C.  An aminopeptidase activity assay 
was then run. (method p138)  B, One synovial fluid was immunodepleted with 1D7, 
WM15, SJ1D1, or all three.  Depleted fluids were then assayed for remaining CD13 
by ELISA.  mean±SD (method p139) 
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Discussion 
It has become clear that RA is not mediated by a single cell type but rather by interactions 
between the various cells in the RA joint: including FLS and T cells.  RA FLS express matrix 
metalloproteinases (MMPs), secrete pro-inflammatory mediators, and produce chemotactic 
agents to attract inflammatory cells to the joint.  T cells are prime producers of multiple pro-
inflammatory cytokines (such as IL-17, TNFα, IFNγ).  In this chapter we examined CD13 on 
FLS as another potential mediator of FLS/T cell interactions in the RA joint.  
 
Although CD13 has been identified in synovial fluids by Western blot and through N-
aminopeptidase enzymatic activity assays, it has never been directly measured.  We developed a 
novel CD13 ELISA and showed that CD13 is significantly higher in RA SFs than in OA SFs, 
HC serum, or RA serum.  We also noted a significantly higher amount of CD13 in HC serum 
when compared to RA serum (Figure 2.3B).  We observed higher co-staining of CD13 and a 
monocytic linage marker (CD11c) in RA synovial tissues than in OA or normal (Figure 2.5).  
These data suggest that activated, CD13 expressing monocytes migrate into the synovium in RA.  
We were specifically interested in whether FLS could contribute to the sCD13 we found in the 
SF.  FLS highly express surface CD13 and are therefore a logical choice for shedding of CD13.  
We were able to show that sCD13 does come from FLS (Figure 2.7C), and can thereby infer that 
FLS contribute to the sCD13 in SF.  We expected that CD13 would be elevated on RA FLS 
when compared to OA FLS, as previously published 
169
.  However, our data showed no 
noticeable difference (Figure 2.7).  We noted a large variation in the intensity of CD13 
expression on our cell lines and in SF and serum samples.  We believe that this variation may 
account for the differences between our results and the previous publication 
169
.   
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There are at least four possible explanations for the higher amount of sCD13 in RA versus OA 
SFs.  First, the RA joint environment includes cytokines and growth factors that could upregulate 
CD13 expression or release from the FLS in vivo in a manner that might not be maintained in 
vitro 
8
.  This is supported by our finding that IL-17 increases surface expression of CD13 (Figure 
2.1A).  Second, synovial tissue undergoes hyperplasia in RA resulting in much higher numbers 
of FLS that could release CD13.  Third, the increase could be due to other cell types.  
Endothelial cells and cells of the monocytic cell lineage express surface CD13 
70,76,85
.  These 
cells are often found in higher numbers in the RA joint and so could account for the increased 
sCD13.  Lastly, there is increased expression of proteases in the RA synovium which could 
increase shedding of CD13 from the FLS 
225
.  The most likely explanation for the higher sCD13 
in RA synovial fluid combines all four possibilities.  The complex milieu present in the RA joint 
contributes to the higher number of FLS and other cells as well as regulation and shedding of 
CD13 from those cells, although monocytic shedding of CD13 has only been observed 
previously in apoptotic cells 
226
.  
 
We wanted to ensure that the aminopeptidase activity we were measuring could be attributed to 
CD13.  1D7 was used for the immunodepletion since it does not block enzymatic activity (Figure 
2.9).  We found that CD13 contributes the majority of the N-aminopeptidase activity to the 
synovial fluids; however, it appears that at least one other protein present has similar activity 
(Figure 2.8)
88
.  The correlation analysis (Figure 2.8A) showed a few synovial fluid samples that 
also appear to have a high concentration of CD13 but lower enzymatic activity.  This could 
indicate the presence of natural inhibitors and/or intrinsic differences in the CD13 protein from 
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post-translational modifications resulting in differing degrees of enzymatic activity.  Natural 
inhibitors may be higher in some people leading to the pattern of high CD13 protein low 
aminopeptidase activity.  Natural inhibitors of metalloproteinases are often found in higher levels 
in RA than OA
180
.  Specifically, one suggested inhibitor of CD13, substance P, has been found in 
RA synovial fluid in higher concentrations than in normal synovial fluid 
110,227
.  The higher 
levels of these types of inhibitors may explain the RA patients with CD13 protein but low 
aminopeptidase activity.  It is also possible that these individuals have lower amounts of other 
aminopeptidases than average leading to lower overall aminopeptidase activity. 
 
In this chapter we also examined the CD13 in serum from various inflammatory conditions 
(Figure 2.6).  It is interesting to note that the only disease with significantly increased amounts of 
serum CD13 over healthy controls was cGVHD.  CD13 has been identified in cGVHD as a 
possible component of a biomarker panel 
129
.  In general the other rheumatologic conditions 
(myositis, lupus, and scleroderma) more closely matched the pattern seen in RA with a decrease 
in serum CD13 or enzymatic activity.  In general due to the high degree of variability of CD13 
between individuals, higher numbers of samples would be needed to reach a definitive 
conclusion about CD13 in these diseases.  However, one interesting observation could be made.  
When scleroderma samples were separated into limited versus diffuse disease types a difference 
was observed.  The limited scleroderma samples contained lower levels of CD13 than HC sera, 
while the diffuse scleroderma sera contained higher levels of CD13 than HC sera.  This may 
implicate systemic CD13, as represented by high serum levels of CD13, in more systemic 
diseases.  This could include both cGVHD and diffuse scleroderma.  While in diseases with 
more specific sites of inflammation (such as RA, myositis, and limited scleroderma), a decrease 
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is seen in systemic CD13 while CD13 increases at the sites of inflammation.  We saw this pattern 
in RA, low serum CD13 and high synovial fluid CD13.  Further studies would be needed to 
determine if this pattern is present in diseases other than RA. 
 
In total, in this chapter we demonstrated that CD13 is elevated in the RA joint.  It is highly 
expressed by FLS and can be released in soluble form from FLS into the synovium.  CD13 is the 
major, but not only, contributor to N-aminopeptidase activity in the RA synovium.  These data 
are suggestive of a role for CD13 in RA pathogenesis. 
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                                                                                                           Chapter 3
CD13 on Fibroblast Like Synoviocytes: Expression, Shedding, and Regulation 
 
In the previous chapter we demonstrated that CD13 is elevated in RA in vivo.  We first identified 
CD13 through a screening to identify a protein on the surface of RA FLS that was differentially 
regulated by IL-17 and TNFα.  However, it became apparent that we had only observed a small 
picture of the regulation of CD13.  The identification was made based on cell surface CD13 at 48 
hours; however, there are other possible locations for CD13 identified in vitro and in vivo.  CD13 
is primarily a cell surface molecule; however, it has also been identified in soluble fractions of 
biological fluids.  We showed that CD13 is upregulated in RA synovial fluid compared to 
osteoarthritis (OA) synovial fluid, normal human serum, or RA serum.  CD13 was also found in 
fibroblast like synoviocytes (FLS) culture supernatants demonstrating that CD13 is released from 
FLS.  CD13 has been identified as a truncated soluble protein in human serum by Western blot; 
however, because CD13 is highly expressed on the cell surface, extracellular vesicles, which can 
reflect the protein composition of the cell surface, are another potential source of CD13 in cell 
free fractions 
90,91
.   
 
Extracellular vesicles (EVs) are composed of a variety of small vesicles including exosomes, 
microparticles, and apoptotic bodies.  Apoptotic bodies are released by dying cells and 
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microparticles are released primarily from platelets, but exosomes can be released from a wide 
variety of cell types including FLS 
202
.   Exosomes are small (40-120 nm diameter) lipid bilayer 
vesicles that typically express a surface profile similar to that of the cells from which they are 
released 
202
.  CD13 has been previously demonstrated to be on exosomes from microglial cells 
and mast cells 
203,207
. 
   
In this chapter we sought to further understand the expression and function of CD13 on human 
RA FLS.  We examined the effect of three pro-inflammatory cytokines linked to RA on CD13 
expression by RA FLS, and determined how CD13 is released from FLS.  We also examined the 
possibility that CD13 is present on exosomes or other extracellular vesicles derived from FLS, 
and measured soluble versus vesicle bound CD13 in sera, synovial fluids, and FLS culture 
supernatants.   
 
CD13 is present on extracellular vesicles including exosomes 
In the last chapter we identified CD13 protein in cell free portions of human synovial fluid, 
serum, and FLS culture supernatants.  While CD13 has been suggested to be present in soluble 
form in serum, the possibility of extracellular vesicle-associated CD13 has not been examined in 
these fluids 
90,91
.  However, CD13 is predominately a cell surface molecule, and as such it may 
be present on the surface of vesicles as opposed to being a true soluble protein.  To test the 
possibility that EVs also contain CD13, we isolated EVs from fluids identified to have CD13 in 
the cell depleted fractions (FLS culture supernatants, normal human plasma, and RA synovial 
fluids) and measured CD13 in the EV and soluble protein fractions.  We used differential 
ultracentrifugation to isolate EVs specifically around the size of exosomes.  We identified CD13 
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in both soluble protein and exosome fractions in plasma, RA FLS culture supernatant, and RA 
synovial fluid (Figure 3.1).  Plasma contained an average of 109.96±48.63 ng/ml of CD13 on 
EVs with an activity of 2753.38±531.20μM/hr and 235.85±164.52 ng/ml of soluble CD13 with 
an activity of 3484.21±657.93 μM/hr.  FLS culture supernatant contained an average of 
58.79±16.36 ng/ml of CD13 on EVs with an activity of 253.37±63.92 μM/hr and 59.56±32.76 
ng/ml of soluble CD13 with an activity of 435.47±225.64 μM/hr.  RA synovial fluid contained 
an average of 56.24±9.14 ng/ml of CD13 on EVs with an activity of 681.06±156.26 μM/hr and 
141.48±21.98 ng/ml of soluble CD13 with an activity of 1852.39±200.68 μM/hr.   
 
Although differential centrifugation is a suitable protocol for isolation of exosomes, there may be 
other contaminants of similar density (including apoptotic bodies and protein aggregates).  To 
further define where CD13 is located we divided the EV fraction over a discontinuous Optiprep 
density gradient with seven fractions from 1.268g/ml to 1.031 g/ml.  We visually confirmed a 
band at the density gradient between fractions 4 and 5 around where exosomes would be 
expected (density between 1.084g/ml and 1.163 g/ml fractions 3-5).  We also found CD13 
present by ELISA in all seven gradients plus originally isolated soluble protein fractions (Figure 
3.2).  The three fluids run (RA FLS culture supernatant, healthy control plasma, and RA synovial 
fluid) each contained a distinct pattern of CD13 localization (Figure 3.3).  FLS culture 
supernatant was the most balanced with 48.67% soluble CD13, 29.76% exosomal CD13, and 
21.58% other EV CD13.  Healthy control plasma was predominantly soluble with 85.60% 
soluble CD13, 7.09% exosomal, and 7.31% CD13 on other EVs.  The RA synovial fluid 
contained 67.55% soluble CD13, 11.92% exosomal CD13, and 20.53% CD13 from other EVs. 
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Figure 3.1 CD13 was found as a soluble protein and on extracellular vesicles 
in FLS culture supernatant, normal human plasma, and RA synovial fluid. 
Supernatants from 3 flasks of RA fibroblasts were concentrated through a 30K 
centrifugal filter.  RA synovial fluid was diluted with PBS (4:1), and 10mls of 
plasma was obtained from a healthy individual.  Vesicle fractions were isolated 
from the samples by serial centrifugation.  Supernatants from the final 
centrifugation were collected as the soluble protein fraction.  The vesicle pellet 
was resuspended in 1ml PBS. mean±SEM  n≥3 (method p142) 
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Figure 3.2 CD13 was found as a soluble protein and in multiple fractions of a density gradient 
separation of extracellular vesicles of FLS culture supernatant, normal human plasma, and RA 
synovial fluid.    
A discontinuous optiprep gradient was created in seven fractions from 1.268g/ml to 1.031g/ml.  500ul of 
the resuspended vesicles was layered onto the top of the gradient.  The loaded gradients were centrifuged 
at 100kg for one hour.  Fractions were collected in reverse.  Fractions were washed in PBS at 110kg for 
2hr and the pellets were resuspended in 500ul PBS. mean±SEM  n≥3 (method p142) 
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Figure 3.3 CD13 was found as a soluble protein and in multiple fractions of a 
density gradient separation of extracellular vesicles with distinct localization for 
FLS culture supernatant, normal human plasma, and RA synovial fluid. 
Supernatants from 3 flasks of RA fibroblasts were concentrated through a 30K centrifugal 
filter.  RA synovial fluid was diluted with PBS (4:1), and 10mls of plasma was obtained 
from a healthy individual.  Vesicle fractions were isolated from the samples by serial 
centrifugation.  Supernatants from the final centrifugation were collected as the soluble 
protein fraction.  The vesicle pellet was resuspended in 1ml PBS.  A discontinuous 
optiprep gradient was created in seven fractions from 1.268g/ml to 1.031g/ml.  500ul of 
the resuspended vesicles was layered onto the top of the gradient.  The loaded gradients 
were centrifuged at 100kg for one hour.  Fractions were collected in reverse.  Fractions 
were washed in PBS at 110kg for 2hr and the pellets were resuspended in 500ul PBS. 
Data is expressed as percentage of total fluid. n≥3 (method p142) 
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Metalloproteinases cleave CD13 from FLS 
Since CD13 exists as a soluble molecule in cell-free portions of biological fluids separate from 
vesicle-associated CD13, soluble CD13 must be released from cells.  Since soluble CD13 was 
also found in FLS culture supernatants, we decided to explore how CD13 was being released 
from FLS.  CD13 is highly expressed on the cell surface of FLS and as such the most likely 
hypothesis is that CD13 is shed from the cell surface.  To test this mechanism we added protease 
inhibitors to FLS cultures covering all classes of proteases.  We tested five protease inhibitors: 
pepstatin A (aspartic), aprotinin (serine), leupeptin (serine/cysteine), GM6001 
(metalloproteinase), and E-64 (cysteine), and found that only one, GM6001, blocked CD13 
release from FLS. GM6001significantly reduced CD13 protein found in the supernatant by 
93.62±4.78%, p≤0.0001 (Figure 3.4A).  Leupeptin led to a significant (p≤0.05) increase 
(48.40±14.29%) in CD13 released.  To confirm that we were affecting cleavage and not 
expression, CD13 was also measured in the FLS cell lysates.  In the cell lysates no significant 
difference was observed with GM6001; however, aprotinin did induce a significant increase 
(22.17±6.18%, p≤0.05) in CD13 expression (Figure 3.4B).  These results indicate that CD13 is 
cleaved from FLS by metalloproteinases.   
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Figure 3.4 Metalloproteinases cleave CD13 from the surface of FLS.   
Five different protease inhibitors were added to FLS cultures covering all classes of proteases.  Data is 
expressed as % change from untreated FLS (untreated FLS at line 0).  (A) The only inhibitor to decrease 
shedding of CD13 into the supernatant of the cultures was GM6001.  (B) No significant decreases were 
seen in cell lysate CD13 concentrations.  Cultures were incubated with serum free media containing 
protease inhibitors for 48 hours: Pepstatin A (aspartic) 10M, Aprotinin (serine) 100nM, Leupeptin 
(serine/cysteine) 10M, GM6001 (metalloproteinase) 25M, and E-64 (cysteine) 10M.  n=3 mean of 
% change ± SEM *p<0.05; ***p<0.0001 (methods p138-139) 
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MMP14/MT1-MMP cleaves CD13 from FLS 
MMP14/MT1-MMP is a cell surface metalloproteinase on FLS that is critical to FLS invasion of 
collagenous structures
49,177
.  To test the hypothesis that MMP14 also releases CD13, we knocked 
down this protease on RA FLS using siRNA.  Figure 3.5 shows an example of successful 
knockdown of MMP14.  Fold change of MMP14 mRNA over GAPDH (Ct) of FLS was 20.52 
and was decreased to 0.50 with addition of an MMP14 siRNA cocktail (p=5.63x10
-7
, Figure 
3.5A).  GFP plasmid transfection was used to determine transfection efficiency.  Higher 
fluorescence was observed with both flow cytometry and fluorescent microscopy over mock 
transfection controls.  Green fluorescence measured by flow cytometry went from 6.77 mean 
fluorescent intensity (MFI) in the negative control (mock transfected) to 111.23 MFI in the 
transfected FLS (Figure 3.5B).  Knockdowns (KDs) were done with siRNA cocktails of 3 
individual siRNAs.  KD was confirmed with each siRNA separately, and mRNA and protein 
results were measured in the same group of cells harvested on the same day 
 
KD of MMP14 significantly decreased the CD13 released from FLS (Figure 3.6A).  Samples 
were normalized to mock transfection in order to compare between experiments (n≥5) and mock 
transfection levels are shown on the graph as a line at one.  The only significant difference in the 
siRNA KD was seen with MMP14, in which case the KD cells released CD13 at 68%±7% of 
control levels, p=0.00045 (Figure 3.6A).  To confirm we were measuring cleavage and not a 
decrease in CD13 expression, CD13 protein was also measured in cell lysates.  KD of MMP14 
did not significantly alter cellular CD13; MMP14 KD ratio over mock was 1.25±0.53 (Figure 
3.6B).  Because MMP14 KD resulted in an average decrease of only 32% in supernatant CD13, 
this indicates that more than one protease cleaves CD13.  To confirm that the other CD13-
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releasing protease(s) are also metalloproteinases, GM6001 was added to MMP14 KD cultures 
(Figure 3.6A, n=2).  Similar to previous results, GM6001 prevented the release of CD13 into the 
culture supernatant (mock to mock+GM6001, 1 to 0.10±0.05 p=1.42x10
-9
).  Addition of 
GM6001 to MMP14 KD cultures decreased supernatant CD13 to a similar level, 0.11±0.081, 
significantly lower than MMP14 KD without GM6001, p=3.21x10
-9
.  GM6001 treatment 
significantly increased CD13 in the cell lysate of mock transfected cells, mock+GM6001 ratio 
1.38±0.20 p=0.0070.   
 
To confirm MMP14 as a cleaver of CD13, confocal microscopy was used to look for co-
localization on the surface of RA FLS (Figure 3.7).  Cells were stained with DAPI for nuclei 
(blue), anti-CD13-FITC (green), and anti-MMP14-PE (red).  Anti-CD90-PE was used as a 
positive control for FLS and negative control for co-localization.  We observed co-localization of 
CD13 and MMP14 on all tested FLS.  The co-localization was predominant on all cell lines 
tested with minor areas of individual staining.  Images shown in Figure 3.7 are representative of 
n=5. 
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Figure 3.5 MMP14 siRNA knocks down MMP14 in RA FLS.   
A, MMP14 mRNA was almost completely removed by transfection with MMP14 
siRNA. n=3 representative of 7 transfections mean±SD * p<0.05, **** p<0.00001 
B, Transfection efficiency was determined by increase in GFP by flow cytometry 
and flourescent microscopy with transfection of a GFP vector.  The flourescent 
microscopy image shows green above mock control background. n=1, representative 
of 7 transfections (methods p141) 
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Figure 3.6 MMP14 knockdown partially inhibits the shedding of CD13 from FLS.  
A, Shedding of CD13 into FLS culture supernatant was inhibited by knockdown of MMP14.  
Further inhibition is seen with GM6001. B, CD13 in FLS lysate was not changed by 
knockdown of MMP14.  FLS were grown to confluence then transfected with siRNA using 
an Amaxon nucleofector kit.  Cells were grown to 75% confluence then switched to serum 
free growth media (Peprogrow) supplemented with 1ng/ml IL-1 and 10ng/ml TNFα for 48 
hours with or without 25M GM6001 . * p<0.05; **p<0.0005; ***p<0.0001 mean±SEM 
(n≥2) (methods p141 and 138) 
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Figure 3.7 Fluorescent staining of FLS shows co-localization of CD13 and MMP14.   
RA FLS were grown to 90% confluence on 8-well glass chamber slides.  Cells were fixed with 1% 
Formalin and blocked with Fc block (10% human serum/10% mouse serum in PBS).  Cells were 
incubated for 1hour at room temperature with anti-CD13-FITC (1D7) 1g/100l and anti-MMP14-PE 
(128527) at 1.67g/100l (appropriate isotype controls and single staining were also done, not shown).  
The nuclei were counter stained with DAPI at 1g/ml.  Cells were mounted using anti-fade media.  
Confocal microscopy was done using an Olympus microscope.  All images corrected for background – 
thresholds determined by DAPI alone, MsIg-FITC alone, and MsIg-PE alone. Representative of n=5 
(method p142) 
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Regulation of CD13 
CD13 is strongly upregulated in RA SF over OA.  However, in vitro RA and OA FLS cultures 
expressed similar amounts of CD13.  One possibility to explain this observation is that the pro-
inflammatory cytokines in the RA joint could contribute to the upregulation of CD13.  Our initial 
screening experiments identified CD13 as being upregulated by IL-17 and downregulated by 
TNFα (Figure 2.1); however, as these studies progressed we realized that CD13 has multiple 
cellular locations (surface, soluble, EV-associated, intracellular).  Our initial study had only 
examined CD13 cell surface expression at 48 hours.  We decided to further examine the effect of 
pro-inflammatory cytokines on FLS CD13 expression.  Cultured RA FLS were treated with 
IFNγ, TNFα, or IL-17 over a time course from 0 to 72 hours.  CD13 mRNA was measured by 
quantitative PCR, and was upregulated by all three cytokines with a peak expression around 48 
hours (Figure 3.8A).  Data shown are a ratio of cytokine treated FLS CD13 mRNA to untreated 
FLS CD13 mRNA at the same time point.  Figure 3.1 shows one FLS cell line and is 
representative of three FLS cell lines.  Peak mRNA following exposure to IFNγ was at 48 hours 
and was 3.46±0.76 fold higher than in untreated FLS (p=0.0066).  The peak IL-17 effect on 
CD13 mRNA was also at 48 hours and was 2.59±0.077 fold higher (p=0.0011).  The effect of 
TNFα peaked at 24 hours with a fold increase of 3.43±0.67 (p=0.0034).  Overall IFNγ and TNFα 
significantly upregulated CD13 mRNA (p≤0.05) at 12, 24, 48 and 72 hours, and the effect of IL-
17 was significant at 12, 24, and 48 hours.  However, cell surface expression of CD13 on the 
three cell lines exhibited variability and fluctuations that did not match the change in CD13 
mRNA.  Figure 3.8B shows the results of one cell line examined by flow cytometry with staining 
by anti-CD13 (1D7).   
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We also examined the correlation between the cytokines (IFNγ, TNFα, and IL-17) and CD13 in 
vivo.  We measured CD13 and the cytokines in serum from a variety of immune-mediated 
rheumatologic conditions including: RA, scleroderma, lupus, Sjogren’s syndrome, and myositis.  
Cytokines in serum can be low and difficult to accurately measure so the data shown here is only 
for the samples that had measureable amounts of the cytokine.  IFNγ levels did not significantly 
correlate to CD13 amounts in the serum, R
2
=0.036 ANOVA p=0.45 (Figure 3.9A).  TNFα levels 
were significantly correlated to CD13 levels, ANOVA p=0.026, but the correlation was not 
strong, R
2
=0.22 (Figure 3.9B).  The strongest correlation was between IL-17 and CD13, 
R
2
=0.61, and the correlation was also highly significant, ANOVA p=1.33x10
-14
 (Figure 3.9C). 
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Figure 3.8 CD13 is upregulated on FLS by IFNγ, TNFα, and IL-17 at the mRNA 
level but the effects on surface CD13 are varied.   
FLS were stimulated over a time course of 0-72 hours with IFNγ (1U/ml), TNFα 
(10ng/ml), or IL-17 (10ng/ml) (method p137).  Cells were harvested and processed for 
either mRNA (A) or surface expression (B).  mRNA was measured by qRT-PCR 
(method p140).  CD13 was measured on the surface with anti-CD13 (1D7) and flow 
cytometry (method p138).  Gating was done to isolate the major cell population and 
exclude debris and dead cells.  Data is expressed as a ratio to unstimulated FLS at the 
same time point in either ΔΔCt normalized to GAPD (mRNA) or mean fluorescent 
intensity corrected for MsIg (surface)  mRNA n=3 flow n=1  Figures are for 1 cell line 
and representative of 3  *p<0.05 
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Figure 3.9 CD13 correlates with TNFα and IL-17 in the serum of patients with 
inflammatory, rheumatologic diseases.   
Serum was collected from patients with a variety of autoimmune diseases.  Levels of 
CD13, IFNγ (A), TNFα (B), and IL-17 (C) were measured by ELISA.  Data shown are 
samples with measureable levels of the cytokines.  Correlation significance was 
determined by ANOVA. (methods p137 and 141) 
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Discussion 
CD13 has been identified as a protein highly expressed by RA FLS, and may contribute to T 
cell-FLS interactions.  In the joint, T cells are known to activate RA FLS through cell-cell 
interactions and the release of pro-inflammatory cytokines.  This activation can result in greater 
production of chemokines and other pathogenic proteins by the FLS resulting in a self-
perpetuating, pro-inflammatory cycle 
65
.  To determine whether CD13 was part of this loop, we 
examined the effect of three pro-inflammatory cytokines on CD13 expression by FLS.  CD13 
mRNA was upregulated by IFNγ, TNFα, and IL-17 in FLS.  However, the primary location for 
CD13 expression by FLS (the cell surface) did not match this regulation pattern.  Even before the 
mRNA was upregulated (peak around 48 hours) the cytokines were inducing fluctuations in cell 
surface CD13 (Figure 3.8).  This led us to infer that the cytokines were also likely leading to 
changes in the localization of CD13 protein.  CD13 has also been found in the cell free portions 
of various biological fluids, raising the possibility that CD13 could be released by the FLS from 
the cell surface 
88,89
.   
 
We also examined the correlation of this putative soluble CD13 in serum with the pro-
inflammatory cytokines present in serum.  Interestingly despite the increase in CD13 mRNA in 
FLS with treatment by IFNγ, we did not see a correlation between CD13 and IFNγ in serum from 
patients with inflammatory conditions.  This may indicate a difference in protein production 
versus mRNA; however, there were increases in surface CD13 at some time points on FLS with 
IFNγ treatment.  This could also represent a difference in biological localization.  While IFNγ 
can increase CD13 in the joint by an effect on FLS, this effect may not carry over to other cell 
types and sera concentrations.  Alternatively, this could indicate difference in the strength of 
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regulation when in a complex biological environment.  In our experiments we treated FLS with 
one cytokine at a time.  In the body, represented by the serum, there are multiple cytokines with 
possible regulatory effects on CD13.    The lack of correlation with IFNγ in sera could indicate 
that in an IFNγ dominated disease other cytokines are also upreguated that downregulate CD13.  
The effect of these hypothetical down-regulators could be stronger than the upregulation of 
IFNγ.   We did see correlations between CD13 amounts and both TNFα and IL-17 sera 
concentrations.  These data corroborate what we saw with RA FLS CD13 mRNA regulation.  
This could indicate that in IL-17 or TNFα dominated disease states, the upregulation of CD13 by 
these cytokines is the dominate effect on CD13 expression.  A third possibility is that the three 
cytokines differentially regulate release of CD13.  The correlation of sCD13 in serum with TNFα 
and IL-17 could indicate that these cytokines aid in the release of CD13 as well as upregulate the 
mRNA, while IFNγ upregulates the mRNA but more specifically leads to cellular localization of 
CD13. 
 
There are three possible mechanisms by which FLS may release CD13.  First, as a cell surface 
molecule, CD13 may be cleaved by a protease.  Second, CD13 could be secreted, a process 
which involves the golgi apparatus forming secretory vesicles (containing the soluble proteins) 
that undergo exocytosis.  Third, CD13 could be secreted on the surface of extracellular vesicles 
such as exosomes.  First we examined the possibility of CD13 as a shed molecule.  Soluble 
CD13 identified in serum is truncated and lacks the intracellular and transmembrane domains, 
suggesting cleavage from the cell membrane 
90
.  We examined this mechanism using inhibitors 
specific for different classes of proteases: pepstatin A (aspartic), aprotinin (serine), leupeptin 
(serine/cysteine), GM6001 (metalloproteinases), and E64 (cysteine).  Our data indicate that 
82 
 
CD13 is cleaved from FLS by metalloproteinases (Figure 3.4A).  Metalloproteinases fall 
primarily into one of two groups, either matrix metalloproteinases (MMPs) or a disintegrin and 
metalloproteinase (ADAMs).  Transmembrane proteases which are known to participate in 
cleavage and release of proteins anchored in the membrane are most likely responsible for 
release of CD13.  Several of these proteases are members of the metalloproteinase family 
(MMPs14,15,16,17 and ADAMs).   
 
Of the membrane-type metalloproteinases, MMP14 is found in the highest amount on RA FLS 
178,181
.  In RA, MMP14 has already been linked to matrix degradation by FLS and osteoclast-
mediated bone resorption 
178
.  One study showed that of the MMPs found by RT-PCR on RA 
synoviocytes (MMP1,2,13,14,15) only MMP14 was shown to function as a type I and type II 
collagenase under biological conditions 
49
.  The same study also demonstrated that RA 
synoviocytes can induce angiogenesis at tissue sites proximate to the cells, a function that can be 
blocked by silencing MMP14.  This data indicate that MMP14 can cleave a pro-angiogenic 
factor that may mediate angiogenesis in RA.  Because CD13 is strongly linked to angiogenesis in 
tumors we hypothesized that MMP14 could cleave CD13 leading to subsequent angiogenesis 
102,228,229
.  Indeed, siRNA inhibition of MMP14 resulted in a significant decrease in CD13 
cleaved from FLS (Figure 3.6A).  Inhibition of all metalloproteinases by GM001 further reduced 
the CD13 released into the supernatant.  However, MMP14 may be more involved than indicated 
in our results.  While KD did result in most of the MMP14 mRNA being removed, the MMP14 
protein was not successfully measured.  As such there may be MMP14 protein remaining which 
cleaves the CD13, but even at the lowest CD13 in the supernatant was only reduced to around 
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35% (in one cell line).  While some MMP14 protein may still remain, it seems likely that at least 
one other metalloproteinase, besides MMP14, sheds CD13 from FLS. 
 
Looking at overall MMP expression in RA, stimulated RA synoviocytes have been shown to 
express mRNA for MMP1, 2, 13, 14, and 15 
49
.  Although it is possible that the soluble MMPs 
(MMP1-13) may cleave CD13, cell surface enzymes are much more common in the role of 
sheddases.  In addition, CD13 can be cleaved in vitro under serum free conditions.  Soluble 
MMP activity is dependent on zymogen conversion, typically by plasmin 
49
.  Though MMP 
zymogen conversion can occur under serum free culture conditions, we did not see a decrease in 
CD13 shedding with aprotinin.  Aprotinin inhibits plasmin activity and would therefore decrease 
the active forms of soluble MMPs in the culture supernatants.  This is biologically relevant as 
serum and synovial fluid contain anti-proteinases that have been shown to limit collagenolytic 
activity of soluble MMPs from RA synoviocytes 
49
.   
 
It is widely known that members of the metalloproteinase family are redundant, with multiple 
proteins performing the same functions.  Collagenolytic activity is the most predominant, with 
most MMPs demonstrating this function.  However, the similarity of cleavage sites and activity 
may also carry over to other substrates 
177
.  It is possible that other membrane bound MMPs 
(MMP15, 16, or 17) are also involved in CD13 shedding.  MMP15 mRNA has previously been 
found in RA synoviocytes, and MMP16 has been found on synovial tissue biopsies 
49,178
.  The 
other possible group of CD13 sheddases is the ADAMs.  In particular the two related ADAMs, 
ADAM10 and ADAM17, have been linked to shedding of various cytokines and chemokines 
230
.  
In general ADAM10 is linked to constitutive cleavage while ADAM17 cleavage is in response to 
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a stimulus 
231
.  ADAM17 is particularly of interest as a recent publication has shown that CD13 
and ADAM17 can associate on the cell surface.  This study examined acute monocytic 
leukeumia cells and showed that when anti-CD13 antibodies were used to target CD13 it resulted 
in a downregulation of both surface CD13 and surface ADAM17
232
.  This indicates that CD13 
and ADAM17 co-localize on the cell surface and thus can be internalized together.  Therefore 
the most likely molecules on FLS that could cleave CD13, other than MMP14, are 
MMP15/MT2-MMP, MMP16/MT3-MMP, and/or the ADAMs 
181
.  Attempts at single 
knockdown of MMPs15 or 16 or various ADAMs (ADAM10, 15, and 17) did not result in any 
significant reduction in CD13 released (data not shown).  Based on our observations the most 
probable explanation of our data is that MMP14 is the primary cleaver of CD13 from FLS with 
multiple other metalloproteinases acting in a similar but redundant fashion. 
 
To confirm MMP14 as a cleaver of CD13, we also looked for co-localization of CD13 and 
MMP14 on FLS.  CD13 and MMP14 have previously been found in similar cell surface 
domains, but their proximity has not been determined.  Both CD13 (FLS) and MMP14 (breast 
carcinoma and glioma cells) have been found in caveolae-enriched lipid rafts 
86,197
.  We show 
that on the surface of FLS CD13 and MMP do co-localize and in some cells we have observed a 
punctate pattern which may be indicative of inclusion into lipid raft structures.  Overall these 
data are supportive of the conclusion that MMP14 can cleave CD13. 
 
Because cleavage of CD13 did not appear to account for all of the CD13 in the supernatant we 
also looked at the possibility of CD13 as a vesicle-bound molecule.  We used differential 
ultracentrifugation to isolate soluble proteins and exosomes/extracellular vesicles.  We identified 
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CD13 both in the soluble fraction and around the density of exosomes (Figure 3.1).  Further 
density separation identified CD13 at all densities (1.268-1.031 ng/ml), indicating its presence on 
exosomes as well as other extracellular vesicles of similar density.  One problem with the 
differential centrifugation method is that it can isolate other EVs or large protein aggregates of 
similar density to exosomes.  One group that can fall into this category is apoptotic blebs 
233
.  
However, the additional separation by density gradient can distinguish between exosomes, other 
EVs, and protein aggregates.  Apoptotic blebs float at about a >1.23g/ml density while exosomes 
float at 1.10-1.21g/ml 
233
.  We found CD13 on both exosomes and other EVs.  Our results 
demonstrate that CD13 is present as both a soluble molecule and on extracellular vesicles 
derived from FLS.  However, the proportion of CD13 on EVs in FLS supernatant exceeded the 
residual CD13 in supernatants of GM6001 treated cultures.  This may be because 
metalloproteinase inhibitors, such as GM6001, are able to inhibit exosome release.  Even though 
it is uncertain what role metalloproteinases assume in exosome release from cells, GM6001 
inhibited the release of exosomes from endothelial cells 
206
.  Thus, the addition of GM6001 may 
be blocking both MMP-mediated cleavage of CD13 and some of the release of exosomes from 
FLS, leaving only a small portion of exosomes and other EVs expressing CD13 in the 
supernatant. 
 
Overall, our results point to roles for CD13 in the pro-inflammatory milieu of the RA synovium.  
Previous data showed CD13 to be elevated in RA synovial fluid and present on RA FLS.  In this 
chapter we have shown that CD13 is shed from RA FLS by metalloproteinases and is also 
released on extracellular vesicles.  The CD13 in synovial fluid is predominately soluble, with 
CD13 also present on extracellular vesicles.  While MMP14 has been identified as one molecule 
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that cleaves CD13, future studies will be needed to define other CD13 sheddases.  The current 
results identify both CD13 and MMP14 as potential targets in amelioration of RA synovial 
pathology. 
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                                                                                                         Chapter 4
Functions of CD13 in Rheumatoid Arthritis 
 
We have demonstrated that CD13 is elevated in RA synovial fluid, expressed in RA synovial 
tissue, and expressed on RA FLS.  In the previous chapter we showed that CD13 is not only 
expressed on the surface of FLS but is cleaved by metalloproteinases including MMP14 to 
become a soluble molecule.  It is also found on extracellular vesicles including exosomes.  We 
also demonstrated that it is upregulated by the pro-inflammatory cytokines IL-17, TNFα, and 
IFNγ with differing patterns of localization and kinetics.  Having defined CD13 in the RA joint 
and on RA FLS the next question was: what is the function of CD13 in the RA joint?  We 
examined the effect of CD13 on two cell types important to RA, T cells and FLS.  First, we 
examined the putative function for CD13 as a T cell chemoattractant.  Second, we sought to 
determine if CD13 is involved in FLS growth and migration.  Both functions are important parts 
of RA pathogenesis.  T cell chemotaxis brings T cells to the RA synovium, where they help 
mediate several pathogenic functions.  RA FLS have an aggressive growth and migration 
phenotype which contributes to RA hyperplasia and eventual joint destruction. 
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Recombinant human CD13 aids in the migration of cytokine activated T cells 
Two previous publications have suggested that CD13 is chemotactic for T cells 
169,234
.  We 
sought to verify this observation and to determine whether CD13 could be chemotactic for 
cytokine activated T cells (Tck), an in vitro generated cell population that phenotypically and 
functionally resembles T cells found in RA synovium 
19,156
.  We used a modified under agarose 
chemotaxis system with SDF-1/CXCL12 and TARC/CCL17 as positive controls.  SDF-1 and 
TARC, had chemotactic indices (CI) of 0.45±0.23 (p=0.068) and 0.42±0.12 (p=0.0012) 
respectively without fibronectin and 0.88±0.29 (p=0.0046) and 0.46±0.42 (p=0.28) with 
fibronectin (Figure 4.1).  Recombinant human CD13 (rhCD13) was used over a range of 
concentrations, from 1000ng/ml to 50ng/ml, and was chemotactic for Tcks between 700ng/ml 
and 50ng/ml.  Peak chemotaxis for CD13 was from 200ng/ml (0.34±0.29) to 500ng/ml 
(0.50±0.18) and was significant over medium alone (medium alone CI=0) at both concentrations, 
p=0.029 and 0.0079 respectively.  RhCD13 was also significant at 200ng/ml with fibronectin 
coating (0.72±0.29, p=0.018) (Figure 4.1).  Representative images of the chemotaxis assays are 
shown in Figure 4.2. 
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Figure 4.1 CD13 is chemotactic for cytokine activated T cells.   
Tck were placed in the center well of the under agarose chemotaxis system with a medium only 
control in one of the side wells and a chemotactic agent in the opposite well.  Some plates were coated 
with fibronectin. Positive wells were loaded with chemotactic controls SDF-1/CXCL12 (30ng/ml) or 
TARC/CCL17 (10ng/ml) or rhCD13 (1000 to 50ng/ml) (n≥12). (CI= Ln # of cells migrated to 
stimulus – Ln # of cells migrated to media alone)±SEM.  *p<0.05 paired two tailed T-test between 
media alone and test wells (method p144) 
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Figure 4.2 Representative illustrations of under agarose chemotaxis. 
Tck were placed in the center well of the under agarose chemotaxis system with a medium only 
control in one of the side wells and a chemotactic agent in the opposite well.  Some plates were 
coated with fibronectin. Positive wells were loaded with chemotactic controls SDF-1/CXCL12 
(30ng/ml) or TARC/CCL17 (10ng/ml) or rhCD13 (1000 to 50ng/ml) Pictures are representative 
of images obtained for counting from under agaorse chemotaxis (n≥19).  Positive pictures show 
cells migrating toward the indicated chemotactic solution.  Negative wells show the migration 
toward the medium only control for the same well.  Arrow shows one migrated cell as an 
example. (method p144) 
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CD13 contributes to the chemotactic activity of SF independent of its enzymatic activity 
We next asked whether CD13 contributes to the chemotactic potential of RA SF.   To test for a 
potential role of CD13 in Tck chemotaxis, we immunodepleted SFs with anti-CD13 (1D7) or a 
mock (MsIg) depleted control (n=3).  The mock depleted SFs had a CI of 1.37±0.44 which was 
significantly chemotactic, p=0.0065.  Immunodepleting CD13 from the SFs resulted in a 
significant decrease in chemotaxis p=0.041, CI of 0.35±0.21 (Figure 4.3A).  
 
We next examined whether CD13’s chemotactic ability required its enzymatic activity.  COS-1 
cells were used to express plasmids containing either wild type (WT) CD13 or an enzymatically 
inactive mutant CD13 (E355Q)
72
.  The CD13 ELISA was used to measure CD13 concentration, 
and loss of enzymatic activity in the mutant was confirmed by the N-aminopeptidase assay 
(Figure 4.3B).  We supplemented CD13 depleted synovial fluids with 200ng/ml of either WT or 
mutant CD13 from the COS-1 supernatants, both of which partially restored the chemotactic 
activity of the depleted SFs to a similar level.  WT CD13 brought the CI from 0.35±0.21 to 
1.02±0.31 and the mutant brought the CI to 1.10±0.30, each representing significant chemotaxis 
above medium alone, p=0.0031 and p=0.0018 respectively (Figure 4.3A).    
 
 
 
 
 
 
 
92 
 
 
 
 
 
 
 
Figure 4.3 CD13 is a significant portion of RA synovial fluid T cell chemotaxis, independent of its 
enzymatic activity.   
Tcks were placed in the center well of the under agarose chemotaxis system with a medium only control 
in one of the side wells and a chemotactic agent in the opposite well.  A, Positive wells were loaded with 
synovial fluid (3 different random donors), MsIgG control depleted or CD13 depleted (1D7), at a 1:10 
dilution, or with CD13 depleted synovial fluid supplemented with supernatant from transfected COS-1 
cells containing wild type or enzymatic inactive mutant CD13 (n≥19).  CI= Ln # of cells migrated to 
stimulus – Ln # of cells migrated to media alone±SEM.  *p<0.05 paired two tailed T-test between media 
alone and test wells; +p<0.05 unpaired two tailed T-test  B, The CD13 amount in the COS-1 supernatants 
was determined by ELISA and was used at 200ng/ml in assays shown in panel A.  Values expressed as 
mean±SEM.  Enzymatic activity was measured by N-aminopeptidase activity assay.  Values expressed as 
mean±SD. (method p144-146) 
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CD13 initiates chemotaxis of T cells through a G-protein coupled receptor 
Most known chemokines function through a G-protein coupled receptor (GPCR)
235
.  We used 
Pertussis toxin (PTX) to determine whether the mechanism for CD13-induced chemotaxis 
functions similarly.  PTX is an ADP-ribosylating toxin produced by the bacteria Bordetella 
pertussis.  It catalyzes the ribosylation of α subunits of Gi/o proteins meaning that they cannot 
interact with GPCRs
236,237.  This keeps the Gαi/o proteins in an inactive state and prevents the 
function of associated GPCRs.  Through this mechanism PTX treatment of cells can be used to 
inhibit chemotaxis that functions through Gi/o associated GPCRs.  PTX treatment of Tcks 
significantly reduced chemotaxis toward 200ng/ml rhCD13 either with a fibronectin coating 
(0.42±0.20 to -0.50±0.50, p=0.047) or without (0.44±0.15 to -0.84±0.44, p=0.00096), and also 
inhibited migration toward SDF-1 and TARC positive controls (significant for TARC, uncoated, 
at p=0.05) (Figure 4.4).  Background cellular movement, indicated by migration toward medium 
alone control, was not affected by PTX treatment.  We examined average cell counts in both 
PTX treated and untreated Tcks and saw no decrease in cellular migration except for the directed 
chemotaxis (data not shown).   
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Figure 4.4 CD13 chemotaxis functions through a pertussis toxin sensitive G-protein coupled 
receptor.   
Tcks were placed in the center well of the under agarose chemotaxis system with a media only negative 
control in one of the side wells and a chemotactic agent (SDF-1, TARC or rhCD13) at indicated 
concentration in the opposite well.  Plates were left untreated (A) or fibronectin (10g/ml) coated 
overnight (B).  Some Tcks were treated with 100ng/ml of pertussis toxin for 2hr at 37°C. (n≥20)  Cell 
counts were Ln transformed and data is expressed as a chemotactic index (CI= Ln # of cells migrated to 
stimulus – Ln # of cells migrated to media alone) with error expressed as SEM.  *p<0.05; *p<0.001 
paired two tailed T-test between media alone and test wells; + p0.05 un-paired two tailed T-test 
between two groups of chemotactic indices (method p144) 
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CD13 aids in growth and migration of RA FLS 
We identified CD13 as a soluble molecule and on extracellular vesicles released by FLS.  
Because we did not observe a correlation between the upregulation seen at the mRNA level and 
cell surface CD13, we looked at the effect of IFNγ, TNFα, and IL-17 on CD13 in FLS culture 
supernatants.  We found results similar to what was observed on the cell surface with variable, 
fluctuating regulation from 0 to 72 hours (Figure 4.5).  This indicates that CD13 may be taken up 
by the RA FLS in an autocrine manner.  To determine possible functions for CD13 on FLS we 
looked at the effect of anti-CD13 antibodies (WM15 or 1D7) or CD13 chemical inhibitors 
(bestatin or actinonin) on RA FLS growth and migration.  Anti-CD3 was used as a negative 
control.  We observed a significant slowing of cell growth with both CD13 inhibitors and both 
anti-CD13 antibodies (Figure 4.6A).  Data are expressed as the change from 0hr as a ratio to 
untreated FLS of the same cell line at the same time point.  Actinonin was the strongest inhibitor 
of FLS cell proliferation and significant decreases were seen with actinonin treatment at time 
points between 24 and 120 hours.  Significant decreases (p≤0.05) in FLS proliferation were also 
seen with bestatin from 24-60 hours and at 120 hours, with 1D7 at 36-120 hours, and with 
WM15 24-60 hours and at 120 hours.   Significant decreased (p≤0.05) were also seen in RA FLS 
migration in a wound healing assay with actinonin, WM15 and 1D7 primarily from 36 hours to 
72 hours (Figure 4.6B).  Figure 4.7 shows example images of control anti-CD3, actinonin, and 
1D7 treated scratch wounds.  Antibodies were tested at both 25ng/ml and 50ng/ml.  A significant 
decrease in migration was seen with both concentrations and the data for the lower concentration 
is shown.  While a decrease was seen in growth with 25ng/ml, the significance was borderline.  
The data shown are for the 50ng/ml concentration in which the decrease was more definitively 
significant. 
96 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 CD13 released by FLS fluctuates in response to IFNγ, TNFα, and IL-17. 
FLS were stimulated over a time course of 0-72 hours with IFNγ (1U/ml), TNFα 
(10ng/ml), or IL-17 (10ng/ml).  Culture supernatants were collected and concentrated 
through at 30KDa centrifugation filter.  Data are expressed as a ratio of cytokine treated 
to untreated FLS at the same time point.  n=1 representative of n=3 (methods p138 and 
140) 
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Figure 4.6 CD13 chemical inhibitors or antibodies significantly slow growth and 
migration of RA FLS in vitro.   
FLS were seeded on 96-well plates overnight.  An Essen Incucyte system was used for 
both growth (A) and migration (B).  Growth was calculated as the difference in percent 
confluence from time 0.  Migration was measured in a scratch wound assay using 
relative wound density.  All data is expressed as a ratio to untreated FLS of the same cell 
line.  mean±SEM   n≥4   *p<0.05 (method p147) 
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Figure 4.7 Sample images from scratch wound assay.   
Actinonin and 1D7 suppress migration of RA FLS into a scratch wound.  Anti-CD3 is used as an irrelevant 
negative control.  Dark areas show the edges of the initial wound.  Images are representative of n≥6 for 
n≥4 experiments (method  p147) 
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Discussion 
Two publications have suggested that CD13 may act as a chemokine for T cells 
169,234
.  We 
wanted to further explore this function as one possible aspect of the interaction between FLS and 
T cells in the RA joint.  We tested for chemotaxis with SDF-1, TARC, or rhCD13 using not only 
Tcks, but also resting T cells, anti-CD3/CD28 activated, Jurkat, HUT78, and mitogen activated T 
cells (data not shown).  We chose Tck because we achieved the most consistent and significant 
chemotaxis with both positive control chemokines and rhCD13 with this cell type.  This is of 
particular interest as Tck phenotypically resemble T cells found in the RA joint 
19
.  Chemotaxis 
assays with rhCD13 were performed both over a fibronectin coated and uncoated plate, to 
explore both a basic chemotaxis (uncoated) and a matrix invasion type function (fibronectin 
coating).  Even though rhCD13 and synovial fluid were significantly chemotactic in both 
systems, the two known T cell chemokines (TARC and SDF-1) were each significantly 
chemotactic in only one of the systems.  Fibronectin improved adhesion of the Tck to the plate, 
magnifying both specific and non-specific movement.  This could be primarily noted by the 
difference in time to optimally measure chemotaxis.  With an uncoated plate, we found the 
optimal time to distinguish chemotaxis was around 20-22 hours.  When plates were coated with 
fibronectin cells migrated faster, and the optimal time to count cells was at around 5 hours.   
 
We selected two chemokines as positive controls for chemotaxis.  SDF-1/CXCL12 was chosen 
because the receptor (CXCR4) is upregulated on Tcks, and SDF-1 is the only chemokine that has 
been previously shown to be chemotactic for Tcks specifically 
156
.  TARC/CCL17 specifically 
binds to the CCR4 receptor.  CCR4 is specific for T cells and has been found on high numbers of 
T cells in RA synovial tissue 
155,238
.  We did note some differences between the two known 
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chemokines, TARC and SDF-1.  While we expected that both would be chemotactic for T cells, 
we found SDF-1 was significant only across a fibronectin coated surface while TARC was 
significant only over an untreated plate.  As the chemotactic indices are similar this may be a 
reflection of the high background.  However, observation of the chemotactic assays and the total 
cell counts indicate that this may be a real phenomenon.  The difference is the fibronectin, and 
one possible explanation for the difference in the two chemokines is proposed by Patel et al.  
This group found that chemokines bind to ECM components with different degrees of strength 
239
.  Solid phase versus soluble chemokines may have different functions in the different stages 
of cell migration with solid phase chemokines being needed for firm adhesion 
239,240
.  While it is 
unknown if TARC binds to fibronectin, SDF-1 does and this association with fibronectin aids in 
cell migration 
241
.  Our data could indicate a difference in the ability of SDF-1 and TARC to bind 
to fibronectin, and this could explain the difference in significance.  Related data is also 
supportive of an in vivo role for CD13 chemotaxis.  It has been suggested that for in vivo 
chemotaxis, chemokines need to bind to cell surface glycosaminoglycans 
239,242
.  CD13 is already 
expressed as a cell surface protein on endothelial cells, a placement linked to monocyte 
migration/invasion 
85
.  The cell surface CD13 could act to aid in cellular migration/invasion 
without the extra step of binding to a glycosaminoglycan.  Thus, both soluble CD13 and cell 
surface CD13 may aid in chemotaxis.   
 
It is important to note that the optimal levels of CD13 in the chemotaxis assays correspond to 
sCD13 levels found in vivo indicating this process is likely biologically relevant (Figure 4.1).  
Although the average CD13 concentration in RA synovial fluid is higher than the peak 
chemotactic range, it is possible that this serves to create a gradient between the joint and the 
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serum with the high concentration in the joint aiding in T cell retention.  Consistent with this 
hypothesis, the average concentration of CD13 in OA SF is similar to normal serum 
concentrations (Figure 2.3).   
 
It is known that there are multiple chemokines that contribute to the migration of T cells to the 
RA joint
243,244
.  Notwithstanding the effects of other chemokines, CD13 appears to significantly 
contribute to the chemotactic activity of RA SF as Tck chemotaxis decreases when CD13 is 
depleted from such samples (Figure 4.3A).  CD13 is capable of regulating other chemokines, but 
in vitro studies with rhCD13 indicate that CD13 can initiate chemotaxis directly 
60,95,166,167
.  To 
determine whether the CD13 dependent chemotaxis in SF was direct or through enzymatic 
effects on other molecules, we supplemented rhCD13 back into the depleted SFs using either 
WT or an enzymatically inactive mutant (E355Q).  The glutamic acid at amino acid 355 is part 
of the highly conserved GAMEN motif that is involved in substrate binding
73,74
.  Both the WT 
and mutant CD13 proteins were able to partially restore chemotactic activity to a similar degree 
demonstrating that the mechanism of chemotaxis is independent of CD13’s enzymatic activity 
(Figure 4.3).  This also indicates that CD13 likely binds directly to a receptor on the T cells.   
 
To confirm this we used PTX treated Tck.  PTX is known to inhibit cellular responses mediated 
through Gi/o proteins including most chemokine receptors
235,245
.  Here we were able to show that 
CD13 also acts through a PTX-sensitive GPCR (Figure 4.4).  We also saw similar results with a 
fibronectin coating indicating a similar mechanism for basic chemotaxis or migration involving 
ECM.  PTX has been shown to function through both G protein dependent and independent 
pathways.  The G protein dependent pathways involve the A subunit; while, the G protein 
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independent pathways involve the B subunit 
245
.  The B subunit is capable of activating T cells 
246–248
.  The two mechanisms can be distinguished by how the PTX is used.  The A subunit uses 
low concentrations of the PTX and the effect is slow but long lasting 
245,249
.  The B subunit 
requires a high concentration and the effect is rapid but transient 
246–248
.  For our studies we used 
a low concentration of PTX.  We also washed off the PTX before examining the effects over a 
long range of time.  The effect we observed was also specific to the chemotactic effect.  This 
supports the conclusion that CD13 is acting through a PTX sensitive GPCR. 
 
Although we have defined one mechanism for CD13 mediated T cell chemotaxis in RA, CD13 in 
the RA joint is also likely involved in cleaving chemokines, extracellular matrix proteins, and 
other molecules that regulate migration of T cells and interaction of those T cells with FLS. 
Future investigation of these aspects of CD13 function and definition of the T cell receptor for 
CD13 will yield additional insights into the roles of CD13 in RA. 
 
Another component of disease pathology in RA is aggressive outgrowth and migration of FLS, 
manifested clinically as synovial hyperplasia.  Our data indicate a role for CD13 in the growth 
and migration of RA FLS.  It is uncertain whether this is dependent on soluble CD13 or cell 
surface CD13.  We found that while inhibitors of CD13 enzymatic activity and anti-CD13 
antibodies each inhibited FLS proliferation and migration, additional rhCD13 did not 
consistently affect the RA FLS (data not shown).  This may reflect the large amount of CD13 
produced by the FLS that can act in an autocrine fashion.  To help determine if the effects of FLS 
growth and migration were dependent on CD13 enzymatic activity we used two chemical 
inhibitors of enzymatic activity, one anti-CD13 antibody that inhibits enzymatic activity 
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(WM15), and one anti-CD13 antibody that does not inhibit enzymatic activity (1D7).  The fact 
that a chemical inhibitor could block growth and migration indicates that the enzymatic activity 
is likely necessary for these functions of CD13.  Actinonin was the strongest inhibitor of FLS 
proliferation, indicating that FLS growth in particular is dependent on enzymatic activity.  
Though it is uncertain why an antibody that does not inhibit CD13 enzymatic activity can block 
CD13 mediated FLS cell growth similarly to chemical or antibody inhibitors of CD13 enzymatic 
activity, the most likely explanation is steric hindrance.  1D7 does not block cleavage of the 
small molecule L-leu-AMC in the CD13 aminopeptidase activity assay; however, it may block 
the ability of CD13 to associate with larger substrates on FLS, thereby indirectly but effectively 
blocking the enzymatic activity and cell growth or migration.  It is also uncertain why bestatin 
blocked FLS growth but not migration.  It is possible that FLS migration is not dependent on the 
enzymatic activity, but that actinonin is binding to CD13 in such a way to block the area that is 
responsible for mediating migration.  Alternatively, while the antibodies are mediating a CD13 
dependent decrease in FLS migration, actinonin could be acting in a separate CD13 independent 
mechanism.  Actinonin is not specific for CD13 and has been shown to negatively affect tumor 
cells in a CD13 independent fashion 
250
.  Neither bestatin nor actinonin are specific for CD13, 
and as discussed in chapter 1 are not the best measures for CD13 activity.  However, the 
antibody inhibition of RA FLS proliferation and migration supports a specific role for CD13 in 
RA FLS outgrowth.  We included the chemical inhibitors to relate our data to most of the 
previous work done with CD13, which uses bestatin or actinonin.  The conclusion can be drawn 
because it is supported by the specific antibodies. 
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We have demonstrated two mechanisms by which CD13 may contribute to RA pathogenecity.  
First, CD13 is a chemokine for T cells, similar to those in the RA joint.  Second, CD13 aids in 
the proliferation and migration of RA FLS.  Both of these functions could contribute to the 
inflammatory pathogenesis of RA.  Combined with data from previous chapters we can conclude 
that CD13 is upregulated in the RA synovium.  It is found in high levels on RA FLS, and is shed 
by RA FLS into the synovial fluid.  This soluble CD13 contributes to the chemotaxis of T cells 
to the RA joint.  Those T cells can then further upregulate CD13 expression through the 
secretion of pro-inflammatory cytokines.  CD13 also contributes to FLS proliferation and 
migration, further increasing the CD13 in the synovium.  In total, CD13 could play an important 
role as part of a positive feedback loop in the RA joint, in which CD13 has important pro-
inflammatory effects on both T cells and FLS. 
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                                                                                                         Chapter 5
Conclusions and Future Directions 
 
The experiments described here indicate that CD13 may contribute to RA disease pathology.  
Previous work that measured CD13 in RA and proposed that is was chemotactic for T cells relied 
primarily on CD13 aminopeptidase activity measurements.  We developed a novel CD13 ELISA 
to conclusively measure CD13.  Our data is in part supportive of previous conclusions reached 
by measurement of CD13 enzymatic activity.  CD13 is significantly elevated in RA synovial 
fluid compared to OA (Figure 2.3).  However, we also inferred that in synovial fluid, and 
especially in RA synovial fluid, there are other proteins with similar aminopeptidase activity 
(Figure 2.8).  Therefore aminopeptidase activity assays alone do not provide a complete or 
significantly accurate picture of the expression and function of CD13.  This is also likely true of 
other biological fluids such as serum.  We did find that CD13 appears to be the major contributor 
to aminopeptidase activity in synovial fluid; however, this may not be the case for all biological 
fluids.  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Our finding that cultured RA and OA FLS express similar levels of CD13 in vitro is 
contradictory to a prior publication (Figure 2.7)
169
.  However, this study analyzed just three cell 
lines per group and was done with enzymatic activity and Western blot only.  Our data represents 
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a higher n and a quantitative measure of CD13 by ELISA.  We found a high degree of variation 
in CD13 levels that likely explains the differences between the two conclusions.  This leaves the 
conclusion that while CD13 is significantly elevated in RA over OA in vivo there is no 
significant difference in vitro between RA and OA FLS.  We discussed four possible 
explanations for the differences: the cytokine milieu in the RA joint, increased numbers of 
monocytes and endothelial cells in the RA joint, hyperplasia of RA FLS, and increased 
expression of proteases in RA.  All of these mechanisms are likely to be relevant and our data 
directly support the first two.  We have shown that pro-inflammatory cytokines (IL-17, TNFα, 
and IFNγ) upregulate CD13 mRNA in cultured RA FLS (Figure 3.8).  These effects may further 
be magnified when combined in the RA joint along with other stimulatory cytokines.  We 
observed fluctuating kinetics of protein localization and regulation on RA FLS cell lines in 
response to the three different cytokines.  Differing levels of cytokines in the joints of different 
RA patients may help to explain the wide degree of variation in CD13 concentrations in synovial 
fluid.  We also observed higher numbers of monocytes/macrophages expressing CD13 in RA 
synovium sections than in OA or normal synovium.  Evidence of CD13 on neovascular 
structures was also observed in RA synovium (Figure 2.4).  These data demonstrate the presence 
of other CD13 expressing cells in the RA joint.   
 
While we did not specifically examine the latter two possibilities, evidence is supportive of both.  
It is known that RA FLS undergo hyperplasia resulting in more cells present in the joint.  While 
in cultures we examined similar numbers of RA and OA FLS, we also demonstrated that CD13 
itself may play a role in RA FLS proliferation.  We also showed that CD13 is cleaved by 
metalloproteinases and specifically MMP14.  Metalloproteinases and particularly MMP14 are 
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elevated in RA.  In addition pro-inflammatory cytokines such as TNFα increase 
metalloproteinase expression
251
.  In conclusion, our data indicates that a combination of 
increased numbers of CD13 expressing cells (FLS, monoctyes/macrophages, endothelium) and 
upregulation of CD13 and CD13 sheddases (metalloproteinases) on these cells by the pro-
inflammatory milieu results in the higher CD13 levels in the RA synovial fluid.   
 
Another interesting observation was that CD13 is lower in RA sera than in normal sera.  This 
may be explained by the migration of CD13 expressing cells into the RA synovium.  This is 
consistent with our observation of increased CD13 in RA synovial fluid and increased numbers 
of CD13/CD11c co-expressing cells (monocytes/macrophages) in RA synovial tissue.  However, 
circulating monocyte numbers do not go down in RA
252
.  But, CD13 is known to be upregulated 
on activated monocytes.  This may imply that the highly activated, inflammatory monocytes that 
migrate into the synovium express higher levels of CD13 than those that remain in circulation.  
Alternatively, serum CD13 may be taken up and utilized in RA at an accelerated rate over 
normal serum CD13.  This utilization could represent the putative functions in RA, such as 
chemotaxis.  It is also suggestive that the CD13 receptor may be upregulated on cells in RA.  
This could be useful in identification of the CD13 receptor.  It is interesting to note that CD13 is 
not the first metalloenzyme to be found with this phenotype.  CD26, a related protein, has also 
been found in lower amounts in RA sera than in normal sera
253
.  While the mechanism of this 
decreases is also unknown, in the case of CD26 it has been suggested that the decrease may 
function to lower degradation of SDF-1 and increase chemotaxis in RA
106
.  From the conclusions 
that CD13 is increased in RA synovial fluid and decreased in RA serum, we can infer the 
possibility that CD13 is acting as a chemoattractant in RA.  There is no difference in CD13 
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amount between normal sera CD13 and OA synovial fluid; however, the differences in RA 
indicate a potential function for CD13 in the RA joint.  The higher amount of CD13 inside the 
joint and the lower amount in the serum results in a gradient that could bring CD13-responsive 
cells, specifically T cells, into the joint.  Our data confirms that CD13 acts as a T cell 
chemoattractant at biologically significant levels, and that CD13 represents a significant portion 
of the T cell chemotactic ability of RA synovial fluid.   
 
T cell chemotaxis is not the only function for CD13 in the RA joint.  In RA multiple cell types 
contribute to inflammation and pathogenicity.  We found, when examining the effects of 
cytokines on FLS expression of CD13, a fluctuating pattern at both the cell surface and in the 
culture supernatant.  These fluctuations included increases in soluble CD13 followed by 
decreases.  While we could not definitively demonstrate that soluble CD13 is being taken up by 
FLS, these data are suggestive of that possibility.  CD13 has also been implicated in migration of 
dermal fibroblasts 
133
.  Based on these observations we examined the function of CD13 on FLS 
growth and migration by the use of chemical inhibitors or anti-CD13 antibodies.  From the 
results we can conclude that CD13 is likely involved in RA FLS pathogenicity.  We have shown 
that CD13, through its enzymatic activity, can contribute to RA FLS growth and migration, 
processes that are relevant to the FLS hyperplasia that is a clinical and pathological hallmark of 
RA. 
 
Overall we can conclude that CD13 is likely playing a role in the pathogenicity of RA by 
contributing to a pro-inflammatory loop in the joint.  CD13 is expressed on FLS, and during RA 
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CD13 is upregulated on FLS by pro-inflammatory cytokines (IFNγ, TNFα, IL-17) and cleaved 
by metalloproteinases (which are also upregulated in RA).  Soluble and vesicle bound CD13 
accumulates in the intra-articular space.  CD13 from the synovium forms a gradient into the 
surrounding serum where it can bind a GPCR on the surface of T cells bringing the T cells into 
the joint.  Once in the joint the T cells become further activated leading to production of more 
pro-inflammatory cytokines.  This leads the FLS to further upregulate CD13.  The CD13 in the 
joint also aids in proliferation and migration of the FLS, also ultimately leading to more CD13 
production.  Ultimately our data suggests that CD13 participates in a self-perpetuating state of 
inflammation in RA as diagramed in Figure 5.1. 
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Figure 5.1 Diagram of a model for CD13 in a pro-inflammatory loop contributing to RA. 
FLS express CD13 that is upregulated by pro-inflammatory cytokines.  CD13 is cleaved by 
metalloproteinases, and the soluble form can migrate into the serum forming a chemotactic 
gradient.  The CD13 binds to a GPCR on T cells initiating chemotaxis into the joint.  In the 
joint T cells become activated and produce more pro-inflammatory cytokines, which in turn 
leads to increased CD13 expression.  CD13 also contributes to proliferation of the FLS 
increasing CD13 levels further, thus restarting the loop. 
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CD13 in RA: future directions 
We have shown that CD13 is found in high levels in the RA joint and is upregulated in RA 
versus OA synovial fluid.  We also established roles for CD13 in RA in the growth and 
migration of FLS and the migration/invasion of T cells.  However, there are still many other 
possible mechanisms through which CD13 could act in RA.  First, CD13 may also be involved in 
other T cell processes.  Expression of CD13 on T cells has been linked to activation.  This 
activation and CD13 expression require cell-cell adhesion with CD13 expressing cells, including 
FLS 
145,146
.  This may imply that CD13 is involved in FLS-T cell interactions and subsequent T 
cell activation.  While we did not find CD13 expressed on any T cells, we did not examine T 
cell/FLS co-cultures.  Further experiments should be done to examine other effects of CD13 on T 
cells.  Assays could include proliferation (thymidine incorporation), cytokine production (IFNγ, 
IL-17, TNFα, IL-4), and signaling molecule phosphorylation.  First steps would be to do these 
assays with a range of soluble rhCD13 concentrations, from low levels of CD13 up to the high 
concentrations found in RA synovial fluid (10ng/ml-2000ng/ml).  The enzymatically inactive 
mutant could be used to determine whether enzymatic activity is necessary for any effects.  Our 
results demonstrate an effect of CD13 on Tcks; however, the effect of CD13 may not be limited 
to just Tcks.  These assays should also be run on resting T cells, CD3/CD28 activated T cells, 
and mitogen activated T cells.  Subsets of T cells could also be used including naïve T cells 
versus memory T cells, CD4 versus CD8, regulatory T cells, and Th1/Th2/Th17 skewed T cells.  
This could help determine if CD13 has a general effect on T cells or specifically affects different 
subsets or activation states of T cells.  This may provide additional information about the specific 
role for CD13 in RA. 
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Our data demonstrates a chemotactic response of Tcks toward soluble CD13.  Once in the 
synovium, T cells interact directly with FLS and other synovial cells.  CD13 may also participate 
in these cell-cell interactions.  Therefore experiments to assess the role of cell surface CD13 on T 
cells should also be done, through T cell co-culture with CD13 expressing cells.  FLS and 
DCs/monocytes should be tested as potential sources of cell surface CD13 in the joint.  Similar 
experiments to those discussed above with resting or previously activated T cells and irradiated 
FLS/DCs could look at T cell proliferation and cytokine secretion.  In this case CD13 would 
need to either be knocked down by siRNA or inhibited with antibodies on the FLS or DCs.  
Alternatively knock-in of CD13 into a CD13 negative cell line (chinese hamster ovary cells 
[CHO]) could be used.   This could also help determine if CD13 alone is capable of activating T 
cells or if it works in context with other molecules on the FLS/DCs.  Knock-in of the wild type 
versus the enzymatically inactive mutant could help define if effects on T cells are dependent on 
the enzymatic activity.  Wild type versus enzymatically inactive mutant CD13 could also be 
added back to FLS subsequent to CD13 knockdown.  This could help determine a role for 
soluble versus membrane bound CD13.  We have shown that CD13 in the joint is important in T 
cell chemotaxis but further experiments may reveal other roles for CD13 in FLS/T cell 
interactions. 
 
CD13 is expressed on multiple cell types that are involved in RA pathogenesis besides FLS, 
including endothelial cells, monocytes/macrophages, and mesenchymal stem cells.  Functions of 
CD13 on these cell types may also be relevant for RA.  CD13 is involved in 
macrophage/monocyte aggregation and migration in a mouse model of peritonitis 
85,114–116,254
.  
As migration of monoctyes is also important in RA pathogenesis it can be hypothesized that 
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CD13 may play a similar role in RA.  The data presented here is also supportive of a putative 
role for monocytic derived CD13.  We showed an increase in CD11c/CD13 co-expressing cells 
in RA synovial tissue.  This demonstrates the presence of higher numbers of CD13 expressing 
monocytes in RA.  We also found a significantly lower amount of CD13 in serum of RA patients 
compared to healthy controls.  Combined with the elevated levels in the RA synovial fluid this 
could prompt the question: is this chemotactic gradient important for just T cell migration or 
could it also contribute to monocyte chemotaxis?   
 
To address the question of CD13 induced monocyte chemotaxis, chemotaxis experiments similar 
to those done with T cells could be done with monocytes.  A possibility that wasn’t explored in 
the previous studies is whether soluble CD13 is chemotactic for monocytes.  This could be done 
in a standard chemotaxis assay with rhCD13.  To examine a specific role for CD13 associated 
monocyte migration in RA, RA synovial fluids could be depleted of CD13 by immunodepletion 
and used in the chemotaxis assays.  These experiments could also be done with the enzymatically 
inactive mutant compared to the wild type CD13.  Again it would be best to do this with the 
rhCD13 supplemented back into depleted synovial fluid as done with the Tck.  To address the 
question of other cell types shedding CD13 in the synovium, experiments would need to be done 
to examine shedding of CD13 from monocytes, DCs, macrophages, and epithelial cells.  This 
could be done by examining culture supernatants for CD13 by ELISA.  All culture experiments 
would need to be done in serum free conditions to eliminate bovine serum CD13.  Previously 
monocyte shedding of CD13 has only been observed during apopotosis
226
.  Therefore, it may 
also be necessary to examine monoctyes under various stimulation conditions.  Specific 
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conditions that could be tried should include proinflammatory stimuli (such as TNFα) which 
would be elevated in RA and biological conditions (human sera depleted of CD13). 
 
However, basic monocyte chemotaxis may not reveal a complete picture of putative CD13 
mediated monocyte migration.  As previous studies demonstrate a role for endothelial 
cell/monocyte adhesion in monocyte migration, additional chemotaxis studies could be 
performed in a transendothelial system where endothelial cells are cultured on top of the 
membrane 
116,255
.  The transendothelial system should be tested as above with both rhCD13 and 
CD13 depleted or whole RA synovial fluid.  Additionally since both the monocytes and 
endothelial cells express CD13 knockdown experiments should also be done.  These experiments 
would involve knocking down CD13 on the monocytes, the endothelial cells, or both cell types 
before using the cells in the migration assays.  These experiments would further define the role 
for CD13 in monocyte migration while distinguishing its role on the different involved cell 
types.   
 
Human mesenchymal stem cells (MSCs) also express CD13 
256
.  It has not been explored though 
how this may relate to RA.  Interestingly MSCs can be beneficial in RA, even repairing bone and 
cartilage damage.  In fact in a mouse model of RA injection of murine MSCs was shown to 
decrease inflammation and joint destruction
257
.  This may relate back to putative anti-
inflammatory roles for CD13 (as discussed in Chapter 1).  However, MSCs also have the 
potential to differentiate into osteoclasts which can potentiate RA joint destruction.  Another 
future direction would be to examine the effect of CD13 on MSC differentiation.  This could be 
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done by either knocking down CD13 in the MSCs or by addition of exogenous CD13 at 
biologically relevant concentrations and examination of MSC differentiation 
258,259
.  Outcomes 
that could be examined are efficiency of MSC differentiation into osteoclasts versus osteoblasts, 
and the function of those osteoclasts and osteoblasts.  These experiments could help determine 
whether CD13 on MSCs can contribute to the pathogenesis of and/or be beneficial for RA. 
 
Several known substrates of CD13 could impact RA in ways that are governed by the enzymatic 
activity of CD13.  One group has shown that CD13 in conjunction with CD10 on synovial 
fibroblasts can degrade enkephalins, and they propose this as a mechanism for pain and 
inflammation in the RA joint
221
.  This could mean that targeting CD13 or CD13 pathways 
therapeutically in RA could help with pain as well as inflammation.  Further studies examining 
CD13’s ability to degrade enkephalins and the ability of these shortened proteins to bind to the 
opioid receptors would be needed.  Kinins are another group of molecules cleaved by CD13 that 
may be involved in RA pain and inflammation 
260
.  Kinins have been suggested to trigger the 
release of both neurotransmitters (substance P) and inflammatory mediators (IL-1 and TNFα) in 
the joint 
261
.  This may suggest another source of CD13-mediated regulation of pain and 
inflammation in the RA joint.  Neurotransmitters have also been linked to joint processes other 
than pain.  Substance P has been found in high levels in the RA joint and has been linked to FLS 
proliferation and expression of vascular adhesion molecule-1 (VCAM-1) 
262
.  CD13 has also 
been implicated to cleave substance P in cooperation with CD26 
109
.  Further studies would need 
to be done to determine the effects of CD13 cleavage on these various substrates.  The large 
amounts of CD13 in the RA synovium may thus help to contribute to the pathogenicity of 
enkephalins, kinins, and neurotransmitters. 
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CD13 has also been linked to trimming of peptides for presentation on MHC.  This has been 
demonstrated by showing that CD13-mediated degradation has an impact on T cell recognition 
of an artificial peptide 
263
.  Autoantigen presentation is one of the key mechanisms of disease 
pathogenesis in RA.  A possible future study could examine the relationship between known RA 
pathogenic peptides and CD13 degradation.  It would be of particular interest to examine the 
relationships between CD13, pathogenic peptides, and the RA linked MHC allele, HLA-DR4.  
Using various artificial peptides it could be examined whether CD13 degradation leads to 
changes in presentation on HLA-DR alleles linked to RA susceptibility.  Also, it could be 
determined if CD13 preferentially cleaves pathogenic peptides for presentation, such as 
citrulinated proteins. 
 
Yet another possible role for CD13’s enzymatic activity in RA is through an effect on extra 
cellular matrix (ECM).  While it is frequently suggested that CD13 may cleave ECM 
components during cellular migration (usually tumor cell) through matrigel or specific ECM 
components, there is little data about CD13’s actual role in cleavage of ECM.  CD13 has been 
suggested to cleave entactin and type IV collagen but further studies are needed to be conclusive 
264
.  Future studies could examine both these and other ECM components (such as fibronectin 
and type I collagen).  However, these studies are likely to be difficult as CD13 is doubtful as a 
solo degrader.  ECM molecules are very large and CD13 is a peptidase.  Removal of a single 
amino acid at a time is an inefficient degradation mechanism.  However, CD13 may work with 
proteases and/or other peptidases to help in ECM degradation, such as CD26.  ECM degradation 
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assays typically involve looking for invasion and podosome formation of cells into various 
matrixes, often using fluorescent microscopy.  To examine a specific role in joint ECM 
destruction, these studies could be done with RA FLS and siRNA knockdown of CD13.  This 
could be done by culturing FLS on top of a type I collagen matrix, fibronectin, or Matrigel (a 
complex protein system of a basement membrane matrix that is used to mimic in vivo ECM), 
looking for either specific degradation or degradation of complex ECM.  SiRNA knockdown of 
CD13 on fibroblasts would be expected to show a decrease in migration into the gels if CD13 is 
involved in FLS migration into ECM matrices 
49
.  This could indicate the involvement of CD13 
in the degradation of ECM, and this type of study would not be limited by the involvement of 
other proteases/peptidases. 
 
A function for CD13 in FLS invasion could also be examined using a chick chorioallantoic 
membrane (CAM) assay.  In this assay articular cartilage fragments from rabbits are cultured 
with RA or OA FLS and then implanted on top of the CAM of chick embryos.  Invasion of the 
FLS into the cartilage can be then viewed by immunohistochemistry 
49
.  SiRNA knockdown of 
CD13 could be performed on the FLS before implantation which would show whether CD13 is 
important in FLS invasion into cartilage.  While the data shown in this report demonstrates that 
CD13 is important for migration of RA FLS, it is in an in vitro system and only examines basic 
migration.  The CAM assay allows for examination of FLS invasion into cartilage.  It would 
show whether CD13 was involved in cartilage degradation and/or FLS migration into cartilage in 
a more biologically relevant system.   
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One complication in studying CD13 mediated functions of FLS in the joint is that CD13 is 
present as both a cell surface molecule and a shed factor.  A question that remains from this work 
is whether CD13 involvement in FLS migration is dependent on its localization.  Our studies did 
not find a noticeable difference when additional soluble CD13 was added to FLS growth and 
migration experiments (data not shown).  This may however be due to saturation of the system 
by the large amounts of CD13 already expressed and shed by the FLS.  A possible future 
experiment to examine this would be to look at normal human FLS with addition of soluble 
rhCD13.  We did examine OA FLS in growth and migration assays, with results similar to those 
of RA FLS (data not shown).  However, since we did not find a difference in CD13 expression in 
RA versus OA on cultured FLS this is not unexpected.  Our staining of synovial tissues however 
indicates that normal FLS may express lower levels of CD13 than RA or OA FLS, which may 
carry over to culture conditions.  Normal FLS do not easily grow in cultures, and our data 
indicates that one possible difference that may assist in FLS growth is the amount of CD13.  
Therefore, a possible experiment would be to add rhCD13 to normal FLS cultures and measure 
cell proliferation.  This would help to define whether soluble CD13 aids in FLS cell growth.  
Another possibility is that the surface CD13 is needed for FLS growth and migration.  
Knockdown (KD) experiments of CD13 in RA or normal FLS would help in determining 
whether surface CD13 is needed.  CD13 could be knocked down on RA FLS and soluble 
rhCD13 added back to the culture.  If CD13 KD slows FLS cell growth and addition of soluble 
CD13 does not restore proliferation this would indicate that the cell surface localization is 
important in CD13 mediated cell growth.  Alternatively, if sCD13 does not help in increasing 
proliferation of normal FLS, knock-in of CD13 could increase the expression of CD13.  This 
could examine a role for cell associated CD13 in FLS growth. 
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Angiogenesis, the growth of new blood vessels, is also a key part of synovitis and RA 
pathogenesis.  The increased angiogenesis in RA also increases leukocyte invasion into the RA 
joint making it another target to reduce T cell invasion and inflammation.  In RA VEGF has been 
identified as a mediator of angiogenesis 
48,265
.  While VEGF is a potent angiogenic mediator, 
other angiogenic molecules have also been identified in RA such as the family of molecules 
termed Le
y/H, cytokines (TNFα), MMPs, adhesion molecules, and other additional factors 45,152.  
CD13 has been linked to angiogenesis in cancer and may play a similar role in RA.  We 
identified CD13 on the vasculature in RA tissue sections (Figure 2.5).  This implicates CD13 in 
RA angiogenesis.  Data from literature is also suggestive of an angiogneic role for CD13 in RA.  
Angiogenic factors, VEGF and bFGF, have been shown to up-regulate CD13 through the 
endothelial promoter
266
.  VEGF is increased in RA synovium compared to OA, and RA FLS 
production of VEGF is increased in response to pro-inflammatory factors (such as IL-17 and 
TNFα) 48.  This points to a complex up-regulation of CD13 during inflammation that may 
contribute to angiogenesis.  Pro-inflammatory cytokines upregulate VEGF and CD13, and VEGF 
further upregulates CD13.  Then both CD13 and VEGF can act to induce angiogenesis.   
 
Angiogenesis is a multistep process.  Pro-angiogenic molecules activate endothelial cells which 
produce proteolytic enzymes, like MMPs, which degrade the ECM around the existing blood 
vessels.  The endothelial cells then proliferate and migrate forming new blood vessels.  CD13 
has the potential to be involved in any step of this angiogenesis process.  CD13 is expressed on 
the surface of endothelial cells 
267
.  It is also expressed by the FLS and is present in high amounts 
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in the joint as a soluble protein.  Some cell surface proteins can be pro-angiogenic as soluble 
molecules, such as E-selectin
268
.  CD13 mediated angiogenesis could be a function of its cell 
surface expression, its soluble expression, or both.  One basic system that could be used to 
examine the putative function for CD13 in angiogenesis would be an in vitro endothelial culture 
system.  Endothelial cells are grown on Matrigel and new tube formation is counted 
152,185
.  A 
second standard assay would be to examine chemotaxis of endothelial cells (HUVECS or 
HMVECS) in a chamber assay system 
268
.  The matrigel assay could help determine whether 
CD13 is involved in matrix degradation and subsequent invasion by endothelial cells.  The 
chemotaxis assay would help determine if it is more involved in the migration step of 
angiogenesis. 
 
Because CD13 has multiple sources in the joint, the potential for CD13 to be involved in 
angiogenesis in the RA joint should be examined with both soluble and endothelial cell 
associated CD13.  Both the matrigel invasion assay and the HMVEC chemotaxis assay should be 
done with addition of soluble rhCD13.  However, both assays should also be done with either 
siRNA knockdown of CD13 or inhibition of CD13 by antibodies or chemical inhibitors on the 
endothelial cells.  With knockdown experiments it could be necessary to use known inducers of 
angiogenesis (VEGF, RANTES) to stimulate a response and then look for a decrease in matrigel 
invasion or HMVEC chemotaxis.  The results of using soluble CD13 versus inhibition of 
endothelial CD13 could help in determining what function CD13 has in angiogenesis.  The 
CD13 expressed on FLS could also impact the vasculature in the joint.  A tube formation assay 
in matrigel using co-culture of endothelial cells and FLS should be done with siRNA knockdown 
of CD13 in endothelial cells and/or FLS to examine this possibility 
185
.  The chemotaxis assays 
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of HUVECs or HMVECs should also be performed with synovial fluid either whole or depleted 
of CD13 (similar to the Tck assays shown in this report).  This could help determine if CD13 
significantly contributes to angiogenesis in RA. 
 
Angiogenesis could also be further examined using a CAM system.  This system has been used 
to demonstrate that MMP14 is able to induce angiogenesis at sites distal to the FLS
49
.  In this 
work we identified CD13 as a cleavage target of MMP14, and hence one possible mediator of 
this angiogenesis.  Repeating the CAM assays with CD13 siRNA knockdown in place of 
MMP14 knockdown would show whether or not the neovascularization response could be 
attributed to CD13.  The advantage of the CAM assay system is that it is biologically relevant to 
RA.  There are also two in vivo assays for angiogenesis.  The first is the rat corneal implant 
assay
268
.  In this assay a small bead containing test or control substances are implanted into a rat 
cornea and an increase in vasculature can be visualized.  Test substances would include rhCD13 
as well as RA SF, either whole or depleted of CD13.  The second assay is a matrigel plug assay.  
In this assay matrigel is injected below the skin of a mouse.  The matrigel would contain either 
controls or rhCD13.  After several days the mice are sacrificed and the hemoglobin content of 
the plug is measured 
269
.  These two assays would look at CD13 induced angiogenesis under 
biological conditions.  All of the assays could also be performed with both the wild type CD13 
and the enzymatically inactive mutant to determine whether the putative CD13 mediated 
angiogenesis is dependent or independent of its enzymatic activity. 
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While in this study we have demonstrated that CD13 is highly upregulated in the RA joint over 
OA, there is still much work to be done in understanding the impact of this on RA pathology.  
CD13 has been identified to be important in T cell chemotaxis; however, it may also impact 
other T cell functions in the joint.  CD13 is expressed on RA FLS but may also be important 
when expressed on other cell types in joint.  Also, yet to be examined is what effect the 
enzymatic activity of CD13 has on various potential substrates in the synovium, and how this 
relates to RA. 
 
Regulation of CD13 
We have demonstrated that CD13 is upregulated in RA synovial fluid over OA.  However, this 
was not reflected on FLS in vitro.  Cultured RA and OA FLS had similar expression levels of 
CD13.  We also did not find any differences in CD13 released from FLS in culture.  This 
indicates that something in the RA joint is affecting CD13 expression.  As discussed above 
further experiments are needed to define the expression, release, and function of CD13 on other 
cell types in RA.  Another possibility though is that molecules such as cytokines in the RA joint 
affect expression of CD13 on FLS.  Removal of the FLS from the joint and subsequent culture in 
medium on tissue culture plastic could however reduce the expression to levels similar to that of 
OA.  The RA joint is a complex system involving multiple cell types and numerous soluble 
molecules.  One way to further examine CD13 in the joint would be to look at freshly isolated 
joint synovium samples.  Small pieces of RA and OA synovium could be cultured in serum free 
medium and the CD13 released into the medium could be measured.  This would determine 
whether RA tissue releases CD13 at a higher rate than OA; however, it would not isolate the role 
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of FLS versus other cell types.  Another option would be to sort the cells from a fresh piece of 
synovial tissue to isolate the FLS, and then examine the FLS by ELISA for cellular CD13 levels.   
 
The initial screening that identified CD13 as of interest on RA FLS was to look for a TNFα 
independent pathway.  However, when we expanded the cytokine regulation studies we found 
that CD13 regulation is more complicated than initially thought.  We examined the influence of 
three pro-inflammatory cytokines on the expression of CD13 on FLS.  We chose to look at IFNγ, 
TNFα, and IL-17 because these three cytokines are implicated as being pathogenic in 
RA
32,223,270,271
.  Due to high levels of variability between cells lines and fluctuations within cell 
lines, few conclusions can be reached.  The primary observation is that at the mRNA level all 
three cytokines upregulate CD13.  Considerable complexity occurs at the protein level.  All three 
cytokines appear to affect not only the expression of CD13 but the localization of CD13.  We did 
observe the initial pattern of a CD13 increase with IL-17 and a decrease with TNFα at 48 hours 
on the cell surface for most of the cell lines examined.  However, this pattern only appeared true 
for that specific location and time.  Over a time course the regulation and localization fluctuate.  
We have shown that CD13 can be expressed on the cell surface of FLS, as a soluble molecule 
released from FLS, and on extracellular vesicles from FLS.  We also noted that the cytokine 
initiated fluctuations were not consistent between cell surface CD13 and total cell lysate CD13 
(data not shown).  This may imply that CD13 can also be found intracellularly.  These multiple 
sites for CD13 complicate the matter of determining overall CD13 regulation by cytokines.  We 
can infer that cytokine stimulation of FLS results in changes in the localization and expression of 
CD13 with distinct kinetics for each cytokine.  These changes show as both up and 
downregulation compared to untreated FLS over a time course.   
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The natural high variability in CD13 expression by different FLS cell lines further complicates 
these experiments.  To determine overall patterns these experiments would need to be repeated 
with many different cell lines.  The data outlined in this study may help to identify the time 
points to be the focus of examination.  There appear to be differences between early regulation 
(0.5-12 hours) and long term regulation (48-72 hours).  In addition to further studies of IFNγ, 
TNFα, and IL-17, future studies could look at other cytokines found in the RA joint.  CD13 
expression on other cell types has been examined in response to various cytokines.  Cytokines 
that have been shown to have an effect on CD13 include: TGF-β, bFGF, VEGF, IL-4, IL-13, 
EGF, and IL-6
79–82,272
.  Other pro-inflammatory cytokines, like IL-1 and IL-22, or potentially 
regulatory cytokines, like IL-10, should also be investigated.  We did a screening using one RA 
cell line and one OA cell line treated with various cytokines (data not shown).  This study 
implicated TGF-β, IL-1b, GMCSF, IL-4, IL-13, IL-10, IL-12, and IL-15 as potential targets for 
future studies.  Future studies could also examine CD13 regulation on other cell types relevant to 
RA, such as monocytes or endothelial cells.   
 
To determine biological significance it may also be necessary to treat FLS, or other cell types, 
with multiple cytokines.  The correlations between cytokine levels and sCD13 in serum indicate 
that single cytokine treatment may not provide a complete picture of what is going on in vivo 
(Figure 3.9).  Specifically the fact that IFNγ does not correlate with sera sCD13 but does increase 
CD13 mRNA in FLS could indicate that multiple cytokines are affecting biological expression 
levels and localization.  Future studies could include treating cells with gradients of two or more 
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cytokines at a time.  This would be especially relevant if opposite effects are observed for 
different chemokines.  For example, if one cytokine is identified as downregulating CD13 on 
FLS and another upregulates CD13 on FLS, then FLS should be treated with both to identify to 
dominate effect.  Or, if one cytokine promotes cleavage of CD13 and expression in the 
supernatant and another promotes localization to the cell surface and decreases soluble CD13, 
both cytokines could administered to determine the dominate effect. 
 
CD13 receptor 
Our results imply that CD13 has a receptor on T cells.  The fact that rhCD13 has a direct effect 
on T cells inducing chemotactic movement in a buffer containing only BSA protein demonstrates 
that CD13 is either directly interacting with the T cell or with something the T cells are 
producing.  Using pertussis toxin we were able to demonstrate that the first is the most likely 
hypothesis.  Pertussis toxin is known to inhibit function of g-protein coupled receptors 
(GPCR)
273
.  However, one main issue with determining the CD13 receptor is the wide variety of 
possibilities.  We identified CD13 aminopeptidase activity as being irrelevant to CD13 initiated 
Tck chemotaxis.  This eliminates receptors dependent on enzymatic activity, such as the protease 
activated receptors (PARs).  However, GPCRs are one of the largest groups of proteins.  While 
the exact number is unknown one estimate was over 800 
274
.  PTX does help to narrow the field a 
little as it only inhibits Gi/o proteins and their associated receptors, although this still leaves a 
large number of possibilities 
273
.  Another complicating factor was found when we attempted to 
confirm the involvement of a GPCR.  We observed a biphasic effect on cyclic adenosine 
monophosphate (cAMP) when Tcks were stimulated with CD13 (data not shown).  At 200ng/ml 
CD13 increased cAMP levels in Tcks, and at 500ng/ml CD13 decreased cAMP levels in Tcks.  
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With a PTX sensitive receptor a decrease would be expected.  This data may indicate that CD13 
can act through more than one mechanism on T cells, and this could be dependent on the 
concentration of CD13 present. 
 
There are several potential avenues that may help identify the GPCR for CD13.  Identifying the 
intracellular signaling molecules involved may be one direction.  Different GPCRs signal 
through different intracellular pathways including p38, ERK1 and 2, NFκB, JNK, and MAPK 
275–277
.  Stimulating Tcks with CD13 and then looking for subsequent phosphorylation of these 
molecules would identify which molecules are involved in CD13 receptor signaling.  While this 
will not directly identify the GPCR, comparing the signaling pathways activated by CD13 to 
those of known GPCRs may help narrow the field down.  Another way to narrow down the 
alternatives would be to look for receptors associated with known functions of CD13.  Many 
GPCRs have already been associated with RA.  The chemokine receptors in particular have been 
implicated in RA including all CXCRs and several CCRs (1-7)
153
.  CCR5 specifically is 
interesting as it has been linked to T cell chemotaxis in RA as well as activation of RA FLS 
fulfilling two identified roles of CD13 in RA
155,162
.  CXCR4 is also of particular interest as it has 
been identified as being the most upregulated cytokine receptor on Tck 
156
.  Another group of 
GPCRs that are of interest in RA are the sphingosine-I-phosphate receptors (S1P1-5).  Binding of 
S1P1 is known to be involved in T cell migration and FLS survival and migration 
275
.  S1P1 is 
also highly expressed in the RA synovium 
275
.  The angiotensin receptors (AT1 and AT2) are 
another possibility.  AT1 is present on FLS and is linked to FLS survival and growth, while both 
AT1 and AT2 are linked to T cell mediated cardiovascular inflammation in mice 
276,278
.  The 
AT1 receptor in particular has been linked to RA and mouse models of RA, and it has even been 
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proposed as a therapeutic target for RA
279
.  However, there are some problems with looking at 
known GPCRs for the CD13 receptor.  In general CD13 is not structurally typical of the ligands 
for these GPCRs.  CD13 is a large, enzymatically active, glycoprotein.  The ligands for these 
receptors tend to be much smaller proteins or non-protein molecules. 
 
The type of cells that respond to CD13 may also help in identifying the CD13 receptor.  To this 
end, a panel of various different cell types could be run through an assay looking for a response 
to CD13.  This response could be chemotaxis, increase in cAMP, or phosphorylation of 
intracellular signaling pathways.  Cells to be tested could include variously activated T cells, 
monocytes, FLS, and endothelial cells.  Based on our assays we can already identify that T cell 
activation is necessary for chemotaxis, so receptors that are only expressed on activated T cells 
or go up with activation are possibilities.  This offers support for receptors such as AT1, 
cannabinoid receptor 1, and opioid μ receptor, which are upregulated with T cell activation 
280,281
.  A microarray comparing mRNA from resting T cells and Tck has been run.  While it did 
not cover all of the potential GPCRs, this data or similar assays could help identify potential 
receptors.  Since we did not observe chemotaxis of resting T cells but did see chemotaxis with 
Tck, GPCRs that are upregulated on the Tck over resting T cells are potential candidates for the 
CD13 receptor.  In this microarray (covering approximately 2600 sites) receptors that were 
upregulated on Tck over resting T cells included: CCR1 (1.864 fold increase), CCR5 (1.355), 
CXCR3 (1.84), CXCR6 (2.75), prostanoid receptor EP4 (1.648), orphan receptor GPR18 (1.76), 
orphan receptor GPF35 (1.381), orphan receptor GPR44 (1.291), orphan receptor GPR68 
(2.073), and orphan receptor GPR92 (1.216).  The greatest increase was seen in CXCR6 which is 
interesting as this receptor is present on T cells, monocytes, endothelial cells, and FLS, and it is 
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known to be strongly involved in a mouse model of RA 
282
.  This is suggestive of CXCR6 as a 
potential receptor for CD13.  Part of what may complicate the process of looking for a CD13 
receptor is the number of orphan GPCRs with no known ligand.  Since CD13 is not typical of 
most GPCR ligands, an orphan receptor being CD13 appears even more likely.  However, this 
may make identification of the CD13 receptor even more difficult.   
 
One possible direct way of identifying the CD13 receptor is co-immunoprecipitation.  We have 
attempted to identify CD13 bound to T cells (Tck as well as other T cell types) by incubation of 
the cells with rhCD13 and flow cytometry.  We used both rhCD13 followed by antibodies to 
CD13 and biotin-conjugated CD13, but could not detect CD13 bound to the T cells (data not 
shown).  This indicates that the binding of CD13 is either weak or transient.  For co-
immunoprecipitation it would therefore likely be necessary to use a crosslinker.  So, a future 
experiment could entail incubating Tck with rhCD13 in the presence of a crosslinker (such as 
bis-sulfosuccinimidyl suberate) 
117
.  Then immunopreciptation of CD13 could be used to pull 
down CD13 and any associated molecules.  Different anti-bodies may need to be tried to find 
one that binds the CD13-receptor complex.  Gel separation followed by sequencing could then 
be used to identify the protein(s) bound to CD13 (which should include the T cell CD13 
receptor).  Another possibility would be the use of a broad GPCR screening assay.  There are 
now commercial screening assays available for both known GPCRs and orphan GPCRs that look 
for a response (such as internalization or phosphorylation of an intracellular signaling molecule) 
over a wide number of GPCRs 
283
.  While these assays do not cover all the possibilities it may be 
one of the best places to start.  A future direction would be to perform an assay of this type 
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which would at the very least eliminate some possibilities and potentially help identify the CD13 
receptor.   
 
Once potential candidates have been identified, antibody blocking of the receptor would help 
identify and confirm its identity.  Tck could be incubated with antibodies to the candidate 
receptors, and then used in the chemotaxis assay.  Inhibition of Tck chemotaxis toward CD13 
would indicate the correct receptor.  Using the blocking antibody in the FLS growth and 
migration assays could identify whether CD13 acts through the same receptor on both T cells 
and FLS.   
 
Cleavage of CD13 
We have conclusively shown that soluble CD13 is shed by FLS, and that molecules from the 
metalloproteinase family are responsible.  Both main subgroups of metalloproteinases (MMPs 
and ADAMs) are possible candidates for cleavage of CD13.  Membrane bound MMPs (MT-
MMPs) and ADAMs are more commonly identified as sheddases than the soluble MMPs.  Based 
on previous studies with RA FLS, we identified MT1-MMP/MMP14 as a possible CD13 
sheddase 
49
.  And indeed, knockdown of MMP14 in FLS showed that MMP14 was involved in 
the cleavage of CD13.  However, the inhibition of cleavage with MMP14 KD was only partial 
indicating multiple sheddases of CD13.  We attempted knockdowns of some of the other 
potential metalloproteinases (including double knockdowns with MMP14); however, since no 
other knockdown resulted in a significant decrease we can conclude that MMP14 is the major 
contributor to CD13 cleavage (data not shown).  Other possibilities include the transmembrane 
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MMPs, MMP15 and MMP16, or ADAMs.  ADAMs that have been identified in RA (either 
mRNA or protein) include ADAMs 8,9,10,15, and 17 
182,184,185
.   
 
We examined FLS by qRT-PCR following MMP14 knockdown to determine whether other 
metalloproteinases were upregulated following knockdown of MMP14.  This could indicate 
compensation.  However, we did not see any significant changes in MMP15, MMP16, 
ADAM10, ADAM15, or ADAM17 mRNA with MMP14 KD (data not shown).    We did note in 
our cells only very low levels of MMP15 and MMP16 at the mRNA level (data not shown).  
Although this may not reflect protein levels, it is supportive of a hypothesis that ADAMs are the 
other shedders of CD13.  We also attempted to use COS-1 versus CHO shedding of transfected 
recombinant human CD13.  COS-1 (African green monkey kidney epithelial) cells are known to 
have ADAM molecules but no MMPs; while CHO (Chinese hamster ovary) cells have both 
ADAMs and MMPs
183,284,285
.  While CD13 was found as a soluble molecule in culture 
supernatants from both cell types, the data was inconclusive.  Attempts to block shedding with 
GM6001 only yielded small decreases in the release of CD13 from both cell types (data not 
shown).  This indicates that release of the transfected CD13 from COS-1 or CHO cells occurs 
primarily through a metalloproteinase-independent mechanism.  Therefore, this data does not 
help in determining a role for MMPs versus ADAMs in CD13 shedding. 
 
All of our data points towards a complex mechanism involving MMP14 along with other MMPs 
or ADAMs cleaving CD13 from the surface of FLS.  Another potential direction for this research 
could involve determining which other metalloproteinases are involved.  However, one major 
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problem with determining which MMPs or ADAMs are contributors is that ADAMs can be 
redundant and frequently compensate for each other
183
.  It is possible that to completely abrogate 
CD13 shedding three or more metalloproteinases would need to be suppressed at the same time.  
Transient knockdown experiments would be difficult to use, since creating a knockdown 
involving more than two proteins is difficult.  One possible way to explore this would be to 
attempt to determine which other cells shed CD13 and what stimuli can induce CD13 shedding.  
After determining which cells shed CD13 it could then be determined which metalloproteinases 
are expressed on those cells and a better profile of involved metalloproteinases could be 
developed.   
 
Stimuli resulting in either upregulation or downregulation of shedding could also be tied back to 
creating a profile of which metalloproteinases are involved in the shedding.  Another alternative 
would be to attempt double knock-in of CD13 and each of the potential cleavers into a cell line 
looking for an increase in CD13 release.  However, this would only give information on which 
molecules are capable of cleaving CD13 and would not aid in determining how this occurs 
naturally.  In conclusion MMP14 is the major cleaver of CD13 on FLS, and while at least one 
other metalloproteinase also cleaves CD13, determining which one will likely prove difficult. 
 
CD13 in murine models 
We have conclusively shown a role for CD13 in RA in human samples in vitro.  One of the next 
steps in looking at the function of CD13 in arthritis is examining CD13 in a mouse model.  We 
have shown that CD13 may be involved in multiple processes in the RA joint.  As such, looking 
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at CD13 in vivo will help define its broader impact on disease processes.  CD13 knockout mice 
have been created and appear to be generally healthy 
138,228
.  The main difference discovered in 
the CD13 KO mice was a deficiency in pathogenic angiogenesis (in response to hypoxic 
conditions, VEGF, bFGF, or TGFα) but not in normal development angiogenesis or 
neovascularization 
228
.  CD13-KO mice develop collagen antibody induced arthritis (CAIA) 
normally, and this was suggested to show that CD13 is not necessary for inflammatory 
infiltration into the synovium 
138
.  However, CAIA is characterized by polymorphonuclear 
leukocyte and macrophage infiltrate not a T cell response 
286
.  Our results indicate that CAIA is 
not a good model for CD13 in RA, and that instead studies should be run in a T cell dependent 
model such as collagen induced arthritis (CIA).   
 
Development of a CIA model in CD13-KO mice would be a better model.  One difficulty here is 
that the current CD13-KO mouse is in a C57BL/6 background 
138
.  CIA does not develop well in 
C57BL/6 mice, and the preferred background is the DBA/1 strain 
287
.  There are three possible 
ways this could be handled.  First, a new CD13-KO could be created using DBA/1 mice.  
Second, extensive backcrossing could be done to transfer the current CD13-KO model from the 
C57BL/6 background to the DBA/1 background.  Third, the current C57BL/6 CD13-KO mice 
could be used.  However, since the ability of these mice to develop arthritis is variable higher 
numbers of mice would be needed.  Measurements of general disease activity (joint counts and 
diameter of joints) in the CIA CD13-KO model would provide insight into how important CD13 
is in disease progression.  Of particular interest would be T cell infiltrate into the joints 
(observable by histopathology) and level of angiogenesis (immunohistochemistry).  Another 
possible mouse model of RA is the K/BxN serum transfer model.  While the K/BxN model is 
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similar to the CAIA model in that it is not T cell dependent, this model could be used to examine 
angiogenesis.  The K/BxN serum transfer model has high levels of angiogenesis in the joints 
288
.  
This model could be used with the CD13-KO mice on either the DBA/1 or C57BL/6 
backgrounds.  While it may yield similar results to the CAIA when examining the overall disease 
severity in CD13-KO, it would be interesting to determine if there are differences in the 
angiogenesis in the joints.  This could be examined by histopathology, and while T cells are not 
as important in K/BxN mice, overall leucocyte counts in the joints could be made. 
 
CD13 should also be measured in a WT CIA model in DBA mice.  CD13 aminopeptidase 
activity is elevated in the synovial fluid, plasma, and the soluble fraction of synovial tissue 
homogenates in CIA rats 
289
.  However, our results indicate that at least in human samples CD13 
activity is not a completely accurate measure of CD13.  A mouse CD13 ELISA should be 
created and CD13 measured in the joint tissue homogenates and serum of CIA mice.  
Histopathology could also be used to examine CD13 on murine joint synovium sections.  
Another way to look at a role for CD13 would involve the use of anti-CD13 antibodies or 
enzymatic inhibitors in prevention or treatment of CIA in DBA mice.  This would help to 
determine whether CD13 has potential as a therapeutic target. 
 
To further examine the T cell chemotaxis specifically, an RA ST-SCID (rheumatoid arthritis 
synovial tissue – severe combined immunodeficiency) mouse model could be used.  In this 
model a piece of synovial tissue is engrafted under the skin of a SCID mouse.  After the graft 
heals CD13 would be injected into the graft and labeled human T cells would be injected 
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intravenously.  The graft is harvested and the number of T cells migrated into the tissue can be 
counted under a microscope 
290
.  This model has the advantage of being able to examine 
chemotaxis and tissue invasion specifically but in an in vivo system which could provide 
additional factors that may influence the mechanism.   
 
CD13 and other diseases 
This research focused on CD13 in RA; however, CD13 is likely also involved in other diseases.  
CD13’s variety of functions and presence throughout the body indicates that it may have an 
important role in multiple diseases.  CD13 is already a target for drug discovery in cancer, 
primarily due to its role in angiogenesis.  However, our research specifically points to 
involvement in more immune mediated diseases.  Since CD13 has been linked to FLS growth, T 
cell migration, and inflammation it is logical that it may be involved in inflammatory joint 
conditions other than RA.  It may also implicate CD13 in systemic inflammation.  We did 
examine some serum samples from lupus, scleroderma, myositis, and Sjogren’s syndrome 
patients (Figure 2.6).  Similar to RA we found lower levels of serum CD13 by ELISA, in 
myositis and lupus, or by enzymatic activity assay, in scleroderma and myositis.  Our data shows 
that aminopeptidase levels were decreased in scleroderma samples compared to healthy controls.  
However, there was no significant difference in CD13 amounts.  This may indicate that another 
aminopeptidase is decreased in the sera of scleroderma patients, that scleroderma sera CD13 has 
a lower specific activity, or that there are increased levels of a natural inhibitor of CD13 in 
scleroderma sera.  Further experiments would need to be done to clarify this result.  Similar to 
what we did with RA SF, the CD13 should be immunoprecipitated out from scleroderma and 
healthy sera.  Then both the immunoprecipitated CD13 and the depleted fractions could be 
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examined for aminopeptidase activity.  The sample numbers for lupus, myositis, and Sjogren’s 
syndrome were limited and higher numbers would be needed to confirm the results.   
 
Studies involving scleroderma, lupus, and other inflammatory diseases could measure CD13 in 
fluids and cells from various disease sites.  As we noted in RA, CD13 may be elevated in one 
location (synovial fluid) but decreased in another (serum).  Therefore CD13 should be measured 
not only in serum but at all accessible sites of disease activity.  For example, in scleroderma 
CD13 levels could be measured in serum (systemic), bronchoalvelolar lavage (lung), and skin 
homogenates.  Histopathology could also be used to look at disease tissues to identify which 
cells are expressing CD13.  A previous paper found higher amounts of CD13 enzymatic activity 
in bronchoalveolar lavage fluid from patients with scleroderma, RA, Sjogren’s syndrome, and 
myositis compared to healthy controls 
222
.  However, this group also found elevated levels of 
CD13 enzymatic activity in the sera of patients with RA, lupus, scleroderma, and myositis 
compared to healthy controls 
222
.  This is contrary to what we observed; that RA, scleroderma, 
and myositis have decreased levels of aminopeptdiase activity in sera compared to healthy 
controls.  There is some uncertainty here as these are measurements of enzymatic activity and 
not directly of CD13.  Larger sample numbers of sera, synovial fluid, and bronchoalveloar 
lavage fluid should be run on the CD13 ELISA, as this would be the best way to determine 
CD13 levels from specific sites in the various inflammatory diseases.   
 
The presence of CD13 in specific tissue sites or fluids may help to identify possible functions for 
CD13 in each disease.  Lower amounts of CD13 at a particular site could indicate more 
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uptake/usage of CD13 at those sites.  For example, a lower amount in serum may indicate an 
uptake by the endothelial cells or circulating T cells.  Combined with high expression at a 
disease specific site, joint or lung, this could indicate CD13 acting as a chemoattractant.  High 
expression by a specific cell type may indicate a role in growth and migration of those cells, 
similar to RA FLS.  CD13 involvement should also be examined in other immune mediated 
conditions.  Our data demonstrates that CD13 can act as a T cell chemokine.  This could be 
important in diseases such as psoriasis, asthma, and multiple sclerosis.   All of these are diseases 
linked to T cell involvement and have CD13 present on cells are disease sites (skin, lung, 
nervous system).  Overall we have demonstrated that CD13 can act as a pro-inflammatory 
agonist, and this may implicate it more broadly in a range of autoimmune processes. 
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Appendix                                                                                                      
Materials and Methods 
 
Development of 591.1D7.34, a novel anti-CD13 monoclonal antibody 
The investigations summarized in this report commenced as an approach to defining novel 
inflammatory pathways in RA involving FLS, trigged preferentially by IL-17 rather than TNF.  
BALB/C mice were serially immunized with 10
6
 FLS treated with IL-17, 10ng/ml, for 48 hours 
prior to immunization.  A spleen from the most reactive mouse (assessed by flow cytometry of 
FLS using mouse sera) was fused to a non-secreting myeloma cell line.  The resulting hybridoma 
clones were screened on resting FLS, TNFα treated FLS, and IL-17 treated FLS, then selected 
for subcloning.  The clone producing the antibody 591.1D7.34 was identified as being of interest.  
An OA FLS cell line was biotinylated and lysed.  Immunopreciptiation was used to isolate the 
protein recognized by mAb 1D7. Controls included mouse IgG (MsIgG, isotype control) and 
anti-CD98 (an FLS positive control).  The proteins eluted from the immunoprecipitation beads 
were electrophoresed under reducing or non-reducing conditions on a 4-20% Tris-glycine 
polyacrylamide gel.  Protein from the same number of cells was loaded in each lane.  The gel 
was transferred to an immobilon-P membrane and incubated with streptavidin-HRP then ECL.  
U937 myeloid cells were also lysed and 1D7 was used to immunoprecipitate the recognized 
protein which was resolved by electrophoresis on two identical polyacrylamide gels.  One was 
stained with Coomassie blue, and the other was excised at a spot corresponding to the primary 
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band in the stained gel.  The protein was subjected to trypsin digestion in-gel and the resulting 
peptide mixture was analyzed by LC-MS/MS on a Qtof premier instrument (Waters Inc).  
Protein Lynx Global Server and Mascot search engines were used to search the Uniprot and 
NCBI databases.  The protein identified matched Aminopeptidase N/CD13.   
 
Cell Culture 
All procedures involving specimens obtained from human subjects were performed under a 
protocol approved by the University of Michigan Institutional Review Board. FLS were cultured 
from human synovial tissue obtained at arthroplasty or synovectomy from RA or OA joints 
following digestion with 1% collagenase and separation through a 70 micron cell strainer.  The 
diagnosis of RA was based upon the presence of at least four of the seven 1987 American 
College of Rheumatology criteria
291
.  The diagnosis of OA was based upon characteristic clinical 
and radiographic features, and confirmed by pathological findings at joint surgery.  U937 cells 
were cultured in RPMI 1640 (10% fetal bovine serum [FBS], 2% L-Glutamine, 1% HEPES, 1% 
Sodium Pyruvate, 0.5% glucose).  FLS were maintained in Connaught Medical Research Lab 
(CMRL) medium supplemented with 20% FBS, 2mM L-glutamine, and 1% 
penicillin/streptomycin and were used between passages 4 and 10.  Cultures were moved to 
serum free Dulbecco’s modified Eagle’s medium [DMEM]/F-12 with Peprogrow serum 
replacement (Peprotech) for 24-72 hours before harvesting.  Some cultures were treated with 
protease inhibitors for 72 hours in serum-free medium: pepstatin A (Sigma-Aldrich), aprotinin 
(Sigma-Aldrich), leupeptin (Sigma-Aldrich), GM6001 InSolution (EMD), or E-64 (Thermo 
Scientific).  Other cultures were treated with cytokines: recombinant human IFNγ (rhIFNγ) 
(1U/ml), rhTNFα (10ng/ml), or rhIL-17 (10ng/ml) (Peprotech) for 0, 0.5, 1, 2, 6, 8, 12, 24, 48, or 
72 hours in serum free medium.  T cells were isolated from peripheral blood of healthy subjects 
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by negative selection using RosetteSep Human T cell enrichment cocktail (Stemcell) and 
Histopaque (Sigma-Aldrich).  Cytokine activated T cells were prepared by culture of T cells in 
IL-6 (100ng/ml), IL-2 (25ng/ml), and TNFα (25ng/ml) (all Peprotech) for 7-10 days in 10%  
FBS RPMI 1640 medium
19,156
.  The COS-1 cell line (ATCC) was grown in 10% FBS/DMEM.   
 
Sample Preparation 
Synovial fluid samples were treated first with 0.05% Hyaluronidase (bovine testis, Sigma-
Aldrich) one drop per 1 mL fluid for 5 min.  Cells were lysed in cell lysis buffer (10% Nonidet 
P40, 10% phenylmethylsulfonyl fluoride, 1% Iodoacetinimide, and 0.1% E-64 in TSA) for one 
hour on ice.  FLS culture supernatants were concentrated by centrifugation through an Amicon 
Ultracel 30K filter (Milliepore).  Plasma was isolated from whole blood using heparin vacutainer 
tubes (BD biosciences).  Serum was isolated from whole blood using serum separation 
vacutainer tubes (BD biosciences). 
 
Flow cytometry 
Fibroblasts were removed from flasks by 3mM EDTA in PBS.  Cells were stained with MsIgG 
(negative control) or anti-CD13 (1D7, SJ1D1 [Abcam], or WM15 [Biolegend]), then goat anti-
mouse IgG-Alexa fluor 488 (Molecular Probes).  Cytometry was performed on a BD Biosciences 
FACSCalibur. 
 
Aminopeptidase enzymatic activity 
CD13 aminopeptidase activity was measured by cleavage of L-Leucine-7-amido-4-methyl 
coumarin (L-leu-AMC, Sigma-Aldrich) to release the fluorescent molecule AMC.  A standard 
curve was constructed using AMC (Sigma-Aldrich).  The assay was run in 0.1 M Tris-HCl 
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buffer (pH 8.0).  Samples were incubated with the substrate at 37°C for one hour then read using 
a fluorescent plate reader at emission 450, excitation 365.  Results were calculated as the amount 
of substrate cleaved in μM/hr. 
 
CD13 Enzyme-Linked Immunosorbent Assay (ELISA) 
High binding ELISA plates were coated with the anti-CD13 monoclonal antibody WM15 in 
0.1M carbonate buffer pH9.5 overnight, and blocked with 1x Animal Free Block (Vector 
Laboratories) overnight.  Between steps the plates were washed 5 times with wash buffer (PBS 
plus 0.05% Tween) and washed 3 times before addition of samples.  Samples were then applied 
to the plates either whole or diluted in block with 10mM EDTA.  The standard curve was 
prepared using recombinant human CD13 (R&D Systems) in block with 10mM EDTA.  Plates 
were incubated overnight then washed 7 times.  1D7 was biotinylated (Biotin-XX Microscale 
Protein Labeling Kit, Molecular Probes) and applied overnight.  Plates were washed 7 times.  
Streptavidin-horseradish peroxidase (Biolegend) was then added.  The plates were visualized 
with tetramethylbenzidine substrate (TMB, BD Biosciences), stopped with 2M H2SO4, and 
analyzed on a colorimetric plate reader. 
 
Tissue Staining 
Tissues were harvested form normal, OA, and RA patients during surgery.  Tissue sections were 
frozen with liquid nitrogen and 7 µm frozen sections were made using a cryostat.  The slides 
were fixed in Acetone at 4⁰C for 30 minutes, washed, and blocked in 20% Fetal Bovine Serum 
and 5% goat serum in PBS.  Slides were incubated with the primary antibodies anti-human CD13 
(1D7, 10µg/mL) and rabbit anti-human CD11c (Abcam, 1:100 dilution) or rabbit anti-human 
Cadherin 11 (Zymed 10µg/mL).  Controls were rabbit and mouse IgG at equivalent 
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concentrations.  Secondary antibodies for both sets of slides were Alexa fluor goat anti-mouse 
488 and goat anti-rabbit 555 (Life Technologies 10µg/mL), and DAPI (Invitrogen, 1:5000 in 
PBS) was used on all slides.  Slides were mounted with Fluoromount-G (Southern Biotech).  
Pictures were taken on an Olympus BX microscope at 40x magnification.  Arrows point to 
examples of co-localization. 
 
Immunoprecipitation 
Immunoprecipitation was performed using the Pierce Direct IP Kit (Thermo Scientific).  In brief 
antibodies were bound to AminoLink Plus beads using cyanoborohydride, either anti-CD13 
(1D7), anti-CD98 (7F8), or isotype control (MsIgG)
292
.  Samples were diluted 1:1 with IP 
lysis/wash buffer and incubated overnight with the beads.  The depleted portion was removed by 
centrifugation.  Protein was eluted off the beads by low pH (2.8) which was neutralized with 1 M 
Tris (pH 9.5). 
 
Quantitative RT-PCR 
mRNA was isolated from FLS (3 wells of a 6-well plate) using the RNAeasy Kit and Qiacube 
(Qiagen).  cDNA was prepared using a High Capacity cDNA Kit (Life Technologies).  
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was done using 
TaqMan Gene Expression Assays on a 7500 Real Time PCR System (Applied Biosystems). 
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Cytokine ELISAs 
Cytokines were measured in human serum samples using ELISA kits.  TNFα and IFNγ were 
measured using the respective OptEIA human cytokine ELISA kits from BD.  IL-17 was 
measured by the human IL-17A ELISA kit from eBioscience.  All three cytokines as well as 
CD13 protein and enzymatic activity were measured on the same day. 
 
siRNA Knockdown 
FLS were transfected by electroporation using an Amaxa Nucleofector and the nucleofector kit 
for dermal fibroblasts (NHDF, Lonza).  In brief, FLS were released by trypsin and 5x10
5
 were 
transfected per condition.  Cells were resuspended in transfection solution and either 300nM 
MMP14 siRNA cocktail (stealth RNAi, Invitrogen), MMP1 siRNA cocktail (stealth RNAi, 
Invitrogen), negative control cocktail (stealth RNAi medium control, Invitrogen), or 2μg 
pmaxGFP (Lonza) was added to each transfection cuvette.  Each cocktail contains three siRNAs 
specific for the target.  Cells were electroporated and transferred to flasks containing 20% 
CMRL.  Transfected cells were grown for 5-7 days then transferred to serum free medium for 2 
days before harvesting.  Transfection of GFP control plasmid was measured by fluorescent 
microscopy (EVOSfl, AME) and flow cytometry (BD Bisoceinces FACSCalibur). 
 
Confocal Microscopy 
RA FLS were grown to 90% confluence on 8-well glass chamber slides.  Cells were fixed with 
1% Formalin and blocked with Fc block (10% human serum/10% mouse serum in PBS).  Cells 
were incubated for 1hour at room temperature with anti-CD13-FITC (1D7) 1g/100l and anti-
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MMP14-PE (clone128527, R&D) 1.67g/100l or anti-CD90-PE 1μg/100μl (3E10, Biolegend).  
All experiments also included staining with MsIgG isotype controls (MsIg-FITC [eBioceinces], 
MsIg-PE [Biolegend]) at the same concentrations.  The nuclei were counter stained with DAPI at 
1g/ml.  Cells were mounted using Pro-gold anti-fade media (Life Technologies).  Images were 
taken with an Olympus Fluo-View 500 confocal microscope system (University of Michigan 
Microscopy and Image Analysis Core).  All images were corrected for background, thresholds 
were determined by DAPI alone, MsIg-FITC alone, and MsIg-PE alone. 
 
Exosome Isolation 
Exosomes were isolated by serial ultracentrifugation 
205
.  Exosomes were isolated from either the 
supernatants of 3 flasks of confluent RA FLS, 10mls of plasma, or 1 ml of RA synovial fluid 
diluted 1:4 with PBS.  Cells were spun out at 1500rpm for 5 minutes.  Then the supernatants 
were cleared of heavier debris by spins at 10,000xg for 30 minutes and 30,000xg for 1 hour.  
Exosomes were then spun down at 110,000xg for 4-20hours.  Exosome pellets were washed in 
PBS at 110,000xg for 1.5 hours – overnight and resuspended in 1ml of PBS.  Some exosomes 
were further purified using a density gradient, Optiprep (Sigma).  Optiprep was diluted with PBS 
to produce the following layers: 5%, 10%, 15%, 20%, 30%, 40%, and 50% w/v (densities of 
1.031, 1.050, 1.084, 1.110, 1.163, 1.215, and 1.268 g/ml).  500μl of extra cellular vesicle 
fractions were floated on the top of the density gradient and the gradients were spun at 
100,000xg for 1hour.  Fractions were carefully pipetted off, washed with PBS, and spun at 
110,000xg for 2 hours.  Pellets from the fractions were resuspended in 500μl PBS. 
 
144 
 
 
Chemotaxis Assay 
The chemotaxis assay was a modified under agarose chemotaxis system (Figure 6.1)
293,294
.  
Some plates were coated with fibronectin (10g/ml) overnight at 4°C then washed 2x with PBS.  
A 2.4% agarose (UltraPure, Invitrogen) solution in 1x HBSS was boiled and combined with 2 
parts 1% BSA in RPMI and 1 part 1x HBSS.  3mls of this solution was added to each well of a 
6-well plate and allowed to cool to room temperature. A 3-hole punch (Figure 6.1C, University 
of Michigan Instrument Shop) was used to create three 4 mm wells, with edges 3 mm apart, and 
the plates were equilibrated to 37°C.  Chemoattractants and T cells were adjusted to appropriate 
concentrations in chemotaxis medium (0.1% BSA, 2% L-glutamine, 1% pen/strep, in RPMI 
without phenol red).  Some Tck samples were treated with 100ng/ml of pertussis toxin for 2hr at 
37°C in 10% RPMI, then washed 1x with 0.1% BSA RPMI.  2.5x10
5
 T cells were added to the 
center well.  A medium only control was added to one of the outside wells while the 
chemoattractant solution was added to the second.  Plates were incubated at 37°C, 5% CO2 
overnight (uncoated) or for 5 hours (fibronectin).  Pictures were taken of the area directly 
between the outside and center wells using an EVOS inverted microscope at 100x magnification.  
Cell counts were Ln transformed and data is expressed as a chemotactic index (CI= Ln cells 
migrated to stimulus – Ln cells migrated to medium alone).   
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Figure 6.1 Setup of modified under agarose chemotaxis system for Tck chemotaxis. 
A, Model of the setup of an under agarose chemotaxis plate.  Red boxes indicate the area where pictures 
were taken to count chemotaxis (toward positive) or background movement (toward negative).  B, 
Images demonstrating gradient formation under the agarose.  Blue dye was placed in wells and pictures 
taken at intervals (10 minutes to overnight) to monitor the spread under the agarose.  C, Picture of the 
three hole punch tool used to create the holes in the agarose. 
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CD13 enzymatic mutation 
A CD13 clone (MGC Human ANPEP Sequence-Verified cDNA, GenBank accession no. 
BC058928) was obtained from Open Biosystems.  An E355Q enzymatic inactive mutant was 
created.  The plasmid (1µg DNA) was linearized by double digestion with SgrAI (2U) and SbfI 
(10U) (New England Biolabs).  The 7.3kb fragment was purified from a 1% agarose gel using 
the QIAquick Gel Extraction Kit (Qiagen).  The plasmid fragment and two gene blocks, (IDT): 
5’-
TGGCCTGCCAGACTTCAACGCCGGCGCCATGCAGAACTGGGGACTGGTGACCTACC
GGGAGAACTCCCTGCTGTTCGACCCCCTGTCCTCCTCCAGCAGCAACAAGGAGCGG
GTGGTCACTGTGATTGCTCATGAGCTGGCCCACCAGTGGTTCGGGAACCTGGTGACC
ATAGAGTGGTGGAATGACCTGTGGCTGAACGAGGGCTTCGCCTCCTACGTGGAGTA
CCTGGGTGCTGACTATGCGGAGCCCACCTGGAACTTGAAAGACCTCATGGTGCTGAA
TGA-3’ and 5’-
GACCTCATGGTGCTGAATGATGTGTACCGCGTGATGGCAGTGGATGCACTGGCCTCC
TCCCACCCGCTGTCCACACCCGCCTCGGAGATCAACACGCCGGCCCAGATCAGTGA
GCTGTTTGACGCCATCTCCTACAGCAAGGGCGCCTCAGTCCTCAGGATGCTCTCCAG
CTTCCTGTCCGAGGACGTATTCAAGCAGGGCCTGGCGTCCTACCTCCACACCTTTGC
CTACCAGAACACCATCTACCTGAACCTGTGGGACCACCTGCAGGAGGCTGTGAACA
ACCGGT-3’,  were assembled and transformed into NEB 5-alpha E. Coli using the Gibson 
Assembly Cloning Kit (New England Biolabs).  Clones were selected by Ampicillin resistance 
and several colonies were sequenced (University of Michigan Sequencing Core) to identify 
correct clones.  Plasmids for wild-type CD13 or enzymatic inactive CD13 were grown up and 
isolated using an EndoFree Plasmid Maxi Kit (Qiagen).  Plasmids were transfected into COS-1 
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cells (ATCC) using Lipofectamine LTX with Plus Reagant (Life Technologies).  Mock 
transfection with Lipofectamine only was used as a control.  Cultures were switched to serum 
free SFM4CHO media (Thermo Scientific) 48 hours after transfection and cultures were 
harvested 24 hours after. 
 
FLS Growth and Migration Assays 
RA FLS were seeded on Essen Image Lock 96-well plates overnight at either 3,000 cells/well for 
growth or 30,000 cells/well for migration.  For growth the 20% media was removed and cells 
washed 1x with PBS.  100μl of medium alone (control) or medium containing anti-CD3 (25 or 
50ng/ml, OKT3, used as a non-reactive control antibody in this experiment), anti-CD13 1D7 or 
WM15 (Biolegend) (25 or 50 ng/ml), or CD13 chemical inhibitors actinonin (Sigma-Aldrich) or 
bestatin (Sigma-Aldrich) (10μM and 50μM respectively) was added to the wells.  Images and 
confluence data were collected using an Essen IncuCyte.  For the scratch wound migration assay 
wounds were made via the Essen scratch wound tool in the seeded 96-well plate.  Plates were 
then washed 2x with PBS and medium was added similar to the growth plates.  Data were 
collected and the confluence or relative wound density calculated by the Essen IncuCyte. 
 
Statistics 
Concentrations, percent remaining, percent change in concentration, ratio of relative wound 
density, ratio of confluence, and chemotactic index are expressed as mean±SEM.  Enzymatic 
activity and fold change over GAPDH are expressed as mean±SD.  Statistically significant 
chemotaxis was assessed by paired student t-test between the Ln stimulus count to Ln medium 
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alone count; an unpaired T-test was used between groups.  Correlations were analyzed by 
ANOVA.  Otherwise significance was determined by unpaired student t-test, unless otherwise 
noted.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
149 
 
 
References 
1. Marcia Vital, O. of C. and P. L. Handout on Health: Rheumatoid Arthritis. at 
<http://www.niams.nih.gov/Health_Info/Rheumatic_Disease/> 
2. Hallowell, R. W. & Horton, M. R. Interstitial lung disease in patients with rheumatoid 
arthritis: spontaneous and drug induced. Drugs 74, 443–450 (2014). 
3. Ogdie, A. et al. Risk of major cardiovascular events in patients with psoriatic arthritis, 
psoriasis and rheumatoid arthritis: a population-based cohort study. Ann. Rheum. Dis. 
(2014). doi:10.1136/annrheumdis-2014-205675 
4. Nordang, G. B. N. et al. HLA-C alleles confer risk for anti-citrullinated peptide antibody-
positive rheumatoid arthritis independent of HLA-DRB1 alleles. Rheumatol. Oxf. Engl. 52, 
1973–1982 (2013). 
5. Jiang, X. et al. Anti-CarP antibodies in two large cohorts of patients with rheumatoid 
arthritis and their relationship to genetic risk factors, cigarette smoking and other 
autoantibodies. Ann. Rheum. Dis. (2014). doi:10.1136/annrheumdis-2013-205109 
6. Rosenstein, E. D., Greenwald, R. A., Kushner, L. J. & Weissmann, G. Hypothesis: the 
humoral immune response to oral bacteria provides a stimulus for the development of 
rheumatoid arthritis. Inflammation 28, 311–318 (2004). 
7. Gizinski, A. M. & Fox, D. A. T cell subsets and their role in the pathogenesis of rheumatic 
disease. Curr. Opin. Rheumatol. 26, 204–210 (2014). 
150 
 
8. Lundy, S. K., Sarkar, S., Tesmer, L. A. & Fox, D. A. Cells of the synovium in rheumatoid 
arthritis. T lymphocytes. Arthritis Res. Ther. 9, 202 (2007). 
9. Horwood, N. J. et al. Activated T lymphocytes support osteoclast formation in vitro. 
Biochem. Biophys. Res. Commun. 265, 144–150 (1999). 
10. Tran, C. N. et al. Interactions of T cells with fibroblast-like synoviocytes: role of the B7 
family costimulatory ligand B7-H3. J. Immunol. Baltim. Md 1950 180, 2989–2998 (2008). 
11. Tran, C. N. et al. Molecular interactions between T cells and fibroblast-like synoviocytes: 
role of membrane tumor necrosis factor-alpha on cytokine-activated T cells. Am. J. Pathol. 
171, 1588–1598 (2007). 
12. Goronzy, J., Weyand, C. M. & Fathman, C. G. Shared T cell recognition sites on human 
histocompatibility leukocyte antigen class II molecules of patients with seropositive 
rheumatoid arthritis. J. Clin. Invest. 77, 1042–1049 (1986). 
13. Nepom, G. T. Structural and genetic features of human leukocytic antigen class II elements 
associated with rheumatoid arthritis. Am. J. Med. 85, 12–13 (1988). 
14. Scally, S. W. et al. A molecular basis for the association of the HLA-DRB1 locus, 
citrullination, and rheumatoid arthritis. J. Exp. Med. 210, 2569–2582 (2013). 
15. Ling, S., Cline, E. N., Haug, T. S., Fox, D. A. & Holoshitz, J. Citrullinated calreticulin 
potentiates rheumatoid arthritis shared epitope signaling. Arthritis Rheum. 65, 618–626 
(2013). 
16. Bang, S.-Y., Lee, H.-S., Lee, K. W. & Bae, S.-C. Interaction of HLA-DRB1*09:01 and 
*04:05 with smoking suggests distinctive mechanisms of rheumatoid arthritis susceptibility 
beyond the shared epitope. J. Rheumatol. 40, 1054–1062 (2013). 
151 
 
17. De Almeida, D. E. et al. Immune dysregulation by the rheumatoid arthritis shared epitope. 
J. Immunol. Baltim. Md 1950 185, 1927–1934 (2010). 
18. Ruth, J. H. et al. Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-
induced arthritis. Arthritis Rheum. 44, 1568–1581 (2001). 
19. Brennan, F. M. et al. Evidence that rheumatoid arthritis synovial T cells are similar to 
cytokine-activated T cells: involvement of phosphatidylinositol 3-kinase and nuclear factor 
kappaB pathways in tumor necrosis factor alpha production in rheumatoid arthritis. 
Arthritis Rheum. 46, 31–41 (2002). 
20. Murphy, K. P. & Janeway, C. Janeway’s Immunobiology. (Garland Science, 2008). 
21. Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A. & Coffman, R. L. Two 
types of murine helper T cell clone. I. Definition according to profiles of lymphokine 
activities and secreted proteins. J. Immunol. Baltim. Md 1950 136, 2348–2357 (1986). 
22. Crane, I. J. & Forrester, J. V. Th1 and Th2 lymphocytes in autoimmune disease. Crit. Rev. 
Immunol. 25, 75–102 (2005). 
23. Takatori, H., Kanno, Y., Chen, Z. & O’Shea, J. J. New complexities in helper T cell fate 
determination and the implications for autoimmune diseases. Mod. Rheumatol. Jpn. Rheum. 
Assoc. 18, 533–541 (2008). 
24. Williams, R. O., Williams, D. G., Feldmann, M. & Maini, R. N. Increased limb 
involvement in murine collagen-induced arthritis following treatment with anti-interferon-
gamma. Clin. Exp. Immunol. 92, 323–327 (1993). 
25. Woods, J. M. et al. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory 
cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J. 
Immunol. Baltim. Md 1950 166, 1214–1222 (2001). 
152 
 
26. Park, H. et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing 
interleukin 17. Nat. Immunol. 6, 1133–1141 (2005). 
27. Harrington, L. E. et al. Interleukin 17-producing CD4+ effector T cells develop via a 
lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6, 1123–1132 
(2005). 
28. Sarkar, S., Tesmer, L. A., Hindnavis, V., Endres, J. L. & Fox, D. A. Interleukin-17 as a 
molecular target in immune-mediated arthritis: immunoregulatory properties of genetically 
modified murine dendritic cells that secrete interleukin-4. Arthritis Rheum. 56, 89–100 
(2007). 
29. Fossiez, F. et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and 
hematopoietic cytokines. J. Exp. Med. 183, 2593–2603 (1996). 
30. Nakae, S., Nambu, A., Sudo, K. & Iwakura, Y. Suppression of immune induction of 
collagen-induced arthritis in IL-17-deficient mice. J. Immunol. Baltim. Md 1950 171, 6173–
6177 (2003). 
31. Chabaud, M. et al. Human interleukin-17: A T cell-derived proinflammatory cytokine 
produced by the rheumatoid synovium. Arthritis Rheum. 42, 963–970 (1999). 
32. Kotake, S. et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent 
stimulator of osteoclastogenesis. J. Clin. Invest. 103, 1345–1352 (1999). 
33. Raza, K. et al. Early rheumatoid arthritis is characterized by a distinct and transient 
synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res. Ther. 7, 
R784–795 (2005). 
34. Leipe, J. et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 62, 
2876–2885 (2010). 
153 
 
35. Miossec, P., Korn, T. & Kuchroo, V. K. Interleukin-17 and Type 17 Helper T Cells. N. 
Engl. J. Med. 361, 888–898 (2009). 
36. Hopkins, S. J. & Meager, A. Cytokines in synovial fluid: II. The presence of tumour 
necrosis factor and interferon. Clin. Exp. Immunol. 73, 88–92 (1988). 
37. Fox, D. A. Biological therapies: a novel approach to the treatment of autoimmune disease. 
Am. J. Med. 99, 82–88 (1995). 
38. Ma, X. & Xu, S. TNF inhibitor therapy for rheumatoid arthritis. Biomed. Rep. 1, 177–184 
(2013). 
39. Guerne, P. A., Zuraw, B. L., Vaughan, J. H., Carson, D. A. & Lotz, M. Synovium as a 
source of interleukin 6 in vitro. Contribution to local and systemic manifestations of 
arthritis. J. Clin. Invest. 83, 585–592 (1989). 
40. Chabaud, M. & Miossec, P. The combination of tumor necrosis factor alpha blockade with 
interleukin-1 and interleukin-17 blockade is more effective for controlling synovial 
inflammation and bone resorption in an ex vivo model. Arthritis Rheum. 44, 1293–1303 
(2001). 
41. Koenders, M. I. et al. Interleukin-17 acts independently of TNF-alpha under arthritic 
conditions. J. Immunol. Baltim. Md 1950 176, 6262–6269 (2006). 
42. Fox, D. A., Gizinski, A., Morgan, R. & Lundy, S. K. Cell-cell Interactions in Rheumatoid 
Arthritis Synovium. Rheum. Dis. Clin. North Am. 36, 311–323 (2010). 
43. Firestein, G. S. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive 
responders or transformed aggressors? Arthritis Rheum. 39, 1781–1790 (1996). 
44. Bottini, N. & Firestein, G. S. Duality of fibroblast-like synoviocytes in RA: passive 
responders and imprinted aggressors. Nat. Rev. Rheumatol. 9, 24–33 (2013). 
154 
 
45. Fox, D. A., Gizinski, A., Morgan, R. & Lundy, S. K. Cell-cell Interactions in Rheumatoid 
Arthritis Synovium. Rheum. Dis. Clin. North Am. 36, 311–323 (2010). 
46. Valencia, X. et al. Cadherin-11 provides specific cellular adhesion between fibroblast-like 
synoviocytes. J. Exp. Med. 200, 1673–1679 (2004). 
47. Lee, D. M. et al. Cadherin-11 in synovial lining formation and pathology in arthritis. 
Science 315, 1006–1010 (2007). 
48. Malemud, C. J. Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis. 
Clin. Chim. Acta Int. J. Clin. Chem. 375, 10–19 (2007). 
49. Sabeh, F., Fox, D. & Weiss, S. J. Membrane-type I matrix metalloproteinase-dependent 
regulation of rheumatoid arthritis synoviocyte function. J. Immunol. Baltim. Md 1950 184, 
6396–6406 (2010). 
50. You, S. et al. Identification of key regulators for the migration and invasion of rheumatoid 
synoviocytes through a systems approach. Proc. Natl. Acad. Sci. U. S. A. 111, 550–555 
(2014). 
51. Lacey, D. et al. Control of fibroblast-like synoviocyte proliferation by macrophage 
migration inhibitory factor. Arthritis Rheum. 48, 103–109 (2003). 
52. Trabandt, A., Gay, R. E. & Gay, S. Oncogene activation in rheumatoid synovium. APMIS 
Acta Pathol. Microbiol. Immunol. Scand. 100, 861–875 (1992). 
53. MacNaul, K. L., Chartrain, N., Lark, M., Tocci, M. J. & Hutchinson, N. I. Discoordinate 
expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in 
rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor 
necrosis factor-alpha on stromelysin expression. J. Biol. Chem. 265, 17238–17245 (1990). 
155 
 
54. Lafyatis, R. et al. Anchorage-independent growth of synoviocytes from arthritic and normal 
joints. Stimulation by exogenous platelet-derived growth factor and inhibition by 
transforming growth factor-beta and retinoids. J. Clin. Invest. 83, 1267–1276 (1989). 
55. Lefèvre, S. et al. Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. Nat. 
Med. 15, 1414–1420 (2009). 
56. Brentano, F., Schorr, O., Gay, R. E., Gay, S. & Kyburz, D. RNA released from necrotic 
synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 
3. Arthritis Rheum. 52, 2656–2665 (2005). 
57. Agarwal, S., Misra, R. & Aggarwal, A. Induction of metalloproteinases expression by TLR 
ligands in human fibroblast like synoviocytes from juvenile idiopathic arthritis patients. 
Indian J. Med. Res. 131, 771–779 (2010). 
58. Kyburz, D. et al. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate 
synovial fibroblasts by toll-like receptor signaling. Arthritis Rheum. 48, 642–650 (2003). 
59. Kim, K.-W. et al. Human rheumatoid synovial fibroblasts promote osteoclastogenic activity 
by activating RANKL via TLR-2 and TLR-4 activation. Immunol. Lett. 110, 54–64 (2007). 
60. Chomarat, P., Rissoan, M. C., Pin, J. J., Banchereau, J. & Miossec, P. Contribution of IL-1, 
CD14, and CD13 in the increased IL-6 production induced by in vitro monocyte-
synoviocyte interactions. J. Immunol. Baltim. Md 1950 155, 3645–3652 (1995). 
61. Joo, Y. S. et al. Evidence for the expression of a second CD6 ligand by synovial fibroblasts. 
Arthritis Rheum. 43, 329–335 (2000). 
62. Saifullah, M. K. et al. Expression and characterization of a novel CD6 ligand in cells 
derived from joint and epithelial tissues. J. Immunol. Baltim. Md 1950 173, 6125–6133 
(2004). 
156 
 
63. Tesmer, L. A., Lundy, S. K., Sarkar, S. & Fox, D. A. Th17 cells in human disease. 
Immunol. Rev. 223, 87–113 (2008). 
64. Yamamura, Y. et al. Effector function of resting T cells: activation of synovial fibroblasts. 
J. Immunol. Baltim. Md 1950 166, 2270–2275 (2001). 
65. Kim, K.-W. et al. Up-regulation of stromal cell-derived factor 1 (CXCL12) production in 
rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of 
interleukin-17 and CD40L-CD40 interaction. Arthritis Rheum. 56, 1076–1086 (2007). 
66. Bernard, A., Boumsell, L. & Hill, C. in Leucocyte Typing (eds. Bernard, P. D. A., 
Boumsell, D. L., Dausset, P. D. J., Milstein, D. C. & Schlossman, P. D. S. F.) 9–142 
(Springer Berlin Heidelberg, 1984). at <http://link.springer.com/chapter/10.1007/978-3-
642-68857-7_3> 
67. Olsen, J. et al. Complete amino acid sequence of human intestinal aminopeptidase N as 
deduced from cloned cDNA. FEBS Lett. 238, 307–314 (1988). 
68. Look, A. T., Ashmun, R. A., Shapiro, L. H. & Peiper, S. C. Human myeloid plasma 
membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N. J. Clin. Invest. 83, 
1299–1307 (1989). 
69. O’Connell, P. J., Gerkis, V. & d’ Apice, A. J. Variable O-glycosylation of CD13 
(aminopeptidase N). J. Biol. Chem. 266, 4593–4597 (1991). 
70. Luan, Y. & Xu, W. The structure and main functions of aminopeptidase N. Curr. Med. 
Chem. 14, 639–647 (2007). 
71. Sjöström, H., Norén, O., Danielsen, E. M. & Skovbjerg, H. Structure of microvillar 
enzymes in different phases of their life cycles. Ciba Found. Symp. 95, 50–72 (1983). 
157 
 
72. Luciani, N. et al. Characterization of Glu350 as a critical residue involved in the N-terminal 
amine binding site of aminopeptidase N (EC 3.4.11.2): insights into its mechanism of 
action. Biochemistry (Mosc.) 37, 686–692 (1998). 
73. Wong, A. H. M., Zhou, D. & Rini, J. M. The X-ray crystal structure of human 
aminopeptidase N reveals a novel dimer and the basis for peptide processing. J. Biol. Chem. 
287, 36804–36813 (2012). 
74. Ashmun, R. A., Shapiro, L. H. & Look, A. T. Deletion of the zinc-binding motif of 
CD13/aminopeptidase N molecules results in loss of epitopes that mediate binding of 
inhibitory antibodies. Blood 79, 3344–3349 (1992). 
75. Firla, B. et al. Extracellular cysteines define ectopeptidase (APN, CD13) expression and 
function. Free Radic. Biol. Med. 32, 584–595 (2002). 
76. Riemann, D., Kehlen, A. & Langner, J. CD13--not just a marker in leukemia typing. 
Immunol. Today 20, 83–88 (1999). 
77. Shapiro, L. H., Ashmun, R. A., Roberts, W. M. & Look, A. T. Separate promoters control 
transcription of the human aminopeptidase N gene in myeloid and intestinal epithelial cells. 
J. Biol. Chem. 266, 11999–12007 (1991). 
78. Koch, A. E. et al. Monoclonal antibodies detect monocyte/macrophage activation and 
differentiation antigens and identify functionally distinct subpopulations of human 
rheumatoid synovial tissue macrophages. Am. J. Pathol. 138, 165–173 (1991). 
79. Kehlen, A., Langner, J. & Riemann, D. Transforming growth factor-beta increases the 
expression of aminopeptidase N/CD13 mRNA and protein in monocytes and monocytic 
cell lines. Adv. Exp. Med. Biol. 477, 49–56 (2000). 
158 
 
80. Petrovic, N., Bhagwat, S. V., Ratzan, W. J., Ostrowski, M. C. & Shapiro, L. H. CD13/APN 
transcription is induced by RAS/MAPK-mediated phosphorylation of Ets-2 in activated 
endothelial cells. J. Biol. Chem. 278, 49358–49368 (2003). 
81. Sorrell, J. M., Brinon, L., Baber, M. A. & Caplan, A. I. Cytokines and glucocorticoids 
differentially regulate APN/CD13 and DPPIV/CD26 enzyme activities in cultured human 
dermal fibroblasts. Arch. Dermatol. Res. 295, 160–168 (2003). 
82. Kunii, R., Nemoto, E., Kanaya, S., Tsubahara, T. & Shimauchi, H. Expression of 
CD13/aminopeptidase N on human gingival fibroblasts and up-regulation upon stimulation 
with interleukin-4 and interleukin-13. J. Periodontal Res. 40, 138–146 (2005). 
83. Kehlen, A., Lendeckel, U., Dralle, H., Langner, J. & Hoang-Vu, C. Biological significance 
of aminopeptidase N/CD13 in thyroid carcinomas. Cancer Res. 63, 8500–8506 (2003). 
84. Piela-Smith, T. H. & Korn, J. H. Aminopeptidase N: a constitutive cell-surface protein on 
human dermal fibroblasts. Cell. Immunol. 162, 42–48 (1995). 
85. Mina-Osorio, P. The moonlighting enzyme CD13: old and new functions to target. Trends 
Mol. Med. 14, 361–371 (2008). 
86. Riemann, D. et al. Caveolae/lipid rafts in fibroblast-like synoviocytes: ectopeptidase-rich 
membrane microdomains. Biochem. J. 354, 47–55 (2001). 
87. Navarrete Santos, A., Roentsch, J., Danielsen, E. M., Langner, J. & Riemann, D. 
Aminopeptidase N/CD13 is associated with raft membrane microdomains in monocytes. 
Biochem. Biophys. Res. Commun. 269, 143–148 (2000). 
88. Favaloro, E. J., Browning, T. & Facey, D. CD13 (GP150; aminopeptidase-N): predominant 
functional activity in blood is localized to plasma and is not cell-surface associated. Exp. 
Hematol. 21, 1695–1701 (1993). 
159 
 
89. Van Hensbergen, Y. et al. Soluble aminopeptidase N/CD13 in malignant and nonmalignant 
effusions and intratumoral fluid. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 8, 3747–
3754 (2002). 
90. Kawai, M., Hara, Y., Miyazato, I. & Hosaki, S. Novel, aberrantly truncated isoform of 
serum CD13 in a family with high serum aminopeptidase N (CD13) activity. Clin. Chem. 
47, 223–230 (2001). 
91. Watanabe, Y., Ito, K., Iwaki-Egawa, S., Yamaguchi, R. & Fujimoto, Y. Aminopeptidase N 
in sera of healthy subjects is a different N-terminal processed derivative from the one 
obtained from maternal serum. Mol. Genet. Metab. 63, 289–294 (1998). 
92. Gabrilovac, J., Breljak, D., Cupić, B. & Ambriović-Ristov, A. Regulation of 
aminopeptidase N (EC 3.4.11.2; APN; CD13) by interferon-gamma on the HL-60 cell line. 
Life Sci. 76, 2681–2697 (2005). 
93. Giros, B., Gros, C., Solhonne, B. & Schwartz, J. C. Characterization of aminopeptidases 
responsible for inactivating endogenous (Met5)enkephalin in brain slices using peptidase 
inhibitors and anti-aminopeptidase M antibodies. Mol. Pharmacol. 29, 281–287 (1986). 
94. Palmieri, F. E., Petrelli, J. J. & Ward, P. E. Vascular, plasma membrane aminopeptidase M. 
Metabolism of vasoactive peptides. Biochem. Pharmacol. 34, 2309–2317 (1985). 
95. Kanayama, N. et al. Inactivation of interleukin-8 by aminopeptidase N (CD13). J. Leukoc. 
Biol. 57, 129–134 (1995). 
96. Hoffmann, T., Faust, J., Neubert, K. & Ansorge, S. Dipeptidyl peptidase IV (CD 26) and 
aminopeptidase N (CD 13) catalyzed hydrolysis of cytokines and peptides with N-terminal 
cytokine sequences. FEBS Lett. 336, 61–64 (1993). 
160 
 
97. Schreiter, A. et al. Pain inhibition by blocking leukocytic and neuronal opioid peptidases in 
peripheral inflamed tissue. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 26, 5161–5171 
(2012). 
98. Núñez, L. et al. Cholesterol crystallization-promoting activity of aminopeptidase-N isolated 
from the vesicular carrier of biliary lipids. FEBS Lett. 329, 84–88 (1993). 
99. Kramer, W. et al. Aminopeptidase N (CD13) is a molecular target of the cholesterol 
absorption inhibitor ezetimibe in the enterocyte brush border membrane. J. Biol. Chem. 
280, 1306–1320 (2005). 
100. Söderberg, C. et al. CD13 (human aminopeptidase N) mediates human cytomegalovirus 
infection. J. Virol. 67, 6576–6585 (1993). 
101. Yeager, C. L. et al. Human aminopeptidase N is a receptor for human coronavirus 229E. 
Nature 357, 420–422 (1992). 
102. Pasqualini, R. et al. Aminopeptidase N Is a Receptor for Tumor-homing Peptides and a 
Target for Inhibiting Angiogenesis. Cancer Res. 60, 722–727 (2000). 
103. Villaseñor-Cardoso, M. I., Frausto-Del-Río, D. A. & Ortega, E. Aminopeptidase N (CD13) 
is involved in phagocytic processes in human dendritic cells and macrophages. BioMed Res. 
Int. 2013, 562984 (2013). 
104. Mina-Osorio, P. & Ortega, E. Aminopeptidase N (CD13) functionally interacts with 
FcgammaRs in human monocytes. J. Leukoc. Biol. 77, 1008–1017 (2005). 
105. Ohnuma, K. et al. Role of CD26/dipeptidyl peptidase IV in human T cell activation and 
function. Front. Biosci. J. Virtual Libr. 13, 2299–2310 (2008). 
161 
 
106. Ospelt, C. et al. Inhibition of fibroblast activation protein and dipeptidylpeptidase 4 
increases cartilage invasion by rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 
62, 1224–1235 (2010). 
107. Williams, Y. N. et al. Dipeptidyl peptidase IV on activated T cells as a target molecule for 
therapy of rheumatoid arthritis. Clin. Exp. Immunol. 131, 68–74 (2003). 
108. Ansorge, S. et al. Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and 
aminopeptidase N (APN) families in immune functions. Clin. Chem. Lab. Med. CCLM 
FESCC 47, 253–261 (2009). 
109. Ahmad, S., Wang, L. & Ward, P. E. Dipeptidyl(amino)peptidase IV and aminopeptidase M 
metabolize circulating substance P in vivo. J. Pharmacol. Exp. Ther. 260, 1257–1261 
(1992). 
110. Xu, Y., Wellner, D. & Scheinberg, D. A. Substance P and bradykinin are natural inhibitors 
of CD13/aminopeptidase N. Biochem. Biophys. Res. Commun. 208, 664–674 (1995). 
111. Reinhold, D. et al. PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and 
aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in 
SJL/J mice. Biol. Chem. 392, 233–237 (2011). 
112. Bank, U. et al. Dipeptidylpeptidase IV (DPIV) and alanyl-aminopeptidases (AAPs) as a 
new target complex for treatment of autoimmune and inflammatory diseases-proof of 
concept in a mouse model of colitis. Adv. Exp. Med. Biol. 575, 143–153 (2006). 
113. Katsanos, G. S. et al. Impact of substance P on cellular immunity. J. Biol. Regul. Homeost. 
Agents 22, 93–98 (2008). 
162 
 
114. Santos, A. N., Langner, J., Herrmann, M. & Riemann, D. Aminopeptidase N/CD13 is 
directly linked to signal transduction pathways in monocytes. Cell. Immunol. 201, 22–32 
(2000). 
115. Mina-Osorio, P. et al. CD13 is a novel mediator of monocytic/endothelial cell adhesion. J. 
Leukoc. Biol. 84, 448–459 (2008). 
116. Ghosh, M. et al. Molecular Mechanisms Regulating CD13-Mediated Adhesion. 
Immunology (2014). doi:10.1111/imm.12279 
117. Ghaffari, A., Li, Y., Kilani, R. T. & Ghahary, A. 14-3-3 sigma associates with cell surface 
aminopeptidase N in the regulation of matrix metalloproteinase-1. J. Cell Sci. 123, 2996–
3005 (2010). 
118. Lai, A., Ghaffari, A., Li, Y. & Ghahary, A. Microarray-based identification of 
aminopeptidase N target genes in keratinocyte conditioned medium-stimulated dermal 
fibroblasts. J. Cell. Biochem. 113, 1061–1068 (2012). 
119. Yang, E., Shim, J. S., Woo, H.-J., Kim, K.-W. & Kwon, H. J. Aminopeptidase N/CD13 
induces angiogenesis through interaction with a pro-angiogenic protein, galectin-3. 
Biochem. Biophys. Res. Commun. 363, 336–341 (2007). 
120. Petrovic, N. et al. CD13/APN regulates endothelial invasion and filopodia formation. Blood 
110, 142–150 (2007). 
121. Wickström, M., Larsson, R., Nygren, P. & Gullbo, J. Aminopeptidase N (CD13) as a target 
for cancer chemotherapy. Cancer Sci. 102, 501–508 (2011). 
122. Bauvois, B. & Dauzonne, D. Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, 
biological evaluations, and therapeutic prospects. Med. Res. Rev. 26, 88–130 (2006). 
163 
 
123. Scornik, O. A. & Botbol, V. Bestatin as an experimental tool in mammals. Curr. Drug 
Metab. 2, 67–85 (2001). 
124. Grujic, M., Zavasnik-Bergant, T., Pejler, G. & Renko, M. Actinonin induces apoptosis in 
U937 leukemia cells. Cancer Lett. 223, 211–218 (2005). 
125. Sekine, K., Fujii, H. & Abe, F. Induction of apoptosis by bestatin (ubenimex) in human 
leukemic cell lines. Leukemia 13, 729–734 (1999). 
126. Ziaber, J., Baj, Z., Paśnik, J., Chmielewski, H. & Tchórzewski, H. Increased expression of 
neutral endopeptidase (NEP) and aminopeptidase N (APN) on peripheral blood 
mononuclear cells in patients with multiple sclerosis. Immunol. Lett. 71, 127–129 (2000). 
127. Rahbar, A., Boström, L. & Söderberg-Naucler, C. Detection of cytotoxic CD13-specific 
autoantibodies in sera from patients with ulcerative colitis and Crohn’s disease. J. 
Autoimmun. 26, 155–164 (2006). 
128. Thielitz, A. et al. Identification of extra- and intracellular alanyl aminopeptidases as new 
targets to modulate keratinocyte growth and differentiation. Biochem. Biophys. Res. 
Commun. 321, 795–801 (2004). 
129. Kitko, C. L. et al. Plasma CXCL9 elevations correlate with chronic GVHD diagnosis. 
Blood 123, 786–793 (2014). 
130. Dimitroulia, E., Spanakis, N., Konstantinidou, A. E., Legakis, N. J. & Tsakris, A. Frequent 
detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. 
Inflamm. Bowel Dis. 12, 879–884 (2006). 
131. Iida, T. et al. Looking for endoscopic features of cytomegalovirus colitis: a study of 187 
patients with active ulcerative colitis, positive and negative for cytomegalovirus. Inflamm. 
Bowel Dis. 19, 1156–1163 (2013). 
164 
 
132. Thielitz, A. et al. The ectopeptidases dipeptidyl peptidase IV (DP IV) and aminopeptidase 
N (APN) and their related enzymes as possible targets in the treatment of skin diseases. 
Front. Biosci. J. Virtual Libr. 13, 2364–2375 (2008). 
133. Lai, A., Ghaffari, A. & Ghahary, A. Inhibitory effect of anti-aminopeptidase N/CD13 
antibodies on fibroblast migration. Mol. Cell. Biochem. 343, 191–199 (2010). 
134. Lai, A. et al. Topical application of aminopeptidase N-neutralizing antibody accelerates 
wound closure. Mol. Cell. Biochem. 372, 95–100 (2013). 
135. Cuvelier, G. D. E. et al. Anti-CD13 Abs in children with extensive chronic GVHD and their 
relation to soluble CD13 after allogeneic blood and marrow transplantation from a 
Children’s Oncology Groups Study, ASCT0031. Bone Marrow Transplant. 45, 1653–1657 
(2010). 
136. Soderberg, C. et al. Cytomegalovirus-induced CD13-specific autoimmunity--a possible 
cause of chronic graft-vs-host disease. Transplantation 61, 600–609 (1996). 
137. Fujii, H. et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host 
disease: a report from the Children’s Oncology Group. Blood 111, 3276–3285 (2008). 
138. Winnicka, B. et al. CD13 is dispensable for normal hematopoiesis and myeloid cell 
functions in the mouse. J. Leukoc. Biol. 88, 347–359 (2010). 
139. Stefanović, V., Vlahović, P. & Mitić-Zlatković, M. Receptor-mediated induction of human 
dermal fibroblast ectoaminopeptidase N by glucocorticoids. Cell. Mol. Life Sci. CMLS 54, 
614–617 (1998). 
140. Shibuya, K. et al. Enhancement of interleukin 1 and interleukin 2 releases by ubenimex. J. 
Antibiot. (Tokyo) 40, 363–369 (1987). 
165 
 
141. Ansorge, S., Schön, E. & Kunz, D. Membrane-bound peptidases of lymphocytes: functional 
implications. Biomed. Biochim. Acta 50, 799–807 (1991). 
142. Spits, H., Lanier, L. L. & Phillips, J. H. Development of human T and natural killer cells. 
Blood 85, 2654–2670 (1995). 
143. Riemann, D., Schwachula, A., Hentschel, M. & Langner, J. Demonstration of 
CD13/aminopeptidase N on synovial fluid T cells from patients with different forms of 
joint effusions. Immunobiology 187, 24–35 (1993). 
144. Riemann, D., Wollert, H. G., Menschikowski, J., Mittenzwei, S. & Langner, J. 
Immunophenotype of lymphocytes in pericardial fluid from patients with different forms of 
heart disease. Int. Arch. Allergy Immunol. 104, 48–56 (1994). 
145. Riemann, D., Kehlen, A., Thiele, K., Löhn, M. & Langner, J. Co-incubation of lymphocytes 
with fibroblast-like synoviocytes and other cell types can induce lymphocytic surface 
expression of aminopeptidase N/CD13. Adv. Exp. Med. Biol. 421, 75–79 (1997). 
146. Riemann, D., Kehlen, A., Thiele, K., Löhn, M. & Langner, J. Induction of aminopeptidase 
N/CD13 on human lymphocytes after adhesion to fibroblast-like synoviocytes, endothelial 
cells, epithelial cells, and monocytes/macrophages. J. Immunol. Baltim. Md 1950 158, 
3425–3432 (1997). 
147. Kunz, D., Bühling, F., Hütter, H. J., Aoyagi, T. & Ansorge, S. Aminopeptidase N (CD13, 
EC 3.3.4.11.2) occurs on the surface of resting and concanavalin A-stimulated 
lymphocytes. Biol. Chem. Hoppe. Seyler 374, 291–296 (1993). 
148. Lendeckel, U. et al. Rapid mitogen-induced aminopeptidase N surface expression in human 
T cells is dominated by mechanisms independent of de novo protein biosynthesis. 
Immunobiology 197, 55–69 (1997). 
166 
 
149. Lendeckel, U. et al. Expression of the aminopeptidase N (CD13) gene in the human T cell 
lines HuT78 and H9. Cell. Immunol. 153, 214–226 (1994). 
150. Koch, A. E. Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis 
Rheum. 52, 710–721 (2005). 
151. Ward, S. G. & Marelli-Berg, F. M. Mechanisms of chemokine and antigen-dependent T-
lymphocyte navigation. Biochem. J. 418, 13–27 (2009). 
152. Bodolay, E., Koch, A. E., Kim, J., Szegedi, G. & Szekanecz, Z. Angiogenesis and 
chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J. 
Cell. Mol. Med. 6, 357–376 (2002). 
153. Szekanecz, Z., Koch, A. E. & Tak, P. P. Chemokine and chemokine receptor blockade in 
arthritis, a prototype of immune-mediated inflammatory diseases. Neth. J. Med. 69, 356–
366 (2011). 
154. Proudfoot, A. E. I. Chemokine receptors: multifaceted therapeutic targets. Nat. Rev. 
Immunol. 2, 106–115 (2002). 
155. Ruth, J. H. et al. Selective lymphocyte chemokine receptor expression in the rheumatoid 
joint. Arthritis Rheum. 44, 2750–2760 (2001). 
156. Bryant, J., Ahern, D. J. & Brennan, F. M. CXCR4 and vascular cell adhesion molecule 1 
are key chemokine/adhesion receptors in the migration of cytokine-activated T cells. 
Arthritis Rheum. 64, 2137–2146 (2012). 
157. Zhang, X., Nakajima, T., Goronzy, J. J. & Weyand, C. M. Tissue trafficking patterns of 
effector memory CD4+ T cells in rheumatoid arthritis. Arthritis Rheum. 52, 3839–3849 
(2005). 
167 
 
158. Nanki, T. et al. Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a 
central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J. Immunol. 
Baltim. Md 1950 165, 6590–6598 (2000). 
159. Yang, M. et al. Expression of CC chemokine ligand 5 in patients with rheumatoid arthritis 
and its correlation with disease activity and medication. Chin. Med. Sci. J. Chung-Kuo 
Hsüeh Ko Hsüeh Tsa Chih Chin. Acad. Med. Sci. 24, 50–54 (2009). 
160. Forrest, M. J., Eiermann, G. J., Meurer, R., Walakovits, L. A. & MacIntyre, D. E. The role 
of CD18 in IL-8 induced dermal and synovial inflammation. Br. J. Pharmacol. 106, 287–
294 (1992). 
161. Koch, A. E. et al. Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and 
epithelial neutrophil activating peptide 78 in the rheumatoid joint. Arthritis Rheum. 44, 31–
40 (2001). 
162. García-Vicuña, R. et al. CC and CXC chemokine receptors mediate migration, 
proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from 
rheumatoid arthritis patients. Arthritis Rheum. 50, 3866–3877 (2004). 
163. Loetscher, P. & Moser, B. Homing chemokines in rheumatoid arthritis. Arthritis Res. 4, 
233–236 (2002). 
164. Min, D.-J. et al. Augmented production of chemokines by the interaction of type II 
collagen-reactive T cells with rheumatoid synovial fibroblasts. Arthritis Rheum. 50, 1146–
1155 (2004). 
165. Murdoch, C. & Finn, A. Chemokine receptors and their role in inflammation and infectious 
diseases. Blood 95, 3032–3043 (2000). 
168 
 
166. Proost, P. et al. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs 
CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell 
migration. Blood 110, 37–44 (2007). 
167. Wulfaenger, J., Niedling, S., Riemann, D. & Seliger, B. Aminopeptidase N (APN)/CD13-
dependent CXCR4 downregulation is associated with diminished cell migration, 
proliferation and invasion. Mol. Membr. Biol. 25, 72–82 (2008). 
168. Lkhagvaa, B. et al. Bestatin, an inhibitor for aminopeptidases, modulates the production of 
cytokines and chemokines by activated monocytes and macrophages. Cytokine 44, 386–391 
(2008). 
169. Shimizu, T. et al. CD13/aminopeptidase N-induced lymphocyte involvement in inflamed 
joints of patients with rheumatoid arthritis. Arthritis Rheum. 46, 2330–2338 (2002). 
170. Gross, J. & Lapiere, C. M. Collagenolytic activity in amphibian tissues: a tissue culture 
assay. Proc. Natl. Acad. Sci. U. S. A. 48, 1014–1022 (1962). 
171. Khokha, R., Murthy, A. & Weiss, A. Metalloproteinases and their natural inhibitors in 
inflammation and immunity. Nat. Rev. Immunol. 13, 649–665 (2013). 
172. Gearing, A. J. et al. Processing of tumour necrosis factor-alpha precursor by 
metalloproteinases. Nature 370, 555–557 (1994). 
173. Murphy, G. et al. Metalloproteinases from rabbit bone culture medium degrade types IV 
and V collagens, laminin and fibronectin. Biochem. J. 199, 807–811 (1981). 
174. Pulyaeva, H. et al. MT1-MMP correlates with MMP-2 activation potential seen after 
epithelial to mesenchymal transition in human breast carcinoma cells. Clin. Exp. Metastasis 
15, 111–120 (1997). 
169 
 
175. Shimizu-Hirota, R. et al. MT1-MMP regulates the PI3Kδ·Mi-2/NuRD-dependent control of 
macrophage immune function. Genes Dev. 26, 395–413 (2012). 
176. Ahn, J. K. et al. The role of α-defensin-1 and related signal transduction mechanisms in the 
production of IL-6, IL-8 and MMPs in rheumatoid fibroblast-like synoviocytes. Rheumatol. 
Oxf. Engl. 52, 1368–1376 (2013). 
177. Sabeh, F., Li, X.-Y., Saunders, T. L., Rowe, R. G. & Weiss, S. J. Secreted versus 
membrane-anchored collagenases: relative roles in fibroblast-dependent collagenolysis and 
invasion. J. Biol. Chem. 284, 23001–23011 (2009). 
178. Pap, T. et al. Differential expression pattern of membrane-type matrix metalloproteinases in 
rheumatoid arthritis. Arthritis Rheum. 43, 1226–1232 (2000). 
179. Mateos, J. et al. Differential protein profiling of synovial fluid from rheumatoid arthritis 
and osteoarthritis patients using LC–MALDI TOF/TOF. J. Proteomics 75, 2869–2878 
(2012). 
180. Yoshihara, Y. et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in 
synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann. Rheum. Dis. 
59, 455–461 (2000). 
181. Yamanaka, H. et al. Expression and tissue localization of membrane-types 1, 2, and 3 
matrix metalloproteinases in rheumatoid synovium. Lab. Investig. J. Tech. Methods Pathol. 
80, 677–687 (2000). 
182. Komiya, K. et al. Expression of ADAM15 in rheumatoid synovium: up-regulation by 
vascular endothelial growth factor and possible implications for angiogenesis. Arthritis Res. 
Ther. 7, R1158–1173 (2005). 
170 
 
183. Seals, D. F. & Courtneidge, S. A. The ADAMs family of metalloproteases: multidomain 
proteins with multiple functions. Genes Dev. 17, 7–30 (2003). 
184. Ainola, M. et al. Involvement of a disintegrin and a metalloproteinase 8 (ADAM8) in 
osteoclastogenesis and pathological bone destruction. Ann. Rheum. Dis. 68, 427–434 
(2009). 
185. Isozaki, T., Rabquer, B. J., Ruth, J. H., Haines, G. K., 3rd & Koch, A. E. ADAM-10 is 
overexpressed in rheumatoid arthritis synovial tissue and mediates angiogenesis. Arthritis 
Rheum. 65, 98–108 (2013). 
186. Van der Laan, W. H. et al. Cartilage degradation and invasion by rheumatoid synovial 
fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3. Gene Ther. 10, 234–242 
(2003). 
187. Böhm, B. B., Freund, I., Krause, K., Kinne, R. W. & Burkhardt, H. ADAM15 adds to 
apoptosis resistance of synovial fibroblasts by modulating focal adhesion kinase signaling. 
Arthritis Rheum. 65, 2826–2834 (2013). 
188. Young, J. et al. Lymphotoxin-alphabeta heterotrimers are cleaved by metalloproteinases 
and contribute to synovitis in rheumatoid arthritis. Cytokine 51, 78–86 (2010). 
189. Marco, M., Fortin, C. & Fulop, T. Membrane-type matrix metalloproteinases: key 
mediators of leukocyte function. J. Leukoc. Biol. 94, 237–246 (2013). 
190. Itoh, Y. MT1-MMP: a key regulator of cell migration in tissue. IUBMB Life 58, 589–596 
(2006). 
191. Thathiah, A. & Carson, D. D. MT1-MMP mediates MUC1 shedding independent of 
TACE/ADAM17. Biochem. J. 382, 363–373 (2004). 
171 
 
192. Hawinkels, L. J. A. C. et al. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin 
shedding inhibits tumor angiogenesis. Cancer Res. 70, 4141–4150 (2010). 
193. Ota, I., Li, X.-Y., Hu, Y. & Weiss, S. J. Induction of a MT1-MMP and MT2-MMP-
dependent basement membrane transmigration program in cancer cells by Snail1. Proc. 
Natl. Acad. Sci. U. S. A. 106, 20318–20323 (2009). 
194. Lauzier, A., Charbonneau, M., Harper, K., Jilaveanu-Pelmus, M. & Dubois, C. M. 
Formation of invadopodia-like structures by synovial cells promotes cartilage breakdown in 
collagen-induced arthritis: Involvement of the protein tyrosine kinase Src. Arthritis Rheum. 
63, 1591–1602 (2011). 
195. Lu, C., Li, X.-Y., Hu, Y., Rowe, R. G. & Weiss, S. J. MT1-MMP controls human 
mesenchymal stem cell trafficking and differentiation. Blood 115, 221–229 (2010). 
196. Savinov, A. Y. & Strongin, A. Y. Defining the roles of T cell membrane proteinase and 
CD44 in type 1 diabetes. IUBMB Life 59, 6–13 (2007). 
197. Rozanov, D. V., Deryugina, E. I., Monosov, E. Z., Marchenko, N. D. & Strongin, A. Y. 
Aberrant, persistent inclusion into lipid rafts limits the tumorigenic function of membrane 
type-1 matrix metalloproteinase in malignant cells. Exp. Cell Res. 293, 81–95 (2004). 
198. Miller, M.-C. et al. Membrane type 1 matrix metalloproteinase is a crucial promoter of 
synovial invasion in human rheumatoid arthritis. Arthritis Rheum. 60, 686–697 (2009). 
199. Karsdal, M. A. et al. Matrix Metalloproteinase-dependent Activation of Latent 
Transforming Growth Factor-β Controls the Conversion of Osteoblasts into Osteocytes by 
Blocking Osteoblast Apoptosis. J. Biol. Chem. 277, 44061–44067 (2002). 
200. Gonzalo, P. et al. MT1-MMP is required for myeloid cell fusion via regulation of Rac1 
signaling. Dev. Cell 18, 77–89 (2010). 
172 
 
201. Gálvez, B. G. et al. Membrane type 1-matrix metalloproteinase is regulated by chemokines 
monocyte-chemoattractant protein-1/ccl2 and interleukin-8/CXCL8 in endothelial cells 
during angiogenesis. J. Biol. Chem. 280, 1292–1298 (2005). 
202. EL Andaloussi, S., Mäger, I., Breakefield, X. O. & Wood, M. J. A. Extracellular vesicles: 
biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov. 12, 347–357 
(2013). 
203. Simpson, R. J., Jensen, S. S. & Lim, J. W. E. Proteomic profiling of exosomes: current 
perspectives. Proteomics 8, 4083–4099 (2008). 
204. Hwang, I. Cell-Cell Communication Via Extracellular Membrane Vesicles and Its Role in 
the Immune Response. Mol. Cells 36, 105–111 (2013). 
205. Théry, C., Amigorena, S., Raposo, G. & Clayton, A. Isolation and characterization of 
exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. 
Editor. Board Juan Bonifacino Al Chapter 3, Unit 3.22 (2006). 
206. Hawari, F. I. et al. Release of full-length 55-kDa TNF receptor 1 in exosome-like vesicles: 
a mechanism for generation of soluble cytokine receptors. Proc. Natl. Acad. Sci. U. S. A. 
101, 1297–1302 (2004). 
207. Théry, C., Zitvogel, L. & Amigorena, S. Exosomes: composition, biogenesis and function. 
Nat. Rev. Immunol. 2, 569–579 (2002). 
208. Segura, E. et al. ICAM-1 on exosomes from mature dendritic cells is critical for efficient 
naive T-cell priming. Blood 106, 216–223 (2005). 
209. Boilard, E. et al. Platelets amplify inflammation in arthritis via collagen-dependent 
microparticle production. Science 327, 580–583 (2010). 
173 
 
210. Boilard, E., Blanco, P. & Nigrovic, P. A. Platelets: active players in the pathogenesis of 
arthritis and SLE. Nat. Rev. Rheumatol. 8, 534–542 (2012). 
211. Berckmans, R. J. et al. Synovial microparticles from arthritic patients modulate chemokine 
and cytokine release by synoviocytes. Arthritis Res. Ther. 7, R536–544 (2005). 
212. Berckmans, R. J. et al. Cell-derived microparticles in synovial fluid from inflamed arthritic 
joints support coagulation exclusively via a factor VII-dependent mechanism. Arthritis 
Rheum. 46, 2857–2866 (2002). 
213. Reich, N. et al. Microparticles stimulate angiogenesis by inducing ELR(+) CXC-
chemokines in synovial fibroblasts. J. Cell. Mol. Med. 15, 756–762 (2011). 
214. Distler, J. H. W. et al. The induction of matrix metalloproteinase and cytokine expression in 
synovial fibroblasts stimulated with immune cell microparticles. Proc. Natl. Acad. Sci. U. 
S. A. 102, 2892–2897 (2005). 
215. Skriner, K., Adolph, K., Jungblut, P. R. & Burmester, G. R. Association of citrullinated 
proteins with synovial exosomes. Arthritis Rheum. 54, 3809–3814 (2006). 
216. Demoruelle, M. K. & Deane, K. Antibodies to citrullinated protein antigens (ACPAs): 
clinical and pathophysiologic significance. Curr. Rheumatol. Rep. 13, 421–430 (2011). 
217. Zhang, H.-G. et al. A membrane form of TNF-alpha presented by exosomes delays T cell 
activation-induced cell death. J. Immunol. Baltim. Md 1950 176, 7385–7393 (2006). 
218. Hakulinen, J., Sankkila, L., Sugiyama, N., Lehti, K. & Keski-Oja, J. Secretion of active 
membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in 
microvesicular exosomes. J. Cell. Biochem. 105, 1211–1218 (2008). 
219. Stoeck, A. et al. A role for exosomes in the constitutive and stimulus-induced ectodomain 
cleavage of L1 and CD44. Biochem. J. 393, 609–618 (2006). 
174 
 
220. Hashida, H. et al. Aminopeptidase N is involved in cell motility and angiogenesis: its 
clinical significance in human colon cancer. Gastroenterology 122, 376–386 (2002). 
221. Bathon, J. M., Proud, D., Mizutani, S. & Ward, P. E. Cultured human synovial fibroblasts 
rapidly metabolize kinins and neuropeptides. J. Clin. Invest. 90, 981–991 (1992). 
222. Dan, H. et al. CD13/aminopeptidase N in collagen vascular diseases. Rheumatol. Int. 23, 
271–276 (2003). 
223. Alvaro-Gracia, J. M., Zvaifler, N. J. & Firestein, G. S. Cytokines in chronic inflammatory 
arthritis. V. Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha 
on HLA-DR expression, proliferation, collagenase production, and granulocyte macrophage 
colony-stimulating factor production by rheumatoid arthritis synoviocytes. J. Clin. Invest. 
86, 1790–1798 (1990). 
224. Di Matteo, P. et al. Immunogenic and structural properties of the Asn-Gly-Arg (NGR) 
tumor neovasculature-homing motif. Mol. Immunol. 43, 1509–1518 (2006). 
225. Mantle, D., Falkous, G. & Walker, D. Quantification of protease activities in synovial fluid 
from rheumatoid and osteoarthritis cases: comparison with antioxidant and free radical 
damage markers. Clin. Chim. Acta Int. J. Clin. Chem. 284, 45–58 (1999). 
226. Brown, S. B., Kluck, R. M. & Ellem, K. A. Loss and shedding of surface markers from the 
leukemic myeloid monocytic line THP-1 induced to undergo apoptosis. J. Cell. Biochem. 
60, 246–259 (1996). 
227. Westermark, T., Rantapää-Dahlqvist, S., Wållberg-Jonsson, S., Kjörell, U. & Forsgren, S. 
Increased content of bombesin/GRP in human synovial fluid in early arthritis: different 
pattern compared with substance P. Clin. Exp. Rheumatol. 19, 715–720 (2001). 
175 
 
228. Rangel, R. et al. Impaired angiogenesis in aminopeptidase N-null mice. Proc. Natl. Acad. 
Sci. U. S. A. 104, 4588–4593 (2007). 
229. Sato, Y. Role of aminopeptidase in angiogenesis. Biol. Pharm. Bull. 27, 772–776 (2004). 
230. Le Gall, S. M. et al. ADAMs 10 and 17 represent differentially regulated components of a 
general shedding machinery for membrane proteins such as transforming growth factor 
alpha, L-selectin, and tumor necrosis factor alpha. Mol. Biol. Cell 20, 1785–1794 (2009). 
231. Klein, T. & Bischoff, R. Active metalloproteases of the A Disintegrin and Metalloprotease 
(ADAM) family: biological function and structure. J. Proteome Res. 10, 17–33 (2011). 
232. Bouchet, S., Tang, R., Fava, F. F., Legrand, O. & Bauvois, B. Targeting CD13 
(aminopeptidase-N) in turn downregulates ADAM17 by internalization in acute myeloid 
leukaemia cells. Oncotarget 5, (2014). 
233. Mathivanan, S., Ji, H. & Simpson, R. J. Exosomes: extracellular organelles important in 
intercellular communication. J. Proteomics 73, 1907–1920 (2010). 
234. Tani, K. et al. CD13/aminopeptidase N, a novel chemoattractant for T lymphocytes in 
pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 161, 1636–1642 (2000). 
235. Allen, S. J., Crown, S. E. & Handel, T. M. Chemokine: receptor structure, interactions, and 
antagonism. Annu. Rev. Immunol. 25, 787–820 (2007). 
236. Katada, T. & Ui, M. ADP ribosylation of the specific membrane protein of C6 cells by 
islet-activating protein associated with modification of adenylate cyclase activity. J. Biol. 
Chem. 257, 7210–7216 (1982). 
237. Burns, D. L. et al. Biochemical properties of pertussis toxin. Tokai J. Exp. Clin. Med. 13 
Suppl, 181–185 (1988). 
176 
 
238. Imai, T. et al. The T Cell-directed CC Chemokine TARC Is a Highly Specific Biological 
Ligand for CC Chemokine Receptor 4. J. Biol. Chem. 272, 15036–15042 (1997). 
239. Patel, D. D. et al. Chemokines have diverse abilities to form solid phase gradients. Clin. 
Immunol. Orlando Fla 99, 43–52 (2001). 
240. Wiedermann, C. J. et al. Different patterns of deactivation of chemotaxis and haptotaxis of 
human peripheral blood mononuclear leukocytes by soluble and surface-bound attractants. 
J. Leukoc. Biol. 58, 438–444 (1995). 
241. Pelletier, A. J. et al. Presentation of chemokine SDF-1 alpha by fibronectin mediates 
directed migration of T cells. Blood 96, 2682–2690 (2000). 
242. Proudfoot, A. E. I. et al. Glycosaminoglycan binding and oligomerization are essential for 
the in vivo activity of certain chemokines. Proc. Natl. Acad. Sci. U. S. A. 100, 1885–1890 
(2003). 
243. Miossec, P., Dinarello, C. A. & Ziff, M. Interleukin-1 lymphocyte chemotactic activity in 
rheumatoid arthritis synovial fluid. Arthritis Rheum. 29, 461–470 (1986). 
244. AL-MUGHALES, J., BLYTH, T. H., HUNTER, J. A. & WILKINSON, P. The 
chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to 
multiple cytokines. Clin. Exp. Immunol. 106, 230–236 (1996). 
245. Mangmool, S. & Kurose, H. G(i/o) protein-dependent and -independent actions of Pertussis 
Toxin (PTX). Toxins 3, 884–899 (2011). 
246. Schneider, O. D., Weiss, A. A. & Miller, W. E. Pertussis toxin signals through the TCR to 
initiate cross-desensitization of the chemokine receptor CXCR4. J. Immunol. Baltim. Md 
1950 182, 5730–5739 (2009). 
177 
 
247. Schneider, O. D., Weiss, A. A. & Miller, W. E. Pertussis toxin utilizes proximal 
components of the T-cell receptor complex to initiate signal transduction events in T cells. 
Infect. Immun. 75, 4040–4049 (2007). 
248. Strnad, C. F. & Carchman, R. A. Human T lymphocyte mitogenesis in response to the B 
oligomer of pertussis toxin is associated with an early elevation in cytosolic calcium 
concentrations. FEBS Lett. 225, 16–20 (1987). 
249. Spangrude, G. J., Sacchi, F., Hill, H. R., Van Epps, D. E. & Daynes, R. A. Inhibition of 
lymphocyte and neutrophil chemotaxis by pertussis toxin. J. Immunol. Baltim. Md 1950 
135, 4135–4143 (1985). 
250. Xu, Y., Lai, L. T., Gabrilove, J. L. & Scheinberg, D. A. Antitumor activity of actinonin in 
vitro and in vivo. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 4, 171–176 (1998). 
251. Lehmann, W. et al. Tumor necrosis factor alpha (TNF-alpha) coordinately regulates the 
expression of specific matrix metalloproteinases (MMPS) and angiogenic factors during 
fracture healing. Bone 36, 300–310 (2005). 
252. Rossol, M., Kraus, S., Pierer, M., Baerwald, C. & Wagner, U. The CD14(bright) CD16+ 
monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 
cell population. Arthritis Rheum. 64, 671–677 (2012). 
253. Ulusoy, H. et al. Serum levels of soluble CD26 and CD30 and their clinical significance in 
patients with rheumatoid arthritis. Rheumatol. Int. 32, 3857–3862 (2012). 
254. Mina-Osorio, P., Shapiro, L. H. & Ortega, E. CD13 in cell adhesion: aminopeptidase N 
(CD13) mediates homotypic aggregation of monocytic cells. J. Leukoc. Biol. 79, 719–730 
(2006). 
178 
 
255. Connolly, M. et al. Acute Serum Amyloid A Induces Migration, Angiogenesis, and 
Inflammation in Synovial Cells In Vitro and in a Human Rheumatoid Arthritis/SCID 
Mouse Chimera Model. J. Immunol. 184, 6427–6437 (2010). 
256. Jones, E. A. et al. Enumeration and phenotypic characterization of synovial fluid 
multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. 
Arthritis Rheum. 50, 817–827 (2004). 
257. Kehoe, O., Cartwright, A., Askari, A., El Haj, A. J. & Middleton, J. Intra-articular injection 
of mesenchymal stem cells leads to reduced inflammation and cartilage damage in murine 
antigen-induced arthritis. J. Transl. Med. 12, 157 (2014). 
258. Oshita, K. et al. Human mesenchymal stem cells inhibit osteoclastogenesis through 
osteoprotegerin production. Arthritis Rheum. 63, 1658–1667 (2011). 
259. Jaiswal, N., Haynesworth, S. E., Caplan, A. I. & Bruder, S. P. Osteogenic differentiation of 
purified, culture-expanded human mesenchymal stem cells in vitro. J. Cell. Biochem. 64, 
295–312 (1997). 
260. Bhoola, K. D., Elson, C. J. & Dieppe, P. A. Kinins--key mediators in inflammatory 
arthritis? Br. J. Rheumatol. 31, 509–518 (1992). 
261. Sidorowicz, W., Zownir, O. & Behal, F. J. Action of human pancreas alanine 
aminopeptidase on biologically active peptides: kinin converting activity. Clin. Chim. Acta 
Int. J. Clin. Chem. 111, 69–79 (1981). 
262. Lambert, N. et al. Substance P enhances cytokine-induced vascular cell adhesion molecule-
1 (VCAM-1) expression on cultured rheumatoid fibroblast-like synoviocytes. Clin. Exp. 
Immunol. 113, 269–275 (1998). 
179 
 
263. Larsen, S. L., Pedersen, L. O., Buus, S. & Stryhn, A. T cell responses affected by 
aminopeptidase N (CD13)-mediated trimming of major histocompatibility complex class II-
bound peptides. J. Exp. Med. 184, 183–189 (1996). 
264. Saiki, I. et al. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular 
matrix degradation. Int. J. Cancer J. Int. Cancer 54, 137–143 (1993). 
265. Boissier, M.-C., Semerano, L., Challal, S., Saidenberg-Kermanac’h, N. & Falgarone, G. 
Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J. Autoimmun. 
39, 222–228 (2012). 
266. Bhagwat, S. V. et al. CD13/APN is activated by angiogenic signals and is essential for 
capillary tube formation. Blood 97, 652–659 (2001). 
267. Favaloro, E. J. CD-13 (’gp150’; aminopeptidase-N): co-expression on endothelial and 
haemopoietic cells with conservation of functional activity. Immunol. Cell Biol. 69 ( Pt 4), 
253–260 (1991). 
268. Koch, A. E., Halloran, M. M., Haskell, C. J., Shah, M. R. & Polverini, P. J. Angiogenesis 
mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376, 
517–519 (1995). 
269. Park, C. C. et al. Evidence of IL-18 as a Novel Angiogenic Mediator. J. Immunol. 167, 
1644–1653 (2001). 
270. Saxne, T., Palladino, M. A., Heinegård, D., Talal, N. & Wollheim, F. A. Detection of tumor 
necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial 
fluid and serum. Arthritis Rheum. 31, 1041–1045 (1988). 
271. Yin, Z. et al. The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in 
synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by 
180 
 
interleukin-4 but not by interleukin-10 or transforming growth factor beta. Rheumatol. Oxf. 
Engl. 38, 1058–1067 (1999). 
272. Kehlen, A. et al. IL-10 and TGF-beta differ in their regulation of aminopeptidase N/CD13 
expression in monocytes. Int. J. Mol. Med. 13, 877–882 (2004). 
273. Mangmool, S. & Kurose, H. Gi/o Protein-Dependent and -Independent Actions of Pertussis 
Toxin (PTX). Toxins 3, 884–899 (2011). 
274. Kroeze, W. K., Sheffler, D. J. & Roth, B. L. G-protein-coupled receptors at a glance. J. Cell 
Sci. 116, 4867–4869 (2003). 
275. Lai, W.-Q., Chia, F. L.-A. & Leung, B. P. Sphingosine kinase and sphingosine-1-phosphate 
receptors: novel therapeutic targets of rheumatoid arthritis? Future Med. Chem. 4, 727–733 
(2012). 
276. Pattacini, L. et al. Angiotensin II protects fibroblast-like synoviocytes from apoptosis via 
the AT1-NF-kappaB pathway. Rheumatol. Oxf. Engl. 46, 1252–1257 (2007). 
277. Noh, H.-J. et al. Quercetin suppresses MIP-1α-induced adipose inflammation by 
downregulating its receptors CCR1/CCR5 and inhibiting inflammatory signaling. J. Med. 
Food 17, 550–557 (2014). 
278. Hoch, N. E. et al. Regulation of T-cell function by endogenously produced angiotensin II. 
Am. J. Physiol. Regul. Integr. Comp. Physiol. 296, R208–216 (2009). 
279. Price, A. et al. Angiotensin II type 1 receptor as a novel therapeutic target in rheumatoid 
arthritis: in vivo analyses in rodent models of arthritis and ex vivo analyses in human 
inflammatory synovitis. Arthritis Rheum. 56, 441–447 (2007). 
280. Kraus, J. Expression and functions of μ-opioid receptors and cannabinoid receptors type 1 
in T lymphocytes. Ann. N. Y. Acad. Sci. 1261, 1–6 (2012). 
181 
 
281. Silva-Filho, J. L. et al. AT1 receptor-mediated angiotensin II activation and chemotaxis of 
T lymphocytes. Mol. Immunol. 48, 1835–1843 (2011). 
282. Isozaki, T. et al. Evidence that CXCL16 is a potent mediator of angiogenesis and is 
involved in endothelial progenitor cell chemotaxis : studies in mice with K/BxN serum-
induced arthritis. Arthritis Rheum. 65, 1736–1746 (2013). 
283. Thomsen, W., Frazer, J. & Unett, D. Functional assays for screening GPCR targets. Curr. 
Opin. Biotechnol. 16, 655–665 (2005). 
284. Velasco-Loyden, G., Arribas, J. & López-Casillas, F. The shedding of betaglycan is 
regulated by pervanadate and mediated by membrane type matrix metalloprotease-1. J. 
Biol. Chem. 279, 7721–7733 (2004). 
285. Kawaguchi, N. et al. Different ADAMs have distinct influences on Kit ligand processing: 
phorbol-ester-stimulated ectodomain shedding of Kitl1 by ADAM17 is reduced by 
ADAM19. J. Cell Sci. 120, 943–952 (2007). 
286. Asquith, D. L., Miller, A. M., McInnes, I. B. & Liew, F. Y. Animal models of rheumatoid 
arthritis. Eur. J. Immunol. 39, 2040–2044 (2009). 
287. Brand, D. D., Latham, K. A. & Rosloniec, E. F. Collagen-induced arthritis. Nat. Protoc. 2, 
1269–1275 (2007). 
288. Amin, M. A. et al. A key role for Fut1-regulated angiogenesis and ICAM-1 expression in 
K/BxN arthritis. Ann. Rheum. Dis. (2014). doi:10.1136/annrheumdis-2013-204814 
289. Yamasaki, S. C., Murari-do-Nascimento, S. & Silveira, P. F. Neutral aminopeptidase and 
dipeptidyl peptidase IV in the development of collagen II-induced arthritis. Regul. Pept. 
173, 47–54 (2012). 
182 
 
290. Amin, M. A. et al. H-2g, a glucose analog of blood group H antigen, mediates mononuclear 
cell recruitment via Src and phosphatidylinositol 3-kinase pathways. Arthritis Rheum. 58, 
689–695 (2008). 
291. Arnett, F. C. et al. The American Rheumatism Association 1987 revised criteria for the 
classification of rheumatoid arthritis. Arthritis Rheum. 31, 315–324 (1988). 
292. Freidman, A. W., Diaz, L. A., Moore, S., Schaller, J. & Fox, D. A. The human 4F2 antigen: 
evidence for cryptic and noncryptic epitopes and for a role of 4F2 in human T lymphocyte 
activation. Cell. Immunol. 154, 253–263 (1994). 
293. Nelson, R. D., Quie, P. G. & Simmons, R. L. Chemotaxis under agarose: a new and simple 
method for measuring chemotaxis and spontaneous migration of human polymorphonuclear 
leukocytes and monocytes. J. Immunol. Baltim. Md 1950 115, 1650–1656 (1975). 
294. Heit, B. & Kubes, P. Measuring chemotaxis and chemokinesis: the under-agarose cell 
migration assay. Sci. STKE Signal Transduct. Knowl. Environ. 2003, PL5 (2003). 
 
